



(22) Date de dépôt/Filing Date: 2006/08/15

(41) Mise à la disp. pub./Open to Public Insp.: 2007/02/22

(45) Date de délivrance/Issue Date: 2014/09/16

(62) Demande originale/Original Application: 2 618 393

(30) Priorités/Priorities: 2005/08/15 (US60/708,720);
2006/08/11 (US11/503,551)

(51) Cl.Int./Int.Cl. *C07D 215/20* (2006.01),
A61K 31/47 (2006.01), *A61K 31/496* (2006.01),
C07D 401/12 (2006.01), *C07D 405/12* (2006.01)

(72) Inventeurs/Inventors:
DIMAURO, ERIN F., US;
BEMIS, JEAN E., US;
CHAFFEE, STUART, US;
CHEN, NING, US;
HU, ESSA, US;
KUNZ, ROXANNE, US;


...

(73) Propriétaire/Owner:
AMGEN INC., US

(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : COMPOSES BIS-ARYL AMIDE ET PROCEDES D'UTILISATION

(54) Title: BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE



(57) Abrégé/Abstract:

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I

(see formula I)

wherein A¹, A², A³, A⁴, L, R¹, R² and R³ are defined herein. The invention also comprises pharmaceutical compositions including


(72) **Inventeurs(suite)/Inventors(continued):** MARTIN, MATTHEW W., US; MCGOWEN, DAVID C., BE;
RUMFELT, SHANNON, US

(57) **Abrégé(suite)/Abstract(continued):**

one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions including one or more compounds of the invention, and intermediates and processes useful for the preparation of compounds of the present invention.

ABSTRACT

The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including autoimmune disease and inflammation. In one embodiment, the compounds have a general Formula I



wherein A¹, A², A³, A⁴, L, R¹, R² and R³ are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of the present invention, methods of use such as treatment of Lck and/or c-Kit kinase mediated diseases by administering the compounds of the invention, or compositions including one or more compounds of the invention, and intermediates and processes useful for the preparation of compounds of the present invention.

- 1 -

BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USEFIELD OF THE INVENTION

The present invention generally relates to bis-aryl
5 amide compounds, pharmaceutical compositions comprising same
and use for treatment of kinase mediated disorders.

BACKGROUND OF THE INVENTION

Inflammatory autoimmune diseases, such as rheumatoid
10 arthritis, polyarthritis scleroderma, inflammatory bowel
disease, type I diabetes, multiple sclerosis, ulcerative
colitis, Crohn's disease, Sjogren's disease, polymyositis,
dermatomyositis, vasculitis, myasthenia gravis, psoriasis,
and lupus, typically activate various inflammatory factors,
15 including T-cells. T cells play a pivotal role in the
regulation of immune responses and are important for
establishing immunity to pathogens. T cell activation is
also an important component of organ transplantation
rejection, allergic reactions, and asthma.

20 T cells are activated by specific antigens through T
cell receptors (TCR) which are expressed on the cell
surface. This activation triggers a series of intracellular
signaling cascades mediated by enzymes expressed within the
cell (Kane, LP et al. Current Opinion in Immunol. 2000, 12,
25 242). These cascades lead to gene regulation events that
result in the production of cytokines, including
interleukin-2 (IL-2). IL-2 is a critical cytokine in T cell
activation, leading to proliferation and amplification of
specific immune responses.

30 Kinase enzymes have been shown to be important in the
intracellular signal transduction. One class of kinase
enzymes involved in signal transduction is the Src-family of
protein tyrosine kinases (PTK's), which includes, for

- 2 -

example: Lck, Fyn(B), Fyn(T), Lyn, Src, Yes, Hck, Fgr and Blk (for review see: Bolen, JB, and Brugge, JS Annu. Rev. Immunol 1997, 15, 371). Gene disruption studies suggest that inhibition of some members of the Src family of kinases would potentially lead to therapeutic benefit. Src(-/-) mice have abnormalities in bone remodeling or osteopetrosis (Soriano, P. Cell 1991, 64, 693), suggesting that inhibition of the Src kinase might be useful in diseases of bone resorption, such as osteoporosis. Lck(-/-) mice have defects in T cell maturation and activation (Anderson, SJ et al. Adv. Immunol. 1994, 56, 151), suggesting that inhibition of the Lck kinase might be useful in diseases of T cell mediated inflammation. In addition, human patients have been identified with mutations effecting Lck kinase activity (Goldman, FD et al. J. Clin. Invest. 1998, 102, 421). These patients suffer from a severe combined immunodeficiency disorder (SCID).

Src-family kinases are also important for signaling downstream of other immune cell receptors. Fyn, like Lck, is involved in TCR signaling in T cells (Appleby, MW et al. Cell 1992, 70, 751). Hck and Fgr are involved in Fcγ receptor signaling leading to neutrophil activation (Vicentini, L. et al. J. Immunol. 2002, 168, 6446). Lyn and Src also participate in Fcγ receptor signaling leading to release of histamine and other allergic mediators (Turner, H. and Kinet, J-P Nature 1999, 402, B24). These findings suggest that Src family kinase inhibitors may be useful in treating allergic diseases and asthma.

Src kinases have also been found to be activated in tumors including sarcoma, melanoma, breast, and colon cancers suggesting that Src kinase inhibitors may be useful anti-cancer agents (Abram, CL and Courtneidge, SA Exp. Cell Res. 2000, 254, 1). Src kinase inhibitors have also been reported to be effective in an animal model of cerebral

- 3 -

ischemia (R. Paul et al. Nature Medicine 2001, 7, 222), suggesting that Src kinase inhibitors may be effective at limiting brain damage following stroke.

Another protein kinase believed to cause autoimmune disease is c-Kit. C-kit is a receptor tyrosine kinase expressed on the surface of mast cells, to which stem cell factor (SCF) is a ligand. Aberrant c-kit signaling is believed to be a mediator of certain autoimmune diseases. Binding of SCF to the c-kit receptor mediates various functions of the mast cell. As an important mediator of mast cell function, c-kit is thought to also play a role in pathologies associated with mast cells (MC). C-kit functions through mast cell generation, which plays an important role in triggering autoimmune diseases. Mast cells are tissue elements derived from a particular subset of hematopoietic stem cells that express CD34, c-kit and CD13 antigens (Kirshenbaum et al., *Blood* 94:2333-2342, 1999 and Ishizaka et al, *Curr. Opinion Immunol.* 5:937-943, 1993). Mast cells are characterized by their heterogeneity, not only regarding tissue location and structure but also at the functional and histochemical levels (Aldenberg and Enerback, *Histochem. J.* 26:587-596, 1994; Bradding et al., *J. Immunol.* 155:297-307, 1995; Irani et al., *J. Immunol.* 147:247-253, 1991).

Mast cells are thought to participate in the destruction of tissues by releasing various proteases and mediators categorized into three groups: pre-formed granule associated mediators (histamine, proteoglycans, and neutral proteases), lipid-derived mediators (prostaglandins, thromboxanes, and leucotrienes), and various cytokines, including IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, TNF α , GM-CSF, MIP-1a, MIP-1b, MIP-2 and IFN γ . The liberation of these mediators induces and activates various components of immune response involved in autoimmune diseases, and also promotes the tissue destruction process.

- 4 -

Activation of the auto-immune response is postulated to be caused by, or stimulated from, the degranulation of mast cells. Immature MC progenitors circulate in the blood stream and differentiate in the tissues. These

5 differentiation and proliferation processes are influenced by various cytokines. Stem Cell Factor (SCF) and IFN γ are two cytokines which are important in influencing such processes. The SCF receptor is encoded by the proto-oncogene c-kit, which belongs to the type III receptor tyrosine

10 kinase subfamily (Boissan and Arock, *J. Leukoc. Biol.* 67:135-148, 2000), along with PDGF and cFMS. Ligation of c-kit receptor by SCF induces its dimerization followed by its transphosphorylation, leading to the recruitment and activation of various intracytoplasmic substrates. IFN γ is

15 another cytokine secreted by mast cells. It has been reported that IFN γ is responsible for major histocompatibility complexes associated with autoimmune diseases (Hooks et al., *New England J. of Med.*, 301:5-8, 1979). These activated substrates induce multiple

20 intracellular signaling pathways responsible for cell proliferation and activation (Boissan and Arock, 2000).

TNF is another cytokine produced by mast cells. More recently, it has been reported that the TNF produced by mast cells is involved in the pathogenesis of auto-antibody

25 mediated vasculitis (Watanabe et al., *Blood* 11:3855-3866, 1994). Mast cells were also shown to control neutrophil recruitment during T-cell mediated delayed-type hypersensitivity reactions through TNF and macrophage inflammatory protein 2 (MIP-2). Accordingly, c-kit

30 regulation may be useful in various types of inflammation including without limitation, rheumatoid arthritis, severe asthma, allergy associated chronic rhinitis, and the like.

Mast cells have also been implicated in liver allograft rejection (Yamaguchi et al., *Hematology* 29:133-

- 5 -

139, 1999) and in liver fibrosis, where hepatic stellate cells produce the SCF that recruits the mast cells (Gaca et al., *J. Hematology* 30:850-858, 1999). These observations suggest that c-kit kinase inhibitors may help prevent organ rejection and fibrosis. Some possible related c-kit mediated therapeutic indications include idiopathic pulmonary fibrosis (IPF) and scleroderma. Mast cells have also been implicated in the pathology of multiple sclerosis (Secor et al., *J. Experimental Medicine* 191:813-822, 1999), and ischemia-reperfusion injury (Andoh et al, *Clinical & Experimental Immunology* 116:90-93, 1999) in experimental models using mice with mutant kit receptors that are deficient in mast cells. In both cases, the pathology of the diseases was significantly attenuated relative to mice with normal c-kit and mast cell populations. Thus, the role of mast cells in these diseases suggests that c-kit modulators might be useful therapeutics.

C-kit signaling is also important for fetal gonadal development, and plays a role in adult fertility (Mauduit et al, *Human Rep. Update* 5: 535-545, 1999). Spermatogenesis is inhibited through a reduction of c-Kit activity in c-kit signaling through the PI3 kinase pathway (Blume-Jensen et al, *Nature Genetics* 24:157-162, 2000). C-kit expression has been observed to be lower in sub-fertile testes than in normal testicular tissue (Feng et al, *Fertility and Sterility* 71:85-89, 1999). C-kit signaling is also important for oogenesis and folliculogenesis (Parrott and Skinner, *Endocrinology* 140:4262-4271, 1999). These reports suggest that modulation of c-kit enzymatic activity may be a method to reduce both male and female infertility.

While various groups have published on inhibitors of c-kit kinase, disclosing various chemical compounds, including 2-phenylamino-imidazo [4,5-h]isoquinolin-9-ones (Snow, RJ et al, *J. Med. Chem.* 2002, 45, 3394), pyrazolo


- 6 -

[3,4-d]pyrimidines (Burchat, AF et al, *Bioorganic and Med. Chem. Letters* 2002, 12, 1987 and Hanke, JH et al, *J. Biol. Chem.* 1996, 271, 695), pyrrolo [2,3-d]pyrimidines (Altmann, E et al, *Bioorganic and Med. Chem. Letters* 2001, 11, 853),
 5 anilinoquinazolines (Wang, YD et al, *Bioorganic and Med. Chem. Letters* 2000, 10, 2477), imidazoquinoxalines (Chen, P. et al, *Bioorganic and Med. Chem. Letters* 2002, 12, 3153),
 PCT publication entitled, "Methods of Modulating C-kit Tyrosine Protein Kinase Function with Indoline Compounds"
 10 and PCT publication entitled, "Use of Tyrosine Kinase Inhibitors for Treating Autoimmune Diseases", none of these groups describe the compounds of the present invention, and particularly as modulators of kinase enzymes such as c-kit, and useful for the regulation of autoimmune disease(s),
 15 allergies, asthma, cancer and the like.

BRIEF DESCRIPTION OF EXEMPLARY EMBODIMENTS OF THE INVENTION

The present invention provides compounds that are capable of modulating the activity of one or more kinase enzymes, thereby regulating various kinase-associated
 20 disorders including, without limitation, inflammation and autoimmune disease.

The compounds of the present invention, including stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof, are
 25 represented by general Formula I:



wherein A¹, A², A³, A⁴, L, R¹, R² and R³ are defined in the Detailed Description below. The compounds of Formula I are

- 7 -

capable of modulating protein tyrosine kinase enzymes of the Src family, such as Lck, as well as other protein kinase enzymes such as c-kit. Accordingly, these compounds are useful in the treatment, including preventative,

5 prophylactic and therapeutic treatment, of protein tyrosine kinase-associated, or mediated, disorders, including but not limited to, T-cell mediated inflammatory disorders and mast cell regulated auto-immune diseases and other c-kit associated or mediated disorders.

10 "Protein kinase-associated disorders" are disorders which result from aberrant kinase activity, and/or which are alleviated by the regulation, and inhibition in particular, of one or more of these kinase enzymes. For example, Lck inhibitors are of value in the treatment of a number of such
15 disorders (for example, the treatment of autoimmune diseases), as Lck inhibition blocks T cell activation. It is believed that the compounds of Formula I modulate T cell activation by way of inhibition of one or more of the multiple protein tyrosine kinases involved in early signal
20 transduction steps leading to T cell activation, for example, by way of inhibition of Lck kinase.

Accordingly, in one embodiment of the invention, the compounds of Formula I are useful for the treatment of T cell mediated diseases, including inhibition of T cell
25 activation and proliferation. Further, the compounds may block the activation of endothelial cell protein tyrosine kinase by oxidative stress thereby limiting surface expression of adhesion molecules that induce neutrophil binding, and they also can inhibit protein tyrosine kinase
30 necessary for neutrophil activation. The compounds would be useful, therefore, in the treatment of ischemia and reperfusion injury. In another embodiment of the invention, there is provided a method for the treatment of protein tyrosine kinase-associated disorder, the method comprising

- 8 -

administering to a subject at least one compound of Formula I in an amount effective to treat the disorder.

Additional tyrosine kinase-associated disorders, or which the compound(s) of the present invention are useful include, without limitation, arthritis (such as rheumatoid arthritis, psoriatic arthritis or osteoarthritis); transplant (such as organ transplant, acute transplant or heterograft or homograft (such as is employed in burn treatment)) rejection; protection from ischemic or reperfusion injury such as ischemic or reperfusion injury incurred during organ transplantation, myocardial infarction, stroke or other causes; transplantation tolerance induction; multiple sclerosis; inflammatory bowel disease, including ulcerative colitis and Crohn's disease; lupus (systemic lupus erythematosus); graft vs. host diseases; T-cell mediated hypersensitivity diseases, including contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy (Celiac disease); Type 1 diabetes; psoriasis; contact dermatitis (including that due to poison ivy); Hashimoto's thyroiditis; Sjogren's syndrome; Autoimmune Hyperthyroidism, such as Graves' Disease; Addison's disease (autoimmune disease of the adrenal glands); Autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome); autoimmune alopecia; pernicious anemia; vitiligo; autoimmune hypopituitarism; Guillain-Barre syndrome; other autoimmune diseases; cancers where Lck or other Src-family kinases such as Src are activated or overexpressed, such as colon carcinoma and thymoma, or cancers where Src-family kinase activity facilitates tumor growth or survival; glomerulonephritis, serum sickness; urticaria; allergic diseases such as respiratory allergies (asthma, hayfever, allergic rhinitis) or skin allergies; scleroderma; mycosis fungoides; acute inflammatory responses (such as acute

- 9 -

respiratory distress syndrome and ischemia/reperfusion injury); dermatomyositis; alopecia areata; chronic actinic dermatitis; eczema; Behcet's disease; Pustulosis palmoplanteris; Pyoderma gangrenum; Sezary's syndrome; atopic dermatitis; systemic sclerosis; and morphea. The present invention also provides methods for treating the aforementioned disorders such as atopic dermatitis by administration of a therapeutically effective amount of a compound of the present invention, which is an inhibitor of protein tyrosine kinase, to a patient suffering from dermatitis and potentially in need of such treatment.

The compounds of the invention are also capable of modulating the activity of c-kit protein kinase and, therefore, are capable of regulating various c-kit related disorders. More specifically, these compounds are useful in the treatment, including preventative, prophylactic and therapeutic treatment, of c-kit kinase-associated or mediated disorders including, but not limited to, mast cell regulated autoimmune disorders and fibrotic diseases, including idiopathic pulmonary fibrosis. In one embodiment of the invention, the compounds of the invention are useful for the treatment of mast cell production, tumors related to mast cell proliferation and mastocytosis, allergic reactions including severe asthma, rheumatoid arthritis, scleroderma, multiple sclerosis and allergy associated chronic rhinitis, and c-kit mediated fibrotic and autoimmune disease.

In one embodiment of the invention, the compounds of the invention are useful for the treatment of an abnormal condition associated with inappropriate c-kit kinase mediated signal transduction in a subject, the treatment method comprising the step of administering to the subject an effective dosage amount of a compound according to the invention.

To treat patients for such disorders and conditions, another embodiment of the invention provides a composition

- 10 -

comprising a compound of Formula I, or II or III, and a pharmaceutically acceptable carrier. Such a pharmaceutical composition, or medicament, can be administered to the subject, such as a human, for the purpose of treating the disorder. Other therapeutic agents such as those described below may be employed in combination with the inventive compounds, such as in a combined composition, in the present methods. Alternatively, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the compound(s) of the present invention.

The compounds described above may particularly relate to compounds of Formula I, or a stereoisomer or pharmaceutically acceptable salt, thereof, wherein

10a

A^1 is CR^4 ;

A^2 is CR^5 ;

A^3 is CR^6 ;

A^4 is CR^7 ; provided that when L is $-NHC(O)-$, A^1 is CR^4 , A^2 is CR^5 , A^3 is CR^6 and A^4 is CR^7 , then R^6 is H;

L is $-C(O)NR^7-$, $-C(S)NR^7-$, $-NR^7C(O)-$, $-NR^7C(S)-$, $-NR^7C(O)NR^7-$, $-NR^7C(S)NR^7-$, $-NR^7C(O)O-$, $-OC(O)NR^7-$, $-S(O)_2NR^7-$, $-NR^7S(O)_2NR^7-$ or $-NR^7S(O)_2-$;

R^1 is quinolinyl or isoquinolinyl, each ring of which is optionally substituted independently with one or more substituents of R^8 , R^9 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^9$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^9$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^9$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$;

R^2 is H, C_{1-10} -alkyl, C_{2-10} -alkenyl or C_{2-10} -alkynyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl and C_{2-10} -alkynyl optionally comprising 1-3 heteroatoms selected from the group consisting of N, O and S and optionally substituted with one or more substituents of R^9 or R^{10} ;

R^3 is C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, 5-6 membered monocyclic or 9-10 membered bicyclic non-aromatic heterocyclic ring system, or a 5-6 membered monocyclic or 9-10 membered bicyclic aromatic ring system, said aromatic ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from the group consisting of O, N, and S, wherein said C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, non-aromatic heterocyclic ring system and aromatic ring system is optionally substituted independently with one or more substituents of R^{11} , R^{12} , R^{13} , $NR^{11}R^{11}$, $NR^{11}R^{12}$, OR^{11} , SR^{11} , OR^{12} , SR^{12} , $C(O)R^{11}$, $C(S)R^{11}$, $CN(CN)R^{11}$, $C(O)R^{12}$, $C(S)R^{12}$, $CN(CN)R^{12}$, $C(O)C(O)R^{11}$, $OC(O)R^{11}$, $COOR^{11}$, $C(O)SR^{11}$, $C(O)C(O)R^{12}$, $OC(O)R^{12}$, $COOR^{12}$, $C(O)SR^{12}$, $C(O)NR^{11}R^{11}$, $C(S)NR^{11}R^{11}$, $C(O)NR^{11}R^{12}$, $C(S)NR^{11}R^{12}$, $OC(O)NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)R^{12}$, $NR^{11}C(S)R^{11}$, $NR^{11}C(S)R^{12}$, $NR^{11}C(O)NR^{11}R^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, $NR^{11}C(S)NR^{11}R^{11}$, $NR^{11}C(S)NR^{11}R^{12}$, $NR^{11}C(O)OR^{11}$,

10b

$\text{NR}^{11}\text{C}(\text{O})\text{OR}^{12}$, $\text{NR}^{11}\text{C}(\text{O})\text{C}(\text{O})\text{R}^{11}$, $\text{NR}^{11}\text{C}(\text{O})\text{C}(\text{O})\text{R}^{12}$, $\text{NR}^{11}\text{C}(\text{O})\text{C}(\text{O})\text{NR}^{11}\text{R}^{12}$,
 $\text{S}(\text{O})_2\text{R}^{11}$, $\text{S}(\text{O})_2\text{R}^{12}$, $\text{S}(\text{O})_2\text{NR}^{11}\text{R}^{11}$, $\text{S}(\text{O})_2\text{NR}^{11}\text{R}^{12}$, $\text{NR}^{11}\text{S}(\text{O})_2\text{NR}^{11}\text{R}^{12}$,
 $\text{NR}^{11}\text{S}(\text{O})_2\text{R}^{11}$ or $\text{NR}^{11}\text{S}(\text{O})_2\text{R}^{12}$;

Each of R^4 , R^5 , R^6 and R^7 , independently, is H, halo, haloalkyl, NO_2 , CN, NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $\text{C}(\text{O})\text{R}^8$, $\text{C}(\text{O})\text{R}^9$, $\text{OC}(\text{O})\text{R}^8$, $\text{C}(\text{O})\text{OR}^8$, $\text{C}(\text{O})\text{NR}^8\text{R}^8$, $\text{C}(\text{O})\text{NR}^8\text{R}^9$, $\text{NR}^8\text{C}(\text{O})\text{R}^8$, $\text{NR}^8\text{C}(\text{O})\text{R}^9$, $\text{NR}^8\text{C}(\text{O})\text{NR}^8\text{R}^8$, $\text{NR}^8\text{C}(\text{O})\text{NR}^8\text{R}^9$, $\text{NR}^8\text{C}(\text{O})\text{OR}^8$, $\text{NR}^8\text{C}(\text{O})\text{OR}^9$, $\text{S}(\text{O})_2\text{R}^8$, $\text{S}(\text{O})_2\text{R}^9$, $\text{S}(\text{O})_2\text{NR}^8\text{R}^8$, $\text{S}(\text{O})_2\text{NR}^8\text{R}^9$, $\text{NR}^8\text{S}(\text{O})_2\text{NR}^8\text{R}^8$, $\text{NR}^8\text{S}(\text{O})_2\text{NR}^8\text{R}^9$, $\text{NR}^8\text{S}(\text{O})_2\text{R}^8$, $\text{NR}^8\text{S}(\text{O})_2\text{R}^9$, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl or C_{4-10} -cycloalkenyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl and C_{4-10} -cycloalkenyl optionally comprising 1-4 heteroatoms selected from the group consisting of N, O and S and optionally substituted with one or more substituents of R^9 or R^{10} ;

alternatively, R^5 and R^6 taken together form a saturated or partially or fully unsaturated 5-6 membered monocyclic ring of carbon atoms optionally including 1-3 heteroatoms selected from the group consisting of O, N, and S, and the ring optionally substituted independently with 1-3 substituents of R^8 , R^9 or R^{10} ;

R^8 is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl optionally comprising 1-4 heteroatoms selected from the group consisting of N, O and S and optionally substituted with one or more substituents of NR^9R^9 , NR^9R^9 , OR^8 , SR^8 , OR^9 , SR^9 , $\text{C}(\text{O})\text{R}^8$, $\text{OC}(\text{O})\text{R}^8$, COOR^8 , $\text{C}(\text{O})\text{R}^9$, $\text{OC}(\text{O})\text{R}^9$, COOR^9 , $\text{C}(\text{O})\text{NR}^8\text{R}^9$, $\text{C}(\text{O})\text{NR}^9\text{R}^9$, $\text{NR}^9\text{C}(\text{O})\text{R}^8$, $\text{NR}^9\text{C}(\text{O})\text{R}^9$, $\text{NR}^9\text{C}(\text{O})\text{NR}^8\text{R}^9$, $\text{NR}^9\text{C}(\text{O})\text{NR}^9\text{R}^9$, $\text{NR}^9(\text{COOR}^8)$, $\text{NR}^9(\text{COOR}^9)$, $\text{OC}(\text{O})\text{NR}^8\text{R}^9$, $\text{OC}(\text{O})\text{NR}^9\text{R}^9$, $\text{S}(\text{O})_2\text{R}^8$, $\text{S}(\text{O})_2\text{NR}^8\text{R}^9$, $\text{S}(\text{O})_2\text{R}^9$, $\text{S}(\text{O})_2\text{NR}^9\text{R}^9$, $\text{NR}^9\text{S}(\text{O})_2\text{NR}^8\text{R}^9$, $\text{NR}^9\text{S}(\text{O})_2\text{NR}^9\text{R}^9$, $\text{NR}^9\text{S}(\text{O})_2\text{R}^8$, $\text{NR}^9\text{S}(\text{O})_2\text{R}^9$ or R^9 ;

R^9 is a partially or fully saturated or unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from the group consisting of O, N, and S, and wherein each ring of said ring system is optionally

10c

substituted independently with 1-3 substituents of R^{10} , oxo, $NR^{10}R^{10}$, OR^{10} , SR^{10} , $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$, $NR^{10}C(O)R^{10}$, $NR^{10}C(O)NR^{10}R^{10}$, $OC(O)NR^{10}R^{10}$, $S(O)_2R^{10}$, $S(O)_2NR^{10}R^{10}$ or $NR^{10}S(O)_2R^{10}$;

R^{10} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl or a saturated or partially or fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from the group consisting of O, N, and S, wherein each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl and ring of said ring system is optionally substituted independently with 1-3 substituents of halo, haloalkyl, CN, NO_2 , NH_2 , OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl or phenyl;

R^{11} is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl optionally comprising 1-4 heteroatoms selected from the group consisting of N, O and S and optionally substituted with one or more substituents of $NR^{12}R^{13}$, $NR^{13}R^{13}$, OR^{12} , SR^{12} , OR^{13} , SR^{13} , $C(O)R^{12}$, $OC(O)R^{12}$, $COOR^{12}$, $C(O)R^{13}$, $OC(O)R^{13}$, $COOR^{13}$, $C(O)NR^{12}R^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{12}$, $NR^{13}C(O)R^{13}$, $NR^{13}C(O)NR^{12}R^{13}$, $NR^{13}C(O)NR^{13}R^{13}$, $NR^{13}C(O)OR^{12}$, $NR^{13}C(O)OR^{13}$, $OC(O)NR^{12}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{12}$, $S(O)_2NR^{12}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2NR^{12}R^{13}$, $NR^{13}S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2R^{12}$, $NR^{13}S(O)_2R^{13}$ or R^{13} ;

R^{12} is a partially or fully saturated or unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6

10d

heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from the group consisting of O, N, and S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R^{13} , oxo, $NR^{13}R^{13}$, OR^{13} , SR^{13} , $C(O)R^{13}$, $COOR^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{13}$, $NR^{13}C(O)NR^{13}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$ or $NR^{13}S(O)_2R^{13}$;

alternatively, R^{11} and R^{12} taken together form a partially or fully saturated or unsaturated 5-6 membered ring of carbon atoms optionally including 1-3 heteroatoms selected from the group consisting of O, N, and S, and the ring optionally substituted independently with 1-5 substituents of R^{13} ; and

R^{13} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, oxo, acetyl, benzyl, cyclopropyl, cyclobutyl or a partially or fully saturated or unsaturated 3-8 membered monocyclic or 6-12 membered bicyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from the group consisting of O, N, and S, and optionally substituted independently with 1-5 substituents of halo, haloalkyl, CN, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, benzyl or phenyl.

In certain non-limiting embodiments, the compounds may include:

N3-(6,7-dimethoxyquinolin-3-yl)-4-methyl-N1-(3-((4-methylpiperazin-1-yl)methyl)-5-

(trifluoromethyl)phenyl)isophthalamide;

N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2-methyl-3-(trifluoromethyl)benzamide;

N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2,2-difluorobenzo[d][1,3]dioxole-4-carboxamide;

N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2,2-difluorobenzo[d][1,3]dioxole-5-carboxamide;


N3-(6,7-dimethoxyquinolin-3-yl)-N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methylisophthalamide;
2-chloro-N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide;
N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-ethylphenyl)-2-methyl-3-(trifluoromethyl)benzamide;
4-methyl-N3-(quinolin-3-yl)-N1-(3-(trifluoromethyl)phenyl)isophthalamide;
4-methyl-N1-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-N3-(quinolin-3-yl)isophthalamide;
N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-N3-(quinolin-3-yl)isophthalamide; and
N~1~-((2-cyclopentylethyl)-4-methyl-N~3~-3-quinolinyl-1,3-benzenedicarboxamide.

- 10f -

The foregoing merely summarizes certain aspects of the
10 invention and is not intended, nor should it be construed,
as limiting the invention in any way.

DETAILED DESCRIPTION OF THE EXEMPLARY EMBODIMENTS OF THE
INVENTION

In one embodiment, the present invention provides a
15 compound of Formula I



or stereoisomer, tautomer, solvate, pharmaceutically
acceptable salt, derivative or prodrug thereof, wherein

20 A¹ is CR⁴ or N;
 A² is CR⁵ or N;
 A³ is CR⁶ or N;

- 11 -

A^4 is CR^7 or N; provided that (1) no more than two of A^1 , A^2 , A^3 and A^4 is N and (2) when L is $-NHC(O)-$, A^1 is CR^4 , A^2 is CR^5 , A^3 is CR^6 and A^4 is CR^7 , then R^6 is H;

L is $-C(O)NR^7-$, $-C(S)NR^7-$, $-NR^7C(O)-$, $-NR^7C(S)-$,
 5 $-NR^7C(O)NR^7-$, $-NR^7C(S)NR^7-$, $-NR^7C(O)O-$, $-OC(O)NR^7-$, $-S(O)_2NR^7-$,
 $-NR^7S(O)_2NR^7-$ or $-NR^7S(O)_2-$;

R^1 is pyrimidyl, pyrazinyl, pyridazinyl, triazinyl,
 quinolinyl, isoquinolinyl, quinazolinyl, isoquinazolinyl,
 aza-quinazolinyl, phthalazinyl and aza-phthalazinyl,
 10 thiophenyl, furyl, pyrrolyl, pyrazolyl, imidazolyl,
 triazolyl, oxazolyl, isoxazolyl, indolyl, isoindolyl,
 benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl,
 benzisoxazolyl, benzothiazolyl or oxo-
 dihydropyrrolopyridinyl, each ring of which is optionally
 15 substituted independently with one or more substituents of
 R^8 , R^9 , NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$,
 $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$,
 $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$,
 $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$,
 20 $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$;

R^2 is H, C_{1-10} -alkyl, C_{2-10} -alkenyl or C_{2-10} -alkynyl, each
 of the C_{1-10} -alkyl, C_{2-10} -alkenyl and C_{2-10} -alkynyl optionally
 comprising 1-3 heteroatoms selected from N, O and S and
 optionally substituted with one or more substituents of R^9
 25 or R^{10} ;

R^3 is C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -
 cycloalkyl, 5-6 membered monocyclic or 9-10 membered
 bicyclic non-aromatic heterocyclic ring system, or a 5-6
 membered monocyclic or 9-10 membered bicyclic aromatic ring
 30 system, said aromatic ring system formed of carbon atoms
 optionally including 1-3 heteroatoms if monocyclic or 1-6
 heteroatoms if bicyclic, said heteroatoms selected from O,
 N, or S, wherein said C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl,
 C_{3-10} -cycloalkyl, non-aromatic heterocyclic ring system and

- 12 -

aromatic ring system is optionally substituted independently with one or more substituents of R^{11} , R^{12} , R^{13} , $NR^{11}R^{11}$, $NR^{11}R^{12}$, OR^{11} , SR^{11} , OR^{12} , SR^{12} , $C(O)R^{11}$, $C(S)R^{11}$, $CN(CN)R^{11}$, $C(O)R^{12}$, $C(S)R^{12}$, $CN(CN)R^{12}$, $C(O)C(O)R^{11}$, $OC(O)R^{11}$, $COOR^{11}$, $C(O)SR^{11}$,
 5 $C(O)C(O)R^{12}$, $OC(O)R^{12}$, $COOR^{12}$, $C(O)SR^{12}$, $C(O)NR^{11}R^{11}$, $C(S)NR^{11}R^{11}$, $C(O)NR^{11}R^{12}$, $C(S)NR^{11}R^{12}$, $OC(O)NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)R^{12}$, $NR^{11}C(S)R^{11}$, $NR^{11}C(S)R^{12}$, $NR^{11}C(O)NR^{11}R^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, $NR^{11}C(S)NR^{11}R^{11}$, $NR^{11}C(S)NR^{11}R^{12}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)OR^{12}$, $NR^{11}C(O)C(O)R^{11}$, $NR^{11}C(O)C(O)R^{12}$, $NR^{11}C(O)C(O)NR^{11}R^{12}$, $S(O)_2R^{11}$,
 10 $S(O)_2R^{12}$, $S(O)_2NR^{11}R^{11}$, $S(O)_2NR^{11}R^{12}$, $NR^{11}S(O)_2NR^{11}R^{12}$, $NR^{11}S(O)_2R^{11}$ or $NR^{11}S(O)_2R^{12}$;

Each of R^4 , R^5 , R^6 and R^7 , independently, is H, halo, haloalkyl, NO_2 , CN, NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$,
 15 $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$, $NR^8S(O)_2R^9$, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl or C_{4-10} -cycloalkenyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl
 20 and C_{4-10} -cycloalkenyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of R^9 or R^{10} ;

alternatively, R^5 and R^6 taken together form a saturated or partially or fully unsaturated 5-6 membered
 25 monocyclic ring of carbon atoms optionally including 1-3 heteroatoms selected from O, N, or S, and the ring optionally substituted independently with 1-3 substituents of R^8 , R^9 or R^{10} ;

R^8 is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl
 30 optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of NR^8R^9 , NR^9R^9 , OR^8 , SR^8 , OR^9 , SR^9 , $C(O)R^8$, $OC(O)R^8$, $COOR^8$,

- 13 -

$C(O)R^9$, $OC(O)R^9$, $COOR^9$, $C(O)NR^8R^9$, $C(O)NR^9R^9$, $NR^9C(O)R^8$,
 $NR^9C(O)R^9$, $NR^9C(O)NR^8R^9$, $NR^9C(O)NR^9R^9$, $NR^9(COOR^8)$, $NR^9(COOR^9)$,
 $OC(O)NR^8R^9$, $OC(O)NR^9R^9$, $S(O)_2R^8$, $S(O)_2NR^8R^9$, $S(O)_2R^9$, $S(O)_2NR^9R^9$,
 $NR^9S(O)_2NR^8R^9$, $NR^9S(O)_2NR^9R^9$, $NR^9S(O)_2R^8$, $NR^9S(O)_2R^9$ or R^9 ;

5 R^9 is a partially or fully saturated or unsaturated 3-8
 membered monocyclic, 6-12 membered bicyclic, or 7-14
 membered tricyclic ring system, said ring system formed of
 carbon atoms optionally including 1-3 heteroatoms if
 monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms
 10 if tricyclic, said heteroatoms selected from O, N, or S, and
 wherein each ring of said ring system is optionally
 substituted independently with 1-3 substituents of R^{10} , oxo,
 $NR^{10}R^{10}$, OR^{10} , SR^{10} , $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$, $NR^{10}C(O)R^{10}$,
 $NR^{10}C(O)NR^{10}R^{10}$, $OC(O)NR^{10}R^{10}$, $S(O)_2R^{10}$, $S(O)_2NR^{10}R^{10}$ or
 15 $NR^{10}S(O)_2R^{10}$;

R^{10} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl or a saturated or partially or
 20 fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from
 25 O, N, or S, wherein each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl and ring of said ring system is optionally substituted independently with 1-3 substituents of halo,
 30 haloalkyl, CN, NO_2 , NH_2 , OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl or phenyl;

- 14 -

R^{11} is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of $NR^{12}R^{13}$, $NR^{13}R^{13}$, OR^{12} , SR^{12} , OR^{13} , SR^{13} , $C(O)R^{12}$, $OC(O)R^{12}$, $COOR^{12}$, $C(O)R^{13}$, $OC(O)R^{13}$, $COOR^{13}$, $C(O)NR^{12}R^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{12}$, $NR^{13}C(O)R^{13}$, $NR^{13}C(O)NR^{12}R^{13}$, $NR^{13}C(O)NR^{13}R^{13}$, $NR^{13}C(O)OR^{12}$, $NR^{13}C(O)OR^{13}$, $OC(O)NR^{12}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{12}$, $S(O)_2NR^{12}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2NR^{12}R^{13}$, $NR^{13}S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2R^{12}$, $NR^{13}S(O)_2R^{13}$ or R^{13} ;

R^{12} is a partially or fully saturated or unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R^{13} , oxo, $NR^{13}R^{13}$, OR^{13} , SR^{13} , $C(O)R^{13}$, $COOR^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{13}$, $NR^{13}C(O)NR^{13}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$ or $NR^{13}S(O)_2R^{13}$;

alternatively, R^{11} and R^{12} taken together form a partially or fully saturated or unsaturated 5-6 membered ring of carbon atoms optionally including 1-3 heteroatoms selected from O, N, or S, and the ring optionally substituted independently with 1-5 substituents of R^{13} ; and

R^{13} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, oxo, acetyl, benzyl, cyclopropyl, cyclobutyl or a partially or fully saturated or unsaturated 3-8 membered monocyclic or 6-12 membered bicyclic ring system, said ring system formed of

- 15 -

carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, and optionally substituted independently with 1-5 substituents of halo, haloalkyl, CN, NO₂, NH₂, OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, benzyl or phenyl.

The compound groups and sub-groups described herein below reveal various embodiments of the present invention wherein compounds in that embodiment include the specified variables as defined in that embodiment. The scope of each defined variable may be taken with any other embodiment described hereinto form a compound of the present invention. For example, the embodiment immediately below described compounds wherein A¹ is CR⁴ and not N, which may be combined with compounds where the remaining variables are as defined in any of the further embodiments described herein. All compounds resulting from such embodiment combinations are contemplated herein and included in the invention.

In another embodiment, in conjunction with any of the above or below embodiments, A¹ is CR⁴.

In another embodiment, in conjunction with any of the above or below embodiments, A¹ is N.

In another embodiment, in conjunction with any of the above or below embodiments, A² is CR⁵.

In another embodiment, in conjunction with any of the above or below embodiments, A² is N.

In another embodiment, in conjunction with any of the above or below embodiments, A³ is CR⁶.

In another embodiment, in conjunction with any of the above or below embodiments, A³ is N.

In another embodiment, in conjunction with any of the above or below embodiments, A⁴ is CR⁷.

- 16 -

In another embodiment, in conjunction with any of the above or below embodiments, A⁴ is N.

In another embodiment, in conjunction with any of the above or below embodiments, one of A¹, A², A³ and A⁴ is N.

5 In another embodiment, in conjunction with any of the above or below embodiments, A¹ is CR⁴ or N, A² is CR⁵ or N, A³ is CR⁶ or N, A⁴ is CR⁷ or N; provided that no more than two of A¹, A², A³ and A⁴ is N.

10 In another embodiment, in conjunction with any of the above or below embodiments, A¹ is CR⁴, A² is CR⁵, A³ is CR⁶; and A⁴ is CR⁷.

In another embodiment, in conjunction with any of the above or below embodiments, A¹ is CR⁴, wherein R⁴ is halo, haloalkyl, NO₂, CN, NR⁸R⁸, OR⁸, SR⁸, C(O)R⁸ or C₁₋₁₀-alkyl;
15 A² is CH; A³ is CH; and A⁴ is CH.

In another embodiment, in conjunction with any of the above or below embodiments, L is -C(O)NR⁷-, -C(S)NR⁷-, -NR⁷C(O)-, -NR⁷C(S)-, -NR⁷C(O)NR⁷-, -NR⁷C(S)NR⁷-, -NR⁷C(O)O-, -OC(O)NR⁷-, -S(O)₂NR⁷-, -NR⁷S(O)₂NR⁷- or -NR⁷S(O)₂-.

20 In another embodiment, in conjunction with any of the above or below embodiments, L is -C(O)NR⁷-, -NR⁷C(O)-, -NR⁷C(O)NR⁷-, -NR⁷C(O)O-, -S(O)₂NR⁷-, -NR⁷S(O)₂NR⁷- or -NR⁷S(O)₂-.

In another embodiment, in conjunction with any of the above or below embodiments, L is -C(O)NH-, -NHC(O)-, -NHC(O)NH-, -NHC(O)O-, -S(O)₂NH-, -NHS(O)₂NH- or -NHS(O)₂-.

In another embodiment, in conjunction with any of the above or below embodiments, when L is -NHC(O)-, A¹ is CR⁴, A² is CR⁵, A³ is CR⁶ and A⁴ is CR⁷, then R⁶ is H.


30 In another embodiment, in conjunction with any of the above or below embodiments, R¹ is pyrimidyl, pyrazinyl, pyridazinyl, triazinyl, quinolinyl, isoquinolinyl, quinazolinyl, isoquinazolinyl, aza-quinazolinyl, phthalazinyl and aza-phthalazinyl, thiophenyl, furyl,

- 17 -

pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl or oxo-

- 5 dihydropyrrolopyridine, each ring of which is optionally substituted independently with one or more substituents of R^8 (alkyl), R^9 (ring), NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$,
 10 $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$.

In another embodiment, in conjunction with any of the above or below embodiments, R^1 is selected from




- 15 wherein each ring is optionally substituted independently with one or more substituents of R^8 (alkyl), R^9 (ring), NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$,
 20 $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$.

- In another embodiment, in conjunction with any of the above or below embodiments, R^1 is pyrimidyl, pyridazinyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl,
 25 quinazolinyl, isoquinazolinyl, aza-quinazolinyl, phthalazinyl or aza-phthalazinyl.

- 18 -

In another embodiment, in conjunction with any of the



above or below embodiments, R^1 is , wherein Z is H, CN, NH_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-, aryl-amino-, heteroaryl-amino- or heterocyclamino-, wherein each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-, aryl-amino, heteroaryl-amino- and heterocyclamino- is optionally substituted independently with 1-3 substituents of halo, haloalkyl, CN, NO_2 , NH_2 , OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl, R^9 (ring), NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$.

In another embodiment, in conjunction with any of the above or below embodiments, R^2 is H, C_{1-10} -alkyl, C_{2-10} -alkenyl or C_{2-10} -alkynyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl and C_{2-10} -alkynyl optionally comprising 1-3 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of R^9 or R^{10} .

In another embodiment, in conjunction with any of the above or below embodiments, R^2 is H or C_{1-10} -alkyl.

In another embodiment, in conjunction with any of the above or below embodiments, R^3 is C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, 5-6 membered monocyclic or 9-

- 19 -

10 membered bicyclic non-aromatic heterocyclic ring system,
 or a 5-6 membered monocyclic or 9-10 membered bicyclic
 aromatic ring system, said aromatic ring system formed of
 carbon atoms optionally including 1-3 heteroatoms if
 5 monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms
 selected from O, N, or S, wherein said C₁₋₁₀-alkyl, C₂₋₁₀-
 alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, non-aromatic
 heterocyclic ring system and aromatic ring system is
 optionally substituted independently with one or more
 10 substituents of R¹¹(alkyl), R¹²(ring), R¹³, NR¹¹R¹¹, NR¹¹R¹²,
 OR¹¹, SR¹¹, OR¹², SR¹², C(O)R¹¹, C(S)R¹¹, CN(CN)R¹¹, C(O)R¹²,
 C(S)R¹², CN(CN)R¹², C(O)C(O)R¹¹, OC(O)R¹¹, COOR¹¹, C(O)SR¹¹,
 C(O)C(O)R¹², OC(O)R¹², COOR¹², C(O)SR¹², C(O)NR¹¹R¹¹, C(S)NR¹¹R¹¹,
 C(O)NR¹¹R¹², C(S)NR¹¹R¹², OC(O)NR¹¹R¹², NR¹¹C(O)R¹¹, NR¹¹C(O)R¹²,
 15 NR¹¹C(S)R¹¹, NR¹¹C(S)R¹², NR¹¹C(O)NR¹¹R¹¹, NR¹¹C(O)NR¹¹R¹²,
 NR¹¹C(S)NR¹¹R¹¹, NR¹¹C(S)NR¹¹R¹², NR¹¹C(O)OR¹¹, NR¹¹C(O)OR¹²,
 NR¹¹C(O)C(O)R¹¹, NR¹¹C(O)C(O)R¹², NR¹¹C(O)C(O)NR¹¹R¹², S(O)₂R¹¹,
 S(O)₂R¹², S(O)₂NR¹¹R¹¹, S(O)₂NR¹¹R¹², NR¹¹S(O)₂NR¹¹R¹², NR¹¹S(O)₂R¹¹
 or NR¹¹S(O)₂R¹².

20 In another embodiment, in conjunction with any of the
 above or below embodiments, R³ is C₁₋₁₀-alkyl, C₃₋₁₀-
 cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, triazinyl,
 quinolinyl, isoquinolinyl, quinazolinyl, isoquinazolinyl,
 thiophenyl, furyl, pyrrolyl, pyrazolyl, imidazolyl,
 25 triazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl,
 indolyl, isoindolyl, benzofuranyl, benzothiophenyl,
 benzimidazolyl, benzoxazolyl, benzisoxazolyl or
 benzothiazolyl, each of which is optionally substituted as
 defined in the first described embodiment of the Detailed
 30 Description herein.

In another embodiment, the compounds of the present
 invention include compounds wherein A¹ is CR⁴, wherein R⁴ is
 halo, haloalkyl, CN, NR⁸R⁸, OR⁸, SR⁸, C(O)R⁸ or C₁₋₁₀-alkyl;
 A² is CH;

A^4 is CH;

5 R^1 is S^1 , wherein Z is H, CN, NH_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-, aryl-amino-, heteroaryl-amino- or heterocyclylamino-, wherein each
10 of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-, aryl-amino, heteroaryl-amino- and heterocyclylamino- is optionally substituted independently
15 with 1-3 substituents of halo, haloalkyl, CN, NO_2 , NH_2 , OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl, R^9 (ring), NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$;

R² is H or C₁₋₆-alkyl; and

R³ is C₁₋₁₀-alkyl, C₃₋₁₀-cycloalkyl, phenyl, naphthyl,
25 pyridyl, pyrimidyl, triazinyl, quinolinyl, isoquinolinyl,
quinazolinyl, isoquinazolinyl, thiophenyl, furyl, pyrrolyl,
pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl,
isoxazolyl, isothiazolyl, indolyl, isoindolyl, benzofuranyl,
benzothiophenyl, benzimidazolyl, benzoxazolyl,
30 benzisoxazolyl or benzothiazolyl, in conjunction with any of
the above or below embodiments.

- 21 -

In another embodiment, in conjunction with any of the above or below embodiments, R^4 is H, halo, haloalkyl, NO_2 , CN, NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$,
 5 $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$, $NR^8S(O)_2R^9$, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl or C_{4-10} -cycloalkenyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl and C_{4-10} -
 10 cycloalkenyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of R^9 or R^{10} .

In another embodiment, the compounds of the present invention include compounds wherein R^4 is halo, haloalkyl,
 15 CN, NR^8R^8 , OR^8 , SR^8 , $C(O)R^8$ or C_{1-10} -alkyl, in conjunction with any of the above or below embodiments.

In another embodiment, in conjunction with any of the above or below embodiments, R^5 is H, halo, haloalkyl, NO_2 , CN, NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$,
 20 $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$, $NR^8S(O)_2R^9$, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl or C_{4-10} -cycloalkenyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl and C_{4-10} -
 25 cycloalkenyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of R^9 or R^{10} .

In another embodiment, the compounds of the present invention include compounds wherein R^5 is H, in conjunction
 30 with any of the above or below embodiments.

In another embodiment, in conjunction with any of the above or below embodiments, R^6 is H, halo, haloalkyl, NO_2 , CN, NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$,

- 22 -

$C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$,
 $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$,
 $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$,
 $NR^8S(O)_2R^8$, $NR^8S(O)_2R^9$, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl,
5 C_{3-10} -cycloalkyl or C_{4-10} -cycloalkenyl, each of the C_{1-10} -alkyl,
 C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl and C_{4-10} -
cycloalkenyl optionally comprising 1-4 heteroatoms selected
from N, O and S and optionally substituted with one or more
substituents of R^9 or R^{10} .

10 In another embodiment, the compounds of the present
invention include compounds wherein R^6 is H, in conjunction
with any of the above or below embodiments.

In another embodiment, in conjunction with any of the
above or below embodiments, R^5 and R^6 taken together form a
15 saturated or partially or fully unsaturated 5-6 membered
monocyclic ring of carbon atoms optionally including 1-3
heteroatoms selected from O, N, or S, and the ring
optionally substituted independently with 1-3 substituents
of R^8 , R^9 or R^{10} .

20 In another embodiment, in conjunction with any of the
above or below embodiments, R^7 is H, halo, haloalkyl, NO_2 ,
CN, NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$,
 $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$,
 $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$,
25 $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$,
 $NR^8S(O)_2R^8$, $NR^8S(O)_2R^9$, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl,
 C_{3-10} -cycloalkyl or C_{4-10} -cycloalkenyl, each of the C_{1-10} -alkyl,
 C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl and C_{4-10} -
cycloalkenyl optionally comprising 1-4 heteroatoms selected
30 from N, O and S and optionally substituted with one or more
substituents of R^9 or R^{10} .

In another embodiment, the compounds of the present
invention include compounds wherein R^7 is H, in conjunction
with any of the above or below embodiments.

- 23 -

In another embodiment, in conjunction with any of the above or below embodiments, R^8 is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of NR^8R^9 , NR^9R^9 , OR^8 , SR^8 , OR^9 , SR^9 , $C(O)R^8$, $OC(O)R^8$, $COOR^8$, $C(O)R^9$, $OC(O)R^9$, $COOR^9$, $C(O)NR^8R^9$, $C(O)NR^9R^9$, $NR^9C(O)R^8$, $NR^9C(O)R^9$, $NR^9C(O)NR^8R^9$, $NR^9C(O)NR^9R^9$, $NR^9(COOR^8)$, $NR^9(COOR^9)$, $OC(O)NR^8R^9$, $OC(O)NR^9R^9$, $S(O)_2R^8$, $S(O)_2NR^8R^9$, $S(O)_2R^9$, $S(O)_2NR^9R^9$, $NR^9S(O)_2NR^8R^9$, $NR^9S(O)_2NR^9R^9$, $NR^9S(O)_2R^8$, $NR^9S(O)_2R^9$ or R^9 .

In another embodiment, in conjunction with any of the above or below embodiments, R^9 is a partially or fully saturated or unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R^{10} , oxo, $NR^{10}R^{10}$, OR^{10} , SR^{10} , $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$, $NR^{10}C(O)R^{10}$, $NR^{10}C(O)NR^{10}R^{10}$, $OC(O)NR^{10}R^{10}$, $S(O)_2R^{10}$, $S(O)_2NR^{10}R^{10}$ or $NR^{10}S(O)_2R^{10}$.

In another embodiment, in conjunction with any of the above or below embodiments, R^{10} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl or a saturated or partially or fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms

- 24 -

selected from O, N, or S, wherein each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, C₄₋₁₀-cycloalkenyl, C₁₋₁₀-alkylamino-, C₁₋₁₀-dialkylamino-, C₁₋₁₀-alkoxyl, C₁₋₁₀-thioalkoxyl and ring of said ring system is optionally substituted independently with 1-3 substituents of halo, haloalkyl, CN, NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl or phenyl.

In another embodiment, in conjunction with any of the above or below embodiments, R¹¹ is H, halo, haloalkyl, CN, NO₂, acetyl, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl or C₃₋₁₀-cycloalkyl, each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl and C₃₋₁₀-cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of NR¹²R¹³, NR¹³R¹³, OR¹², SR¹², OR¹³, SR¹³, C(O)R¹², OC(O)R¹², COOR¹², C(O)R¹³, OC(O)R¹³, COOR¹³, C(O)NR¹²R¹³, C(O)NR¹³R¹³, NR¹³C(O)R¹², NR¹³C(O)R¹³, NR¹³C(O)NR¹²R¹³, NR¹³C(O)NR¹³R¹³, NR¹³C(O)OR¹², NR¹³C(O)OR¹³, OC(O)NR¹²R¹³, OC(O)NR¹³R¹³, S(O)₂R¹², S(O)₂NR¹²R¹³, S(O)₂R¹³, S(O)₂NR¹³R¹³, NR¹³S(O)₂NR¹²R¹³, NR¹³S(O)₂NR¹³R¹³, NR¹³S(O)₂R¹², NR¹³S(O)₂R¹³ or R¹³.

In another embodiment, in conjunction with any of the above or below embodiments, R¹² is a partially or fully saturated or unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R¹³, oxo, NR¹³R¹³, OR¹³, SR¹³, C(O)R¹³, COOR¹³,

- 25 -


$C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{13}$, $NR^{13}C(O)NR^{13}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$ or $NR^{13}S(O)_2R^{13}$.

5 In another embodiment, in conjunction with any of the above or below embodiments, R^{11} and R^{12} taken together form a partially or fully saturated or unsaturated 5-6 membered ring of carbon atoms optionally including 1-3 heteroatoms selected from O, N, or S, and the ring optionally substituted independently with 1-5 substituents of R^{13} .

10 In another embodiment, in conjunction with any of the above or below embodiments, R^{13} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, oxo, acetyl, benzyl, cyclopropyl, cyclobutyl
15 or a partially or fully saturated or unsaturated 5-8 membered monocyclic or 6-12 membered bicyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, and
20 optionally substituted independently with 1-5 substituents of halo, haloalkyl, CN, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, benzyl or phenyl.

25 In another embodiment, the compounds of the present invention include compounds of Formula I:

- 26 -



I

or stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, derivative or prodrug thereof, wherein

5 A^1 is CR^4 or N;

A^2 is CR^5 or N;

A^3 is CR^6 or N;

A^4 is CR^7 or N; provided that (1) no more than two of A^1 , A^2 , A^3 and A^4 is N and (2) when L is $-NHC(O)-$, A^1 is CR^4 ,
 10 A^2 is CR^5 , A^3 is CR^6 and A^4 is CR^7 , then R^6 is H;

L is $-C(O)NR^7-$, $-NR^7C(O)-$, $-NR^7C(O)NR^7-$, $-S(O)_2NR^7-$,
 $-NR^7S(O)_2NR^7-$ or $-NR^7S(O)_2-$;

R^1 is 2-pyridyl, 3-pyridyl or 4-pyridyl, each of which is optionally substituted independently with one or more
 15 substituents of R^8 , R^9 , NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 ,
 $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$,
 $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$,
 $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$,
 $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$;

20 R^2 is H, C_{1-10} -alkyl, C_{2-10} -alkenyl or C_{2-10} -alkynyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl and C_{2-10} -alkynyl optionally comprising 1-3 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of R^9 or R^{10} ;

25 R^3 is C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, 5-6 membered monocyclic or 9-10 membered bicyclic non-aromatic heterocyclic ring system, or a 5-6

- 27 -

membered monocyclic or 9-10 membered bicyclic aromatic ring system, said aromatic ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, wherein said C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, non-aromatic heterocyclic ring system and aromatic ring system is optionally substituted independently with one or more substituents of R¹¹, R¹², R¹³, NR¹¹R¹¹, NR¹¹R¹², OR¹¹, SR¹¹, OR¹², SR¹², C(O)R¹¹, C(S)R¹¹, CN(CN)R¹¹, C(O)R¹², C(S)R¹², CN(CN)R¹², C(O)C(O)R¹¹, OC(O)R¹¹, COOR¹¹, C(O)SR¹¹, C(O)C(O)R¹², OC(O)R¹², COOR¹², C(O)SR¹², C(O)NR¹¹R¹¹, C(S)NR¹¹R¹¹, C(O)NR¹¹R¹², C(S)NR¹¹R¹², OC(O)NR¹¹R¹², NR¹¹C(O)R¹¹, NR¹¹C(O)R¹², NR¹¹C(S)R¹¹, NR¹¹C(S)R¹², NR¹¹C(O)NR¹¹R¹¹, NR¹¹C(O)NR¹¹R¹², NR¹¹C(S)NR¹¹R¹¹, NR¹¹C(S)NR¹¹R¹², NR¹¹C(O)OR¹¹, NR¹¹C(O)OR¹², NR¹¹C(O)C(O)R¹¹, NR¹¹C(O)C(O)R¹², NR¹¹C(O)C(O)NR¹¹R¹², S(O)₂R¹¹, S(O)₂R¹², S(O)₂NR¹¹R¹¹, S(O)₂NR¹¹R¹², NR¹¹S(O)₂NR¹¹R¹², NR¹¹S(O)₂R¹¹ or NR¹¹S(O)₂R¹²;

each of R⁴, R⁵, R⁶ and R⁷, independently, is H, halo, haloalkyl, NO₂, CN, NR⁸R⁸, NR⁸R⁹, OR⁸, OR⁹, SR⁸, SR⁹, C(O)R⁸, C(O)R⁹, OC(O)R⁸, C(O)OR⁸, C(O)NR⁸R⁸, C(O)NR⁸R⁹, NR⁸C(O)R⁸, NR⁸C(O)R⁹, NR⁸C(O)NR⁸R⁸, NR⁸C(O)NR⁸R⁹, NR⁸C(O)OR⁸, NR⁸C(O)OR⁹, S(O)₂R⁸, S(O)₂R⁹, S(O)₂NR⁸R⁸, S(O)₂NR⁸R⁹, NR⁸S(O)₂NR⁸R⁸, NR⁸S(O)₂NR⁸R⁹, NR⁸S(O)₂R⁸, NR⁸S(O)₂R⁹, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl or C₄₋₁₀-cycloalkenyl, each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl and C₄₋₁₀-cycloalkenyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of R⁹ or R¹⁰;

alternatively, R⁵ and R⁶ taken together form a saturated or partially or fully unsaturated 5-6 membered monocyclic ring of carbon atoms optionally including 1-3 heteroatoms selected from O, N, or S, and the ring optionally substituted independently with 1-3 substituents of R⁸, R⁹ or R¹⁰;

- 28 -

R^8 is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of NR^8R^9 , NR^9R^9 , OR^8 , SR^8 , OR^9 , SR^9 , $C(O)R^8$, $OC(O)R^8$, $COOR^8$, $C(O)R^9$, $OC(O)R^9$, $COOR^9$, $C(O)NR^8R^9$, $C(O)NR^9R^9$, $NR^9C(O)R^8$, $NR^9C(O)R^9$, $NR^9C(O)NR^8R^9$, $NR^9C(O)NR^9R^9$, $NR^9(COOR^8)$, $NR^9(COOR^9)$, $OC(O)NR^8R^9$, $OC(O)NR^9R^9$, $S(O)_2R^8$, $S(O)_2NR^8R^9$, $S(O)_2R^9$, $S(O)_2NR^9R^9$, $NR^9S(O)_2NR^8R^9$, $NR^9S(O)_2NR^9R^9$, $NR^9S(O)_2R^8$, $NR^9S(O)_2R^9$ or R^9 ;

R^9 is a partially or fully saturated or unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R^{10} , oxo, $NR^{10}R^{10}$, OR^{10} , SR^{10} , $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$, $NR^{10}C(O)R^{10}$, $NR^{10}C(O)NR^{10}R^{10}$, $OC(O)NR^{10}R^{10}$, $S(O)_2R^{10}$, $S(O)_2NR^{10}R^{10}$ or $NR^{10}S(O)_2R^{10}$;

R^{10} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl or a saturated or partially or fully unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl and ring of said ring system is optionally

- 29 -

substituted independently with 1-3 substituents of halo,
haloalkyl, CN, NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl,
ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl,
isobutyl, tert-butyl, methylamine, dimethylamine,
5 ethylamine, diethylamine, propylamine, isopropylamine,
dipropylamine, diisopropylamine, benzyl or phenyl;

R^{11} is H, halo, haloalkyl, CN, NO₂, acetyl, C₁₋₁₀-alkyl,
C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl or C₃₋₁₀-cycloalkyl, each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl and C₃₋₁₀-cycloalkyl
10 optionally comprising 1-4 heteroatoms selected from N, O and
S and optionally substituted with one or more substituents
of NR¹²R¹³, NR¹³R¹³, OR¹², SR¹², OR¹³, SR¹³, C(O)R¹², OC(O)R¹²,
COOR¹², C(O)R¹³, OC(O)R¹³, COOR¹³, C(O)NR¹²R¹³, C(O)NR¹³R¹³,
NR¹³C(O)R¹², NR¹³C(O)R¹³, NR¹³C(O)NR¹²R¹³, NR¹³C(O)NR¹³R¹³,
15 NR¹³C(O)OR¹², NR¹³C(O)OR¹³, OC(O)NR¹²R¹³, OC(O)NR¹³R¹³, S(O)₂R¹²,
S(O)₂NR¹²R¹³, S(O)₂R¹³, S(O)₂NR¹³R¹³, NR¹³S(O)₂NR¹²R¹³,
NR¹³S(O)₂NR¹³R¹³, NR¹³S(O)₂R¹², NR¹³S(O)₂R¹³ or R¹³;

R^{12} is a partially or fully saturated or unsaturated 3-
8 membered monocyclic, 6-12 membered bicyclic, or 7-14
20 membered tricyclic ring system, said ring system formed of
carbon atoms optionally including 1-3 heteroatoms if
monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms
if tricyclic, said heteroatoms selected from O, N, or S, and
wherein each ring of said ring system is optionally
25 substituted independently with 1-3 substituents of R¹³, oxo,
NR¹³R¹³, OR¹³, SR¹³, C(O)R¹³, COOR¹³, C(O)NR¹³R¹³, NR¹³C(O)R¹³,
NR¹³C(O)NR¹³R¹³, OC(O)NR¹³R¹³, S(O)₂R¹³, S(O)₂NR¹³R¹³ or
NR¹³S(O)₂R¹³;

alternatively, R^{11} and R^{12} taken together form a
30 partially or fully saturated or unsaturated 5-6 membered
ring of carbon atoms optionally including 1-3 heteroatoms
selected from O, N, or S, and the ring optionally
substituted independently with 1-5 substituents of R¹³; and

- 30 -

R^{13} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, oxo, acetyl,
 5 benzyl, cyclopropyl, cyclobutyl or a partially or fully saturated or unsaturated 3-8 membered monocyclic or 6-12 membered bicyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms
 10 selected from O, N, or S, and optionally substituted independently with 1-5 substituents of halo, haloalkyl, CN, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino,
 15 isopropylamino, benzyl or phenyl,

provided that (1) when R^1 is 3-pyridyl, then L^1 is not $-NR^7C(O)NR^7-$ or (2) when R^1 is 2-pyridyl, then R^3 is not -2-pyridyl-3- $C(O)NHR^{11}$ or -2-pyridyl-3- $C(O)NHR^{11}$ or (3) the ring of R^1 does not contain a quaternary nitrogen atom or (4)
 20 the compound is not (a) 5-[(4-methylphenyl)sulfonylamino]-N-3-pyridinyl-6-(3-pyridinylmethoxy)-pyrazine carboxamide or (b) 5-bromo-N,N'-bis-[2-(phenylamino)-3-pyridinyl]-1,3-benzene dicarbaxamide.

In another embodiment, the compounds of the present
 25 invention include compounds of the immediately above embodiment wherein one of A^1 , A^2 , A^3 and A^4 is N, in conjunction with any of the above or below embodiments.

In another embodiment, the compounds of Formula I include compounds wherein A^1 is CR^4 , wherein R^4 is halo,
 30 haloalkyl, NO_2 , CN, NR^8R^8 , OR^8 , SR^8 , $C(O)R^8$ or C_{1-10} -alkyl, A^2 is CH, A^3 is CH and A^4 is CH, in conjunction with any of the above or below embodiments.

In another embodiment, the compounds of Formula I include compounds wherein L is $-C(O)NR^7-$

- 31 -

or $-S(O)_2NR^7-$, in conjunction with any of the above or below embodiments.

In another embodiment, the compounds of Formula I include compounds wherein A^1 is CR^4 , wherein R^4 is halo, haloalkyl, NO_2 , CN , NR^8R^8 , OR^8 , SR^8 , $C(O)R^8$ or C_{1-10} -alkyl;

A^2 is CH ;


A^3 is CH ;

A^4 is CH ;

L is $-C(O)NR^7-$ or $-S(O)_2NR^7-$; and

R^2 is H or C_{1-10} -alkyl, in conjunction with any of the above or below embodiments.

In another embodiment, the compounds of Formula I include compounds wherein




R^1 is , wherein Z is H , CN , NH_2 , acetyl,

C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-, aryl-amino-, heteroaryl-amino-, heterocyclylamino-, C_{3-10} -cycloalkylamido-, aryl-amido-, heteroaryl-amido- or heterocyclylamido-, wherein each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-, aryl-amino, heteroaryl-amino-, heterocyclylamino-, C_{3-10} -cycloalkylamido-, aryl-amido-, heteroaryl-amido- and heterocyclylamido- is optionally substituted independently with 1-3 substituents of halo, haloalkyl, haloalkoxyl, CN , NO_2 , NH_2 , OH , oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, phenyl or benzyl, in conjunction with any of the above or below embodiments.

- 32 -

In another embodiment, the compounds of Formula I include compounds wherein R^3 is C_{1-10} -alkyl, C_{3-10} -cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, triazinyl, quinolinyl, isoquinolinyl, quinazolinyl, isoquinazolinyl, thiophenyl, .
 5 furyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl or benzothiazolyl, in conjunction with any of the above or below embodiments.

10 In another embodiment, the compounds of Formula I include compounds wherein A^1 is CR^4 , wherein R^4 is halo, haloalkyl, NO_2 , CN, NR^8R^8 , OR^8 , SR^8 , $C(O)R^8$ or C_{1-10} -alkyl;
 A^2 is CH ;
 A^3 is CH ;
 15 A^4 is CH ;
 L is $-C(O)NR^7-$ or $-S(O)_2NR^7-$;



R^1 is , wherein Z is H, CN, NH_2 , acetyl, halo, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-,
 20 aryl-amino-, heteroaryl-amino-, heterocyclylamino-, C_{3-10} -cycloalkylamido-, aryl-amido-, heteroaryl-amido- or heterocyclylamido-, wherein each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{3-10} -cycloalkylamino-, aryl-amino,
 25 heteroaryl-amino-, heterocyclylamino-, C_{3-10} -cycloalkylamido-, aryl-amido-, heteroaryl-amido- and heterocyclylamido- is optionally substituted independently with 1-3 substituents of halo, haloalkyl, haloalkoxyl, CN, NO_2 , NH_2 , OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl,
 30 isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine,


- 33 -

propylamine, isopropylamine, dipropylamine,
diisopropylamine, phenyl or benzyl;

R^2 is H or C_{1-10} -alkyl; and

R^3 is C_{1-10} -alkyl, C_{3-10} -cycloalkyl, phenyl, naphthyl,
5 pyridyl, pyrimidyl, triazinyl, quinolinyl, isoquinolinyl,
quinazolinyl, isoquinazolinyl, thiophenyl, furyl, pyrrolyl,
pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl,
isoxazolyl, isothiazolyl, indolyl, isoindolyl, benzofuranyl,
benzothiophenyl, benzimidazolyl, benzoxazolyl,
10 benzisoxazolyl or benzothiazolyl, in conjunction with any of
the above or below embodiments.

In another embodiment, there is provided a compound
defined by Formula II



15

II

or stereoisomer, tautomer, solvate, pharmaceutically
acceptable salt, derivative or prodrug thereof, wherein

A^1 is CR^4 or N;

A^2 is CR^5 or N;

20

A^3 is CR^6 or N;

A^4 is CR^7 or N; provided that no more than two of A^1 ,
 A^2 , A^3 and A^4 is N and A^2 and A^4 are both not N;

L is $-C(O)NR^7-$, $-C(S)NR^7-$, $-NR^7C(O)-$, $-NR^7C(S)-$,
 $-NR^7C(O)NR^7-$, $-NR^7C(S)NR^7-$, $-NR^7C(O)O-$, $-OC(O)NR^7-$, $-S(O)_2NR^7-$,
25 $-NR^7S(O)_2NR^7-$ or $-NR^7S(O)_2-$;

R^1 is 2-pyridyl, 3-pyridyl or 4-pyridyl pyrimidyl,
pyrazinyl, pyridazinyl, triazinyl, quinolinyl,
isoquinolinyl, quinazolinyl, isoquinazolinyl, aza-
quinazolinyl, phthalazinyl and aza-phthalazinyl, thiophenyl,

- 34 -

furyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl or benzothiazolyl, each ring of which is
 5 optionally substituted independently with one or more substituents of R^8 , R^9 , NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$,
 10 $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$;

R^2 is H, C_{1-10} -alkyl, C_{2-10} -alkenyl or C_{2-10} -alkynyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl and C_{2-10} -alkynyl optionally comprising 1-3 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of R^9
 15 or R^{10} ;

R^3 is C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, 5-6 membered monocyclic or 9-10 membered bicyclic non-aromatic heterocyclic ring system, or a 5-6 membered monocyclic or 9-10 membered bicyclic aromatic ring
 20 system, said aromatic ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, wherein said C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, non-aromatic heterocyclic ring system and
 25 aromatic ring system is optionally substituted independently with one or more substituents of R^{11} , R^{12} , R^{13} , $NR^{11}R^{11}$, $NR^{11}R^{12}$, OR^{11} , SR^{11} , OR^{12} , SR^{12} , $C(O)R^{11}$, $C(S)R^{11}$, $CN(CN)R^{11}$, $C(O)R^{12}$, $C(S)R^{12}$, $CN(CN)R^{12}$, $C(O)C(O)R^{11}$, $OC(O)R^{11}$, $COOR^{11}$, $C(O)SR^{11}$, $C(O)C(O)R^{12}$, $OC(O)R^{12}$, $COOR^{12}$, $C(O)SR^{12}$, $C(O)NR^{11}R^{11}$, $C(S)NR^{11}R^{11}$,
 30 $C(O)NR^{11}R^{12}$, $C(S)NR^{11}R^{12}$, $OC(O)NR^{11}R^{12}$, $NR^{11}C(O)R^{11}$, $NR^{11}C(O)R^{12}$, $NR^{11}C(S)R^{11}$, $NR^{11}C(S)R^{12}$, $NR^{11}C(O)NR^{11}R^{11}$, $NR^{11}C(O)NR^{11}R^{12}$, $NR^{11}C(S)NR^{11}R^{11}$, $NR^{11}C(S)NR^{11}R^{12}$, $NR^{11}C(O)OR^{11}$, $NR^{11}C(O)OR^{12}$, $NR^{11}C(O)C(O)R^{11}$, $NR^{11}C(O)C(O)R^{12}$, $NR^{11}C(O)C(O)NR^{11}R^{12}$, $S(O)_2R^{11}$,

- 35 -

$S(O)_2R^{12}$, $S(O)_2NR^{11}R^{11}$, $S(O)_2NR^{11}R^{12}$, $NR^{11}S(O)_2NR^{11}R^{12}$, $NR^{11}S(O)_2R^{11}$
or $NR^{11}S(O)_2R^{12}$;

each of R^4 , R^5 , R^6 and R^7 , independently, is H, halo,
haloalkyl, NO_2 , CN, NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$,
5 $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$,
 $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$,
 $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$,
 $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$, $NR^8S(O)_2R^9$, C_{1-10} -alkyl, C_{2-10} -alkenyl,
10 C_{2-10} -alkynyl, C_{3-10} -cycloalkyl or C_{4-10} -cycloalkenyl, each of
the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl
and C_{4-10} -cycloalkenyl optionally comprising 1-4 heteroatoms
selected from N, O and S and optionally substituted with one
or more substituents of R^9 or R^{10} ;

alternatively, R^4 and R^5 taken together form a
15 saturated or partially or fully unsaturated 5-6 membered
monocyclic ring of carbon atoms optionally including 1-3
heteroatoms selected from O, N, or S, and the ring
optionally substituted independently with 1-3 substituents
of R^8 , R^9 or R^{10} ;

20 R^8 is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl,
 C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl,
 C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl
optionally comprising 1-4 heteroatoms selected from N, O and
S and optionally substituted with one or more substituents
25 of NR^8R^9 , NR^9R^9 , OR^8 , SR^8 , OR^9 , SR^9 , $C(O)R^8$, $OC(O)R^8$, $COOR^8$,
 $C(O)R^9$, $OC(O)R^9$, $COOR^9$, $C(O)NR^8R^9$, $C(O)NR^9R^9$, $NR^9C(O)R^8$,
 $NR^9C(O)R^9$, $NR^9C(O)NR^8R^9$, $NR^9C(O)NR^9R^9$, $NR^9(COOR^8)$, $NR^9(COOR^9)$,
 $OC(O)NR^8R^9$, $OC(O)NR^9R^9$, $S(O)_2R^8$, $S(O)_2NR^8R^9$, $S(O)_2R^9$, $S(O)_2NR^9R^9$,
 $NR^9S(O)_2NR^8R^9$, $NR^9S(O)_2NR^9R^9$, $NR^9S(O)_2R^8$, $NR^9S(O)_2R^9$ or R^9 ;

30 R^9 is a partially or fully saturated or unsaturated 3-8
membered monocyclic, 6-12 membered bicyclic, or 7-14
membered tricyclic ring system, said ring system formed of
carbon atoms optionally including 1-3 heteroatoms if
monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms

- 36 -

if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R^{10} , oxo, $NR^{10}R^{10}$, OR^{10} , SR^{10} , $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$, $NR^{10}C(O)R^{10}$,
 5 $NR^{10}C(O)NR^{10}R^{10}$, $OC(O)NR^{10}R^{10}$, $S(O)_2R^{10}$, $S(O)_2NR^{10}R^{10}$ or $NR^{10}S(O)_2R^{10}$;

R^{10} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl or a saturated or partially or
 10 fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or
 15 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl, C_{3-10} -cycloalkyl, C_{4-10} -cycloalkenyl, C_{1-10} -alkylamino-, C_{1-10} -dialkylamino-, C_{1-10} -alkoxyl, C_{1-10} -thioalkoxyl and ring of said ring system is optionally
 20 substituted independently with 1-3 substituents of halo, haloalkyl, CN, NO_2 , NH_2 , OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine,
 25 dipropylamine, diisopropylamine, benzyl or phenyl;

R^{11} is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and
 30 S and optionally substituted with one or more substituents of $NR^{12}R^{13}$, $NR^{13}R^{13}$, OR^{12} , SR^{12} , OR^{13} , SR^{13} , $C(O)R^{12}$, $OC(O)R^{12}$, $COOR^{12}$, $C(O)R^{13}$, $OC(O)R^{13}$, $COOR^{13}$, $C(O)NR^{12}R^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{12}$, $NR^{13}C(O)R^{13}$, $NR^{13}C(O)NR^{12}R^{13}$, $NR^{13}C(O)NR^{13}R^{13}$, $NR^{13}C(O)OR^{12}$, $NR^{13}C(O)OR^{13}$, $OC(O)NR^{12}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{12}$,

- 37 -

$S(O)_2NR^{12}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2NR^{12}R^{13}$,
 $NR^{13}S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2R^{12}$, $NR^{13}S(O)_2R^{13}$ or R^{13} ;

R^{12} is a partially or fully saturated or unsaturated 3-
 8 membered monocyclic, 6-12 membered bicyclic, or 7-14
 5 membered tricyclic ring system, said ring system formed of
 carbon atoms optionally including 1-3 heteroatoms if
 monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms
 if tricyclic, said heteroatoms selected from O, N, or S, and
 wherein each ring of said ring system is optionally
 10 substituted independently with 1-3 substituents of R^{13} , oxo,
 $NR^{13}R^{13}$, OR^{13} , SR^{13} , $C(O)R^{13}$, $COOR^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{13}$,
 $NR^{13}C(O)NR^{13}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$ or
 $NR^{13}S(O)_2R^{13}$;

alternatively, R^{11} and R^{12} taken together form a
 15 partially or fully saturated or unsaturated 5-6 membered
 ring of carbon atoms optionally including 1-3 heteroatoms
 selected from O, N, or S, and the ring optionally
 substituted independently with 1-5 substituents of R^{13} ; and


R^{13} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , OH, methyl,
 20 methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl,
 butyl, isobutyl, tert-butyl, methylamino, dimethylamino,
 ethylamino, diethylamino, isopropylamino, oxo, acetyl,
 benzyl, cyclopropyl, cyclobutyl or a partially or fully
 saturated or unsaturated 3-8 membered monocyclic or 6-12
 25 membered bicyclic ring system, said ring system formed of
 carbon atoms optionally including 1-3 heteroatoms if
 monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms
 selected from O, N, or S, and optionally substituted
 independently with 1-5 substituents of halo, haloalkyl, CN,
 30 NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl,
 propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-
 butyl, methylamino, dimethylamino, ethylamino, diethylamino,
 isopropylamino, benzyl or phenyl;

- 38 -

provided that (1) when R^1 is 3-pyridyl, then L^1 is not $-NR^7C(O)-$; or (2) when R^1 is 3-pyridyl, then L^1 is not $-NR^7C(O)-(ortho-Ph-Phenyl)$; or (3) when R^1 is 3-pyridyl, it does not contain a quaternary nitrogen atom; or (4) the compound is not (a) N,N' -bis(2,6-diamino-1,4-dihydro-4-oxo-5-pyrimidinyl-1,4)-benzenedicarboxamide or (b) N -(3-pyridyl)-4-[1,2,3,4-tetrahydro-2,4-dioxo-5-pyrimidyl)sulfonyl)amino]benzamide.

In many further embodiments of compounds related to Formula II, A^1 , A^2 , A^3 , A^4 , L , R^1 , R^2 , R^3 and $R's^{4-13}$ are as defined in any of the above embodiments in conjunction with compounds of Formula I hereinabove.

In another embodiment, the present invention provides a compound defined by Formula III



III

or stereoisomer, tautomer, solvate, pharmaceutically acceptable salt, derivative or prodrug thereof, wherein

A^2 is CR^5 or N;

A^3 is CH or N;

A^4 is CR^7 or N, provided that (1) no more than one of A^2 , A^3 and A^4 is N;

A^5 is CH or N;

L is $-C(O)NR^7-$, $-NR^7C(O)-$, $-S(O)_2NR^7-$, $-NR^7S(O)_2NR^7-$ or $-NR^7S(O)_2-$;

R^{1a} is H, R^8 , R^9 , NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$,

- 39 -

NR⁸C(O)R⁹, NR⁸C(O)NR⁸R⁸, NR⁸C(O)NR⁸R⁹, NR⁸C(O)OR⁸, NR⁸C(O)OR⁹,
 S(O)₂R⁸, S(O)₂R⁹, S(O)₂NR⁸R⁸, S(O)₂NR⁸R⁹, NR⁸S(O)₂NR⁸R⁸,
 NR⁸S(O)₂NR⁸R⁹, NR⁸S(O)₂R⁸ or NR⁸S(O)₂R⁹;

R³ is C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-
 5 cycloalkyl, 5-6 membered monocyclic or 9-10 membered
 bicyclic non-aromatic heterocyclic ring system, or 5-6
 membered monocyclic or 9-10 membered bicyclic aromatic ring
 system, said aromatic ring system formed of carbon atoms
 optionally including 1-3 heteroatoms if monocyclic or 1-6
 10 heteroatoms if bicyclic, said heteroatoms selected from O,
 N, or S, wherein said C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl,
 C₃₋₁₀-cycloalkyl, non-aromatic heterocyclic ring system and
 aromatic ring system is optionally substituted independently
 with one or more substituents of R¹¹, R¹², R¹³, NR¹¹R¹¹, NR¹¹R¹²,
 15 OR¹¹, SR¹¹, OR¹², SR¹², C(O)R¹¹, C(S)R¹¹, CN(CN)R¹¹, C(O)R¹²,
 C(S)R¹², CN(CN)R¹², C(O)C(O)R¹¹, OC(O)R¹¹, COOR¹¹, C(O)SR¹¹,
 C(O)C(O)R¹², OC(O)R¹², COOR¹², C(O)SR¹², C(O)NR¹¹R¹¹, C(S)NR¹¹R¹¹,
 C(O)NR¹¹R¹², C(S)NR¹¹R¹², OC(O)NR¹¹R¹², NR¹¹C(O)R¹¹, NR¹¹C(O)R¹²,
 NR¹¹C(S)R¹¹, NR¹¹C(S)R¹², NR¹¹C(O)NR¹¹R¹¹, NR¹¹C(O)NR¹¹R¹²,
 20 NR¹¹C(S)NR¹¹R¹¹, NR¹¹C(S)NR¹¹R¹², NR¹¹C(O)OR¹¹, NR¹¹C(O)OR¹²,
 NR¹¹C(O)C(O)R¹¹, NR¹¹C(O)C(O)R¹², NR¹¹C(O)C(O)NR¹¹R¹², S(O)₂R¹¹,
 S(O)₂R¹², S(O)₂NR¹¹R¹¹, S(O)₂NR¹¹R¹², NR¹¹S(O)₂NR¹¹R¹², NR¹¹S(O)₂R¹¹
 or NR¹¹S(O)₂R¹²;

R⁴ is halo, haloalkyl, haloalkoxyl, NO₂, CN, NH₂, OH,
 25 or C₁₋₁₀-alkyl;

each of R⁵ and R⁷, independently, is H, halo,
 haloalkyl, haloalkoxyl, NO₂, CN, NR⁸R⁸, NR⁸R⁹, OR⁸, OR⁹, SR⁸,
 SR⁹, C(O)R⁸, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl or C₃₋₁₀-cycloalkyl, each
 of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl and C₃₋₁₀-cycloalkyl
 30 optionally comprising 1-4 heteroatoms selected from N, O and
 S and optionally substituted with one or more substituents
 of R⁹ or R¹⁰;

R⁸ is H, halo, haloalkyl, CN, NO₂, acetyl, C₁₋₁₀-alkyl,
 C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl or C₃₋₁₀-cycloalkyl, each of the C₁₋

- 40 -

10-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl and C₃₋₁₀-cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of NR⁸R⁹, NR⁹R⁹, OR⁸, SR⁸, OR⁹, SR⁹, C(O)R⁸, OC(O)R⁸, COOR⁸,
 5 C(O)R⁹, OC(O)R⁹, COOR⁹, C(O)NR⁸R⁹, C(O)NR⁹R⁹, NR⁹C(O)R⁸, NR⁹C(O)R⁹, NR⁹C(O)NR⁸R⁹, NR⁹C(O)NR⁹R⁹, NR⁹(COOR⁸), NR⁹(COOR⁹), OC(O)NR⁸R⁹, OC(O)NR⁹R⁹, S(O)₂R⁸, S(O)₂NR⁸R⁹, S(O)₂R⁹, S(O)₂NR⁹R⁹, NR⁹S(O)₂NR⁸R⁹, NR⁹S(O)₂NR⁹R⁹, NR⁹S(O)₂R⁸, NR⁹S(O)₂R⁹ or R⁹;

R⁹ is a partially or fully saturated or unsaturated 3-8
 10 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and
 15 wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R¹⁰, oxo, NR¹⁰R¹⁰, OR¹⁰, SR¹⁰, C(O)R¹⁰, COOR¹⁰, C(O)NR¹⁰R¹⁰, NR¹⁰C(O)R¹⁰, NR¹⁰C(O)NR¹⁰R¹⁰, OC(O)NR¹⁰R¹⁰, S(O)₂R¹⁰, S(O)₂NR¹⁰R¹⁰ or NR¹⁰S(O)₂R¹⁰;

20 R¹⁰ is H, halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, C₄₋₁₀-cycloalkenyl, C₁₋₁₀-alkylamino-, C₁₋₁₀-dialkylamino-, C₁₋₁₀-alkoxyl, C₁₋₁₀-thioalkoxyl or a saturated or partially or fully unsaturated 3-8 membered monocyclic, 6-12 membered
 25 bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, C₄₋₁₀-cycloalkenyl, C₁₋₁₀-alkylamino-, C₁₋₁₀-dialkylamino-, C₁₋₁₀-alkoxyl, C₁₋₁₀-thioalkoxyl and ring of said ring system is optionally
 30 substituted independently with 1-3 substituents of halo, haloalkyl, CN, NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl,

- 41 -

ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl or phenyl;

- 5 R^{11} is H, halo, haloalkyl, CN, NO_2 , acetyl, C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl or C_{3-10} -cycloalkyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl, C_{2-10} -alkynyl and C_{3-10} -cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents
- 10 of $NR^{12}R^{13}$, $NR^{13}R^{13}$, OR^{12} , SR^{12} , OR^{13} , SR^{13} , $C(O)R^{12}$, $OC(O)R^{12}$, $COOR^{12}$, $C(O)R^{13}$, $OC(O)R^{13}$, $COOR^{13}$, $C(O)NR^{12}R^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{12}$, $NR^{13}C(O)R^{13}$, $NR^{13}C(O)NR^{12}R^{13}$, $NR^{13}C(O)NR^{13}R^{13}$, $NR^{13}C(O)OR^{12}$, $NR^{13}C(O)OR^{13}$, $OC(O)NR^{12}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{12}$, $S(O)_2NR^{12}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2NR^{12}R^{13}$,
- 15 $NR^{13}S(O)_2NR^{13}R^{13}$, $NR^{13}S(O)_2R^{12}$, $NR^{13}S(O)_2R^{13}$ or R^{13} ;

- R^{12} is a partially or fully saturated or unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if
- 20 monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R^{13} , oxo, $NR^{13}R^{13}$, OR^{13} , SR^{13} , $C(O)R^{13}$, $COOR^{13}$, $C(O)NR^{13}R^{13}$, $NR^{13}C(O)R^{13}$,
- 25 $NR^{13}C(O)NR^{13}R^{13}$, $OC(O)NR^{13}R^{13}$, $S(O)_2R^{13}$, $S(O)_2NR^{13}R^{13}$ or $NR^{13}S(O)_2R^{13}$;

- alternatively, R^{11} and R^{12} taken together form a partially or fully saturated or unsaturated 5-6 membered ring of carbon atoms optionally including 1-3 heteroatoms
- 30 selected from O, N, or S, and the ring optionally substituted independently with 1-5 substituents of R^{13} ; and

R^{13} is H, halo, haloalkyl, CN, OH, NO_2 , NH_2 , OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino,

- 42 -

ethylamino, diethylamino, isopropylamino, oxo, acetyl, benzyl, cyclopropyl, cyclobutyl or a partially or fully saturated or unsaturated 5-8 membered monocyclic or 6-12 membered bicyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, and optionally substituted independently with 1-5 substituents of halo, haloalkyl, CN, NO₂, NH₂, OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, benzyl or phenyl,

provided that the compound is not (a) 5-[(4-methylphenyl)sulfonylamino]-N-3-pyridinyl-6-(3-pyridinylmethoxy)-pyrazine carboxamide or (b) 5-bromo-N,N'-bis-[2-(phenylamino)-3-pyridinyl]-1,3-benzene dicarbaxamide.

In another embodiment, in conjunction with the above embodiment related to compounds of Formula III, A⁵ is CH; and L is -C(O)NR⁷-.

In another embodiment, in conjunction with the above embodiment related to compounds of Formula III, R^{1a} is H, NR⁸R⁸, NR⁸R⁹, C(O)NR⁸R⁸, C(O)NR⁸R⁹, NR⁸C(O)R⁸, NR⁸C(O)R⁹, NR⁸C(O)NR⁸R⁸, NR⁸C(O)NR⁸R⁹, S(O)₂NR⁸R⁸, S(O)₂NR⁸R⁹, NR⁸S(O)₂NR⁸R⁸, NR⁸S(O)₂NR⁸R⁹, NR⁸S(O)₂R⁸ or NR⁸S(O)₂R⁹.

In another embodiment, in conjunction with the above embodiment related to compounds of Formula III R⁸ is H or C₁₋₁₀-alkyl, wherein the C₁₋₁₀-alkyl is optionally substituted with one or more substituents of NR⁸R⁹, NR⁹R⁹, OR⁸, SR⁸, OR⁹, SR⁹, C(O)R⁸, OC(O)R⁸, COOR⁸, C(O)R⁹, OC(O)R⁹, COOR⁹, C(O)NR⁸R⁹, C(O)NR⁹R⁹, NR⁹C(O)R⁸, NR⁹C(O)R⁹, NR⁹C(O)NR⁸R⁹, NR⁹C(O)NR⁹R⁹, NR⁹(COOR⁸), NR⁹(COOR⁹), OC(O)NR⁸R⁹, OC(O)NR⁹R⁹, S(O)₂R⁸, S(O)₂NR⁸R⁹, S(O)₂R⁹, S(O)₂NR⁹R⁹, NR⁹S(O)₂NR⁸R⁹, NR⁹S(O)₂NR⁹R⁹, NR⁹S(O)₂R⁸, NR⁹S(O)₂R⁹ or R⁹; and

- 43 -

R^9 is C_{3-10} -cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, piperidinyl, piperazinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyrrolidinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, .

5 tetrahydroisoquinolinyl, quinazolinyl, isoquinazolinyl, tetrahydroquinazolinyl, tetrahydroisoquinazolinyl, morpholinyl, thiophenyl, furyl, dihydrofuryl, tetrahydrofuryl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, indolyl, isoindolyl, indolinyl, benzofuranyl,

10 dihydrobenzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl or benzothiazolyl, each of which is optionally substituted independently with 1-3 substituents of R^{10} , oxo, $NR^{10}R^{10}$, OR^{10} , SR^{10} , $C(O)R^{10}$, $COOR^{10}$, $C(O)NR^{10}R^{10}$, $NR^{10}C(O)R^{10}$, $NR^{10}C(O)NR^{10}R^{10}$, $OC(O)NR^{10}R^{10}$, $S(O)_2R^{10}$,

15 $S(O)_2NR^{10}R^{10}$ or $NR^{10}S(O)_2R^{10}$.

In another embodiment related to compounds of Formula III, in conjunction with any of the above or below embodiments, A^1 is CR^4 , A^2 is CR^5 , A^3 is CH and A^4 is CR^7 .

In another embodiment related to compounds of Formula

20 III, in conjunction with any of the above or below embodiments, R^4 is halo, haloalkyl, NO_2 , CN, NR^8R^8 , OR^8 , SR^8 , $C(O)R^8$ or C_{1-10} -alkyl; R^5 is H; and R^7 is H.

In another embodiment related to compounds of Formula III, in conjunction with any of the above or below

25 embodiments, R^2 is H or C_{1-10} -alkyl.

In another embodiment related to compounds of Formula III, in conjunction with any of the above or below

embodiments, R^3 is C_{1-10} -alkyl, C_{3-10} -cycloalkyl, phenyl, naphthyl, pyridyl, pyrimidyl, triazinyl, quinolinyl, isoquinolinyl, quinazolinyl, isoquinazolinyl, thiophenyl,

30 furyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl or benzothiazolyl, wherein said

- 44 -

C₁₋₁₀-alkyl, C₃₋₁₀-cycloalkyl, and ring, independently, is optionally substituted as the embodiment generally describing compounds of Formula III.

In another embodiment related to compounds of Formula
5 III, in conjunction with any of the above or below
embodiments, R¹² is a ring selected from phenyl, naphthyl,
pyridyl, pyrimidyl, triazinyl, quinolinyl, isoquinolinyl,
quinazolinyl, isoquinazolinyl, thiophenyl, furyl, pyrrolyl,
imidazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl,
10 isothiazolyl, indolyl, isoindolyl, benzofuranyl,
benzothiophenyl, benzimidazolyl, tetrahydrofuranyl,
pyrrolidinyl, oxazolinyl, isoxazolinyl, thiazolinyl,
pyrazolinyl, morpholinyl, piperidinyl, piperazinyl, pyranyl,
dioxozinyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl
15 and cycloheptyl, wherein the ring is optionally substituted
independently with 1-3 substituents of R¹³.

In yet another embodiment, there are provided the
compounds of Examples 1-2 and 6-140 described herein, or a
pharmaceutically acceptable salt thereof, selected from:

20 The compounds of Formulas I, II or III, and
stereoisomers, solvates, tautomers, pharmaceutically
acceptable salts and derivatives, and prodrugs of these
compounds, are useful for treating subjects, typically
mammals such as humans, with various conditions and/or
25 disease states, as previously described. To this end, and in
another embodiment, the invention provides pharmaceutical
compositions comprising one or more of the compounds of
Formula I, II or III, including compounds according to any
of the various embodiments described above, and a
30 pharmaceutically acceptable carrier or diluent.

The compounds of Formula I, II or III, or
pharmaceutical composition comprising such compound(s), may
be administered in an effective amount to the subject to
modulate one or more target proteins, including receptors

- 45 -

and/or kinase enzymes, in the subject thereby treating the target-mediated disease or condition. Accordingly, another embodiment of the invention relates to a method for treating a protein kinase-mediated disorder in a mammal, comprising
5 administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments. In another embodiment, the protein kinase is one of Lck or c-Kit.

Further embodiments of the present invention include
10 methods for treating conditions, disorders or diseases related to the modulation of the activity of protein kinases. Accordingly, embodiments include a method of treating inflammation in a mammal, a method of inhibiting T cell activation in a mammal, a method of lowering plasma
15 concentrations of any one or combination of TNF- α , IL-1, IL-6 or IL-8 in a subject, a method of treating the over-production of histamine in a subject, a method of treating an autoimmune disease, mastocytosis, mast cell tumors, asthma, chronic rhinitis, small cell lung cancer, acute myelocytic
20 leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, colorectal carcinoma, gastric carcinoma, gastrointestinal stromal tumor, testicular cancer, glioblastoma, astrocytoma or a combination thereof in a subject and a method of treating rheumatoid arthritis,
25 Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease,
30 allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury,

- 46 -

atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses, herpes zoster
5 infection or a combination thereof in a subject, wherein each of the above methods, independently, comprise administering to the subject or mammal a therapeutically effective amount, or a therapeutically effective dosage amount, of a compound according to any one of the above embodiments related to
10 Formulas I, II or III.

Another embodiment of the invention relates to a method of treating an abnormal condition associated with inappropriate c-kit kinase mediated signal transduction in a subject, the method comprising the step of administering to
15 the subject an effective dosage amount of a compound according to any one of the above embodiments.

Another embodiment of the invention relates to a method of the immediately above embodiment wherein the condition is selected from the group consisting of fibrotic
20 disease, mastocytosis, the presence of one or more mast cell tumors, severe asthma, rheumatoid arthritis, scleroderma, multiple sclerosis and allergy associated chronic rhinitis.

Another embodiment of the invention relates to a method of treating idiopathic pulmonary fibrosis in a
25 mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments.

Another embodiment of the invention relates to a method of treating multiple sclerosis, inflammatory bowel
30 disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism,

- 47 -

Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleraciema, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea or atopic dermatitis in a mammal, the method comprising administering to the mammal a therapeutically-effective amount of a compound according to any one of the above embodiments.

Another embodiment of the invention relates to a method of treating a proliferative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a compound according to any one of the above embodiments.

Various other embodiments of the invention relate to the manufacture of a medicament for the purposes of administering the compound of Formula I, II or III, or pharmaceutical composition comprising same, to the mammal for treatment thereof, as described herein.

For example, and in another embodiment, the invention relates to the manufacture of a medicament comprising a compound according to any one of the above embodiments related to Formulas I, II or III.

Another embodiment of the invention relates to a method of manufacturing a medicament for the treatment of a protein kinase-mediated disease, for the inhibition of T cell activation and proliferation, for the treatment of cancer, for the treatment of colon carcinoma or thymoma in a mammal, for the treatment of autoimmune disease(s), for the treatment of inflammation, for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, or osteoarthritis in a


- 48 -

mammal, for the treatment of organ transplant, acute transplant or heterograft or homograft rejection, or transplantation tolerance induction in a mammal, for the treatment of ischemic or reperfusion injury, myocardial infarction, or stroke in a mammal, each of the methods, independently, comprise combining a compound according to any one of the above embodiments with a pharmaceutically acceptable carrier to form the medicament.

Another embodiment of the invention relates to a method of manufacturing a medicament for the treatment of multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituitarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, urticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleroderma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic sclerosis, morphea or atopic dermatitis in a mammal, the method comprising combining a compound according to any one of the above embodiments with a pharmaceutically acceptable carrier to form the medicament.

Another embodiment of the invention relates to a method of making a compound according to Formula I or III, as described herein, comprising the step of reacting a compound 51


- 49 -



51

wherein A^1 , A^2 , A^3 , A^4 , R^1 and R^2 are as defined in Claim 1 and L^1 is NH_2 , COOH , $\text{C}(\text{O})\text{Cl}$, SO_2Cl , $\text{OC}(\text{O})\text{OH}$ or $\text{OC}(\text{O})\text{Cl}$, with a compound having a general formula $\text{L}^2\text{-R}^3$,
 5 wherein L^2 is NH_2 , COOH , $\text{C}(\text{O})\text{Cl}$, SO_2Cl , $\text{OC}(\text{O})\text{OH}$ or $\text{OC}(\text{O})\text{Cl}$, to make a compound of Formula I or III.

Another embodiment of the invention relates to a method of making a compound according to Formula II, as described herein, comprising the step of reacting a compound
 10 52



52

wherein A^1 , A^2 , A^3 , A^4 , R^1 and R^2 are as defined in Claim 1 and L^1 is NH_2 , COOH , $\text{C}(\text{O})\text{Cl}$, SO_2Cl , $\text{OC}(\text{O})\text{OH}$ or $\text{OC}(\text{O})\text{Cl}$, with a compound having a general formula $\text{L}^2\text{-R}^3$,
 15 wherein L^2 is NH_2 , COOH , $\text{C}(\text{O})\text{Cl}$, SO_2Cl , $\text{OC}(\text{O})\text{OH}$ or $\text{OC}(\text{O})\text{Cl}$, to make a compound of Formula II.

Meanings and Definitions

Unless otherwise specified, the following terms found in the specification and claims have the following meanings and/or definitions:
 20

aq:	Aqueous
ATP:	Adenosine triphosphate

- 50 -

	BSA:	Bovine Serum Albumin
	DBU:	1,8-diazabicyclo [5.4.0] undec -7-ene
	DCE:	Dichloroethane
5	DCM:	Dichloromethane
	DIEA:	Diisopropylethylamine
	DMA:	N,N-Dimethylacetamide
	DME:	Dimethoxyethane
	DMF:	N,N-Dimethylformamide
10	DMSO:	Dimethylsulfoxide
	dppf:	1,1' (diphenylphosphino) ferrocene
	DTT:	Dithiothreitol
	EDTA:	Ethylene diamine tetraacetic acid
15	EtOAc:	Ethyl acetate
	EtOH:	Ethanol
	FCS:	Fetal Calf Serum
	g:	Gram(s)
	h:	Hour(s)
20	HBTU:	O-Benzotriazol-1-yl-N,N,N',N'- tetramethyluronium hexafluorophosphate
	Hepes:	N-[2-Hydroxyethyl]piperazine-N'- [2-ethanesulfonic acid]
25	IC ₅₀ value:	The concentration of an inhibitor that causes a 50 % reduction in a measured activity.
	IPA	isopropyl alcohol
30	Lck:	Lymphocyte specific tyrosine kinase
	LiHMDS:	Lithium bis(trimethylsilyl) amide
	MeI:	Methyl iodide
	MeCN:	Acetonitrile

- 51 -

	MeOH:	Methanol
	min:	Minute(s)
	mmol:	Millimole(s)
	NBS:	N-Bromo succinimide
5	Ni-NTA:	Nickel-nitriloacetic acid
	NIS:	N-Iodosuccinimide
	NMP:	N-methylpyrrolidone
	RT, rt:	Room temperature
	TFA:	Trifluoroacetic acid
10	THF:	Tetrahydrofuran

Generally, reference to a certain element such as hydrogen or H is meant to include all isotopes of that element. For example, if an R group is defined to include
 15 hydrogen or H, it also includes deuterium and tritium. Compounds comprising radioisotopes such as tritium, C¹⁴, P³² and S³⁵ are thus within the scope of the invention. Procedures for inserting such labels into the compounds of the invention will be readily apparent to those skilled in
 20 the art based on the disclosure herein.

In general, "substituted" as used herein refers to a group, such as those defined below, in which one or more bonds to a hydrogen atom contained therein are replaced by a bond to non-hydrogen or non-carbon atoms including, but not
 25 limited to, a halogen atom such as F, Cl, Br, and I; an oxygen atom in groups such as hydroxyl groups, alkoxy groups, aryloxy groups, and ester groups; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, and sulfonyl groups such
 30 as sulfonyl halides and sulfonyl amides; a nitrogen atom in groups such as amines, amides, alkylamines, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, ureas, imines, imides, and enamines; a silicon atom in groups such as in trialkylsilyl groups, dialkylarylsilyl groups,

- 52 -

alkyldiarylsilyl groups, and triarylsilyl groups; and other heteroatoms in various other groups. Substituted alkyl groups and also substituted cycloalkyl groups and others also include groups in which one or more bonds to a
5 carbon(s) or hydrogen(s) atom is replaced by a bond to a heteroatom such as oxygen in carboxylic acid, ester and carbamate groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.

Substituents, including alkyl and ring groups, may be
10 either monovalent or polyvalent depending on the context of their usage. For example, if description contained the group $R^1-R^2-R^3$ and R^2 was defined as C_{1-6} alkyl, then the R^2 alkyl would be considered polyvalent because it must be bonded to at least R^1 and R^3 . Alternatively, if R^1 were
15 defined as C_{1-6} alkyl, then the R^1 alkyl would be monovalent (excepting any further substitution language).


In general, "unsubstituted" as used herein with reference to a group, means that the group does not have one or more bonds to a hydrogen or carbon atom contained therein
20 replaced by a bond to non-hydrogen or non-carbon atom, as described above.

The term "optionally substituted" as used herein with reference to a group, means that the group may be substituted with a specified number of defined substituents
25 or the group may remain unsubstituted.

In general, "alkyl" as used herein either alone or within other terms such as "haloalkyl", "alkylamino" and "cycloalkyl", refers to linear, branched or cyclic radicals having one to about twelve carbon atoms. "Cycloalkyl" is
30 also used exclusively herein to refer specifically to fully or partially saturated cyclic alkyl radicals. Examples of "alkyl" radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, cyclopropyl, cyclopentyl, cyclohexyl and the like.

- 53 -

In general, "C_{a-b}alkyl" as used herein refers to an alkyl group comprising from a to b carbon atoms in a branched, cyclical or linear relationship or any combination of the three. The alkyl groups described in this section may also contain double or triple bonds. Examples of C₁₋₈alkyl include, but are not limited to the following:



In general, "aralkyl" as used herein refers to linear or branched aryl-containing radicals each having alkyl portions of one to about ten carbon atoms. Examples of such radicals include benzyl, 2-phenyl-propane, and the like.

In general, "Halogen" and "halo" as used herein, refers to a halogen atoms selected from F, Cl, Br and I.

In general, "haloalkyl", as used herein refers to radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals including perhaloalkyl. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.

"Perfluoroalkyl" means alkyl radicals having all hydrogen atoms replaced with fluoro atoms. Examples include trifluoromethyl and pentafluoroethyl.

In general, "C_{a-b}haloalkyl" as used herein refers to an alkyl group, as described above, wherein any number--at

- 54 -

least one--of the hydrogen atoms attached to the alkyl chain are replaced by F, Cl, Br or I. Examples of haloalkyl includes, without limitation, trifluoromethyl, pentafluoroethyl and the like.

5 In general, "heteroalkyl" as used herein refers to an alkyl having one or more of the carbon atoms replaced by a heteroatom, selected from nitrogen, oxygen and sulfur. For example, a heteroalkyl would include an ether or a thioether chain, or an alkoxide moiety, wherein the heteroatom is in
10 the linear region of the moiety. The term also includes moieties where the heteroatom is in a branched region. For example, the term includes 2-amino-n-hexane or 5-hydroxy-pentane.

 In general, "hydroxyalkyl" as used herein refers to
15 linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl.

20 In general, "alkoxy" as used herein refers to linear or branched oxy-containing radicals each having alkyl portions of one to about ten carbon atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. Alkoxy radicals may be further substituted with one
25 or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Examples of lower haloalkoxy radicals having one to three carbon atoms include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.

30 In general, "sulfonyl", as used herein whether alone or linked to other terms such as alkylsulfonyl, refers respectively to divalent radicals $-SO_2-$.

 In general, the term "amino", as used herein whether alone or linked to other terms, refers to a nitrogen radical

- 55 -

containing two hydrogen atoms (NH_2), a nitrogen radical which is mono-substituted such as an alkylamine (methylamine for example), or a nitrogen radical which is disubstituted such as a dialkylamine (dimethylamine for example).

5 Generally, the amine nitrogen is the point of attachment to the group in question. Accordingly, the term "alkylamino" or dialkylamino" as used herein, means a mono-alkyl or bis-alkyl substituted amine-linked group. The term "cycloalkylamino" refers to an amine-linked cycloalkyl
10 group. The term "arylamino" refers to an amine-linked aryl group. The term "heteroarylamino" refers to an amine-linked heteroaryl group. The term "heterocyclylamino" refers to an amino-linked heterocyclyl group.

In general, "aryl", as used herein alone or in
15 combination, refers to a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a fused manner. The term "aryl" includes, without limitation, aromatic radicals such as phenyl, naphthyl, indenyl, tetrahydronaphthyl, and indanyl.
20 The "aryl" group may have 1 to 3 substituents such as alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and alkylamino. "Aryl" also includes the moiety wherein the aromatic carbocycle is fused with a C_{3-6} cycloalkyl bridge, wherein the bridge optionally includes 1, 2 or 3 heteroatoms
25 selected from N, O and S. For example, phenyl substituted with $-\text{O}-\text{CH}_2-\text{O}-$ forms the aryl benzodioxolyl substituent.

In general, "heterocyclic" as used herein, refers to fully or partially saturated heteroatom-containing ring radicals, where the heteroatom(s) may be selected from
30 nitrogen, sulfur and oxygen. "Heterocycle" is used herein synonymously with heterocycloalkyl.

In general, "heterocycloalkyl" as used herein, refers to saturated and partially saturated (or partially unsaturated) heteroatom-containing ring radicals, where the

- 56 -

heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing -O-O-, -O-S- or -S-S- portions. Said "heterocycloalkyl" group may have 1 to 3 substituents such as hydroxyl, Boc, halo, haloalkyl, cyano, lower alkyl, oxo, alkoxy, amino and alkylamino.

Examples of saturated heterocycloalkyl radicals include saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl]; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl]. Examples of partially saturated heterocyclyl radicals include dihydrothienyl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl.

In general, "heteroaryl" as used herein, refers fully unsaturated or aromatic heteroatom-containing ring radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of heteroaryl radicals, include unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl]; unsaturated 5- to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 5- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5-oxadiazolyl]; unsaturated 5 to 6-membered heteromonocyclic group




- 57 -

containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl].

The term "heteroaryl" also embraces radicals where
 5 heterocyclic radicals are fused/condensed with aryl radicals (also referred to herein as "arylheterocycloalkyl"):
 unsaturated condensed heterocyclic group containing 1 to 5
 nitrogen atoms, for example, indolyl, isoindolyl,
 indolizinyll, benzimidazolyl, quinolyl, isoquinolyl,
 10 indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g.,
 tetrazolo [1,5-b]pyridazinyl]; unsaturated condensed
 heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3
 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl];
 unsaturated condensed heterocyclic group containing 1 to 2
 15 sulfur atoms and 1 to 3 nitrogen atoms [e.g.,
 benzothiazolyl, benzothiadiazolyl]; and saturated, partially
 unsaturated and unsaturated condensed heterocyclic group
 containing 1 to 2 oxygen or sulfur atoms [e.g. benzofuryl,
 benzothienyl, 2,3-dihydro-benzo[1,4]dioxinyl and
 20 dihydrobenzofuryl]. Preferred heterocyclic radicals include
 five to ten membered fused or unfused radicals. More
 preferred examples of heteroaryl radicals include quinolyl,
 isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl,
 oxazolyl, furyl, and pyrazinyl. Other preferred heteroaryl
 25 radicals are 5- or 6-membered heteroaryl, containing one or
 two heteroatoms selected from sulfur, nitrogen and oxygen,
 selected from thienyl, furyl, pyrrolyl, indazolyl,
 pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl,
 isoxazolyl, isothiazolyl, pyridyl, piperidinyl and
 30 pyrazinyl.

Further examples of suitable heterocyclic and heteroaryl radicals, some of which have been described above, include, without limitation, the following:

- 58 -



5

"Saturated or unsaturated" with reference to a group or substitution means a substituent that is completely saturated, completely unsaturated, or has any degree of unsaturation in between. Examples of a saturated or

- 59 -

unsaturated 6-membered ring carbocycle would include phenyl, cyclohexyl, cyclohexenyl and cyclohexadienyl.

In general, the term "salt" refers to a salt form of a free base compound of the present invention, as appreciated by persons of ordinary skill in the art. Salts may be prepared by conventional means, known to those skilled in the art. In general, "pharmaceutically-acceptable", when used in reference to a salt, refers to salt forms of a given compound, which are within governmental regulatory safety guidelines for ingestion and/or administration to a subject. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is safe and considered pharmaceutically-acceptable.

Suitable pharmaceutically-acceptable acid addition salts of compounds of Formula I-III may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, camphoric, camphorsulfonic, digluconic, cyclopentanepropionic, dodecylsulfonic, glucoheptanoic, glycerophosphonic, heptanoic, hexanoic, 2-hydroxy-

- 60 -

ethanesulfonic, nicotinic, 2-naphthalenesulfonic, oxalic, palmoic, pectinic, persulfuric, 2-phenylpropionic, picric, pivalic propionic, succinic, tartaric, thiocyanic, mesylic, undecanoic, stearic, algenic, β -hydroxybutyric, salicylic, galactaric and galacturonic acid.

Suitable pharmaceutically-acceptable base addition salts of compounds of Formula I-III include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine, lysine, morpholine, N-ethyl morpholine, piperazine, piperidine, triethylamine, trimethylamine.

Additional examples of such acid and base addition salts can be found in Berge et al., J. Pharm. Sci., 66, 1 (1977). All of these salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formula I-III.

Also, the basic nitrogen-containing groups of compounds of Formulas I-III can be quaternized with such agents as lower alkyl halides including, without limitation, methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates including dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products may be obtained by quaternizing such basic nitrogen groups in compounds of Formula I-III. Certain quaternized nitrogen compounds of the present invention are not included in the invention, as specified herein in the claims.

- 61 -

In general, "Derivative" as used herein, refers to simple modifications, readily apparent to those of ordinary skill in the art, on the parent core structure of Formula I, II or III, which does not significantly affect (generally decrease) the activity of the compound in-vitro as well as in vivo, in a subject. The term, "derivative" as used herein, is contemplated to include pharmaceutically acceptable derivatives of compounds of Formula I, II or III.

In general, "Pharmaceutically acceptable" when used with reference to a derivative, is consistent in meaning with reference to a salt, and refers to a derivative that is pharmacologically safe for consumption, generally as determined by a governmental or authorized regulatory body.

In general, "Leaving group" as used herein, refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.

In general, "Protecting group" as used herein, refers to groups well known in the art which are used to prevent selected reactive groups, such as carboxy, amino, hydroxy, mercapto and the like, from undergoing undesired reactions, such as nucleophilic, electrophilic, oxidation, reduction and the like. Preferred protecting groups are indicated herein where appropriate. Examples of amino protecting groups include, but are not limited to, aralkyl, substituted aralkyl, cycloalkenylalkyl and substituted cycloalkenyl alkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, silyl and the like. Examples of aralkyl include, but are not limited to, benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally substituted

- 62 -

with halogen, alkyl, alkoxy, hydroxy, nitro, acylamino, acyl and the like, and salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthyl, indanyl, anthracenyl, 9-(9-phenylfluorenyl), phenanthrenyl, 5 durenyl and the like. Examples of cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals, preferably have 6-10 carbon atoms, include, but are not limited to, cyclohexenyl methyl and the like. Suitable acyl, alkoxycarbonyl and aralkoxycarbonyl groups include 10 benzyloxycarbonyl, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloro acetyl, phthaloyl and the like. A mixture of protecting groups can be used to protect the same amino group, such as a primary amino group can be protected 15 by both an aralkyl group and an aralkoxycarbonyl group. Amino protecting groups can also form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups 20 can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, such as nitrophthalimidyl. Amino groups may also be protected against undesired reactions, such as oxidation, through the formation of an addition salt, such as 25 hydrochloride, toluenesulfonic acid, trifluoroacetic acid and the like. Many of the amino protecting groups, including aralkyl groups for example, are also suitable for protecting carboxy, hydroxy and mercapto groups. Alkyl groups are also suitable groups for protecting hydroxy and mercapto groups, 30 such as tert-butyl.

Silyl protecting groups are groups containing silicon atoms which are optionally substituted by one or more alkyl, aryl and aralkyl groups. Suitable silyl protecting groups include, but are not limited to, trimethylsilyl,

- 63 -

triethylsilyl, tri-isopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl.


Silylation of an amino groups provide mono- or di-silylamino groups. Silylation of aminoalcohol compounds can lead to a N,N,O-tri-silyl derivative. Removal of the silyl function from a silyl ether function is readily accomplished by treatment with, for example, a metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during a reaction with the alcohol group. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyl-dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethyl silyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.

Protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of a protecting group, such as removal of a benzyloxycarbonyl group by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. A t-butoxycarbonyl protecting group can be removed utilizing an inorganic or organic acid, such as HCl or trifluoroacetic acid, in a suitable solvent system, such as dioxane or methylene chloride. The resulting amino salt can readily be neutralized to yield the free amine. Carboxy protecting group, such as methyl, ethyl, benzyl, tert-butyl, 4-

- 64 -

methoxyphenylmethyl and the like, can be removed under hydrolysis and hydrogenolysis conditions well known to those skilled in the art.

It should be noted that compounds of the invention may contain groups that may exist in tautomeric forms, such as cyclic and acyclic amidine and guanidine groups, heteroatom substituted heteroaryl groups ($Y' = O, S, NR$), and the like, which are illustrated in the following examples:



and though one form is named, described, displayed and/or claimed herein, all the tautomeric forms are intended to be inherently included in such name, description, display and/or claim.

15 Prodrugs of the compounds of this invention are also contemplated by this invention. The term "prodrug", as used herein, refers to a compound, which when administered to the body of a subject (such as a mammal), breaks down in the subject's metabolic pathway to provide an active compound of

20 Formula I, II or III. More specifically, a prodrug is an active or inactive "masked" compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this

- 65 -

invention following administration of the prodrug to a subject or patient. The suitability and techniques involved in making and using prodrugs are well known by those skilled in the art. For a general discussion of prodrugs involving
5 esters see Svensson and Tunek Drug Metabolism Reviews 165 (1988) and Bundgaard Design of Prodrugs, Elsevier (1985).

One common form of a prodrug is a masked carboxylic acid group. Examples of a masked carboxylate anion include a variety of esters, such as alkyl (for example, methyl,
10 ethyl), cycloalkyl (for example, cyclohexyl), aralkyl (for example, benzyl, p-methoxybenzyl), and alkylcarbonyloxyalkyl (for example, pivaloyloxymethyl). Amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and
15 formaldehyde (Bundgaard J. Med. Chem. 2503 (1989)). Also, drugs containing an acidic NH group, such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as phosphate
20 esters, esters and ethers. EP 039,051 (Sloan and Little, 4/11/81) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.

In general, the term "stereoisomer" as used herein refers to a compound having one or more asymmetric centers.
25 Chiral centers in a compound generally cause that compound to exist in many different conformations or stereoisomers. The term "stereoisomers" includes enantiomers, diastereomers, atropisomers and geometric isomers. Stereoisomers generally possess different chemical
30 properties and/or biological activity, as appreciated by those skilled in the art. For example, one stereoisomer may be more active and/or may exhibit beneficial effects in comparison to other stereoisomer(s) or when separated from the other stereoisomer(s). However, it is well within the

- 66 -

skill of the ordinary artisan to separate, and/or to selectively prepare said stereoisomers. Accordingly, "stereoisomers" of the present invention necessarily include mixtures of stereoisomers, including racemic mixtures, individual stereoisomers, and optically active forms.

In general, the term "solvate" when used with reference to a compound refers to a compound, which is associated with one or more molecules of a solvent, such as an organic solvent, inorganic solvent, aqueous solvent or mixtures thereof. The compounds of Formula I, II or III may also be solvated, especially hydrated. Hydration may occur during manufacturing of the compounds or compositions comprising the compounds, or the hydration may occur over time due to the hygroscopic nature of the compounds. Compounds of the invention may exist as organic solvates as well, including DMF, ether, and alcohol solvates among others. The identification and preparation of any particular solvate is within the skill of the ordinary artisan of synthetic organic or medicinal chemistry.

In general, the term "Cytokine" as used herein, refers to a secreted protein that affects the functions of other cells, particularly as it relates to the modulation of interactions between cells of the immune system or cells involved in the inflammatory response. Examples of cytokines include but are not limited to interleukin 1 (IL-1), preferably IL-1 β , interleukin 6 (IL-6), interleukin 8 (IL-8) and TNF, preferably TNF- α (tumor necrosis factor- α).

In general, the term "treatment" as used herein, includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a pre-clinically evident stage of disorders in individuals).

In general, the term "therapeutically-effective" as used herein, is intended to qualify the amount of each

- 67 -

compound of Formula I, II or III, which will achieve the goal of treatment, for example, improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies.

In general, "Lck- or C-kit- mediated disease or disease states" refer to all disease states wherein Lck or C-kit plays a role, either directly as Lck and/or C-kit itself, or by Lck and/or C-kit inducing other proteins, cytokines, enzymes or disease-causing agents and the like to be released, activated or otherwise directly or indirectly regulated.

The specification and claims contain a listing of species using the language "selected from . . . and . . ." and "is . . . or . . ." (sometimes referred to as Markush groups). When this language is used in this application, unless otherwise stated it is meant to include the group as a whole, or any single members thereof, or any subgroups thereof. The use of this language is merely for shorthand purposes and is not meant in any way to limit the removal of individual elements or subgroups from the genus.


1. Synthesis

Compounds of Formula I, II and III can be synthesized according to one or more of the following schematic procedures and specific methods wherein the substituents are as defined for Formula I, II and III, above, except where further noted. The procedures and methods as shown relate to preparation of compounds having unspecified stereochemistry. However, such procedures and methods may generally be applicable to those compounds of a specific stereochemistry, e.g., where the stereochemistry about a group is (S) or (R). In addition, the compounds having one stereochemistry (e.g., (R)) can often be utilized to produce those having opposite

- 68 -

are either named with conventional IUPAC naming system or with the naming system utilized in ChemDraw, software version 8.0, or the convention used by MDL.

5

Scheme 1

Scheme 1 describes a general method for preparing meta-substituted **5a** and para-substituted **5b** bis-aryl amide compounds, of Formulas I, II and III. As shown, an amine **1** can be reacted with an aromatic carboxylic acid **2a** or **2b** to generate the corresponding amide **3a** or **3b** by known methods (Step A), such as in the presence of a conventional coupling


- 69 -

reagent, in a suitable basic media or solvent. Methods which are suitable and may be used to form the amide are described in further detail in Scheme 2 below, which generally describes various methods of forming the linker "L", in compounds **5a** and **5b** above, from linker pieces L^1 and L^2 , as shown in compounds **3a** and **3b**, and **4**, respectively. Note that intermediates **3a** and **3b** already have in place linker piece L^1 which may be reacted with linker piece L^2 on a desired R^3 ring. As shown, an R^3 intermediate **4** can be reacted with a compound **3a** or a compound **3b** utilizing known methods (Step B), such as those described in further detail in Scheme 3 below, to prepare a meta-substituted **5a** or a para-substituted **5b** bis-aryl amide compound, of Formula I, II or III.

15

Scheme 2

- 70 -




Scheme 2 describes a general method for preparing meta-substituted **11a** and para-substituted **11b** bis-aryl amide compounds, of Formulas I, II and III. As shown, an amine **6**

5 can be reacted with an iodo-aromatic carboxylic acid **7a** or

- 71 -

7b to generate the corresponding amide **8a** or **8b** by known methods, such as in the presence of a conventional coupling reagent, in a suitable basic media or solvent. Methods which are suitable and may be used to form the amide are described in further detail in Scheme 3 below. In this manner desired R^1 groups or rings may be installed first. The iodo-aromatic amides **8a** or **8b** may be reacted with carbon monoxide and methanol in the presence of a palladium catalyst to generate the corresponding methyl ester adduct, which ester may then be hydrolyzed by conventional methods, such as with a suitable base, such as aqueous LiOH, to provide the corresponding carboxylic acids **9a** and **9b**. As shown, an R^3 substituted amine **10** can be reacted with compound **9a** or **9b** utilizing known methods (scheme 3), to prepare a meta-substituted **11a** or a para-substituted **11b** bis-aryl amide compound, of Formula I, II or III.

Scheme 3

5 Scheme 3 describes various exemplary coupling methods whereby desired linkers "L" may be made or formed between the 6-membered central ring and a desired R³ ring, as illustrated in Formulas I, II and III herein. The 6-membered

- 73 -

central ring, illustrated in Formulas I, II and III, is generally designated and referred to in Scheme 3, and throughout the specification, as the "B" ring. The R³ rings, illustrated in Formulas I, II and III, are generally designated and referred to in Scheme 3, and throughout the specification, as the "A" ring.

Each of the seven sub-schemes, numbered 1-7 above and described below, utilize the following meanings for R', (R)_n, X, Nu⁻, E⁺, W and m: R' in sub-schemes 1-4 represent R¹R²N- as defined in Formulas I, II and III; (R)_n refers to n number of R⁴, R⁵, R⁶ and R⁷ substitutions wherein n is an integer from 0-4; X refers generally to a "leaving group" such as a halide (bromine, chlorine, iodine or fluorine), alkylsulfonate and other known leaving groups (also see definitions herein); Nu⁻ refers generally to a nucleophile or nucleophilic species such as a primary or secondary amine, an oxygen, a sulfur or a anionic carbon species - examples of nucleophiles include, without limitation, amines, hydroxides, alkoxides and the like; E⁺ refers generally to an electrophile or electrophilic species, such as the carbon atom of a carbonyl or carbon atom attached to an activated leaving group, the carbon atom of which is susceptible to nucleophilic attack or readily eliminates - examples of suitable electrophilic carbonyl species include, without limitation, acid halides, mixed anhydrides, aldehydes, carbamoyl-chlorides, sulfonyl chlorides (sulfonyl electrophile), acid carbonyls activated with activating reagents such as TBTU, HBTU, HATU, HOBT, BOP, PyBOP, carbodiimides (DCC, EDC and the like), pentafluorophenyl, and other electrophilic species including halides, isocyanates (see ring A reagent of sub-scheme 3), diazonium ions and the like; W is either O or S; and m is either 0 or 1. The protected carbonyl, as shown in sub-schemes 5-7, allows one to take a desired B-linked-A ring intermediate

- 74 -

and attach various "D" ring intermediates or selected R¹ coupled primary or secondary amines. This allows one the advantage of modifying the R¹ group in a single step.

The coupling of rings B and A, as shown as products in
5 sub-schemes 1-7, can be brought about using various
conventional methods to link rings B and A together. For
example, an amide or a sulfonamide linker "L", as shown in
sub-schemes 1 (where m=0), 2, 4, 5, 6 and 7 where the Nu- is
an amine, respectively, can be made utilizing an amine on
10 either the B or A rings and an acid chloride or sulfonyl
chloride on the other of either the A or B rings. The
reaction proceeds generally in the presence of a suitable
solvent and/or base. The reaction proceeds generally in the
presence of a suitable solvent and/or base. Suitable
15 solvents include, without limitation, generally non-
nucleophilic, aprotic solvents such as toluene, CH₂Cl₂, THF,
DMF, DMSO, N,N-dimethylacetamide and the like, and solvent
combinations thereof. The solvent(s) may range in polarity,
as appreciated by those skilled in the art. Suitable bases
20 include, for example, mild bases such as tertiary amine
bases including, without limitation, DIEA, TEA, N-
methylmorpholine; and stronger bases such as carbonate bases
including, without limitation, Na₂CO₃, K₂CO₃, Cs₂CO₃; hydrides
including, without limitation, NaH, KH, borohydrides,
25 cyanoborohydrides and the like; and alkoxides including,
without limitation, NaOCH₃, and the like. The base itself
may also serve as a solvent. The reaction may optionally be
run neat, i.e., without any base and/or solvent. For simple
structurally unhindered substrates, these coupling reactions
30 are generally fast and conversion occurs typically in
ambient conditions. However, depending upon the particular
substrate, steric hindrance, concentration and other
stoichiometric factors, such reactions may be sluggish and

- 75 -

may require a basicity adjustment or heat, as appreciated by those skilled in the art.

As another example, a urea linker (or a sulfonylurea linker), as shown in sub-scheme 3, may be made by reacting an amine with a desired isocyanate. As isocyanates are generally highly reactive species, the urea formation generally proceeds quickly, at ambient temperatures with a minimal amount of solvent, as appreciated by those of ordinary skill in the art. The reaction may optionally be run neat, i.e., without any base and/or solvent.

Similarly, carbamate linkers are illustrated in sub-scheme 1 (where $m=1$) where Nu^- would be an amine, anhydride linkers are illustrated in sub-scheme 1 where Nu^- would be an oxygen, reverse amide linkers are generally illustrated in sub-scheme 6 where Nu^- would be an amine and E^+ would be an acid chloride, urea linkers are illustrated in sub-scheme 3, thioamide and thiourea linkers are illustrated in sub-schemes 2 and 3 where the respective carbonyl oxygen is a sulfur, and thiocarbamates are illustrated in sub-schemes 1 where the respective carbonyl oxygen and/or carbamate oxygen is a sulfur. While the above methods are so described, they are not exhaustive, and other methods for linking rings A and B together may be utilized as appreciated by those skilled in the art.

Although sub-schemes 1-7 are illustrated as having the nucleophilic and electrophilic coupling groups, such as the amino group and acid chloride groups illustrated in sub-scheme 2, directly attached to the substrate, either the A or B ring, in question, the invention is not so limited. It is contemplated herein that these nucleophilic and/or electrophilic coupling groups may be tethered from their respective ring. For example, the amine group on the B ring, and/or the acid halide group on the A ring, as illustrated in sub-scheme 2, may be removed from direct attachment to

- 76 -

the ring by a one or more atom spacer, such as by a methylene, ethylene, propylene spacer or the like. As appreciated by those skilled in the art, such spacer may or may not affect the coupling reactions described above, and accordingly, such reaction conditions may need to be modified to affect the desired transformation.

The coupling methods described in sub-schemes 1-7 are also applicable for coupling desired A rings to desired $R^1-N(R^2)C(O)-B$ ring intermediates (sub-schemes 1-4), to synthesize desired compounds of Formulas I, II and III. For example, an amine-protected B ring intermediate may be first coupled to a desired R^1R^2N- group, as illustrated in Formulas I, II and III and as R' in sub-schemes 1-4, to form the $R^1-N(R^2)C(O)-B$ intermediate. The protected amine may then be de-protected and used to form an amide linker, or converted to an isocyanate, for example, or any other desired group for coupling the A ring via the desired linker. Suitable B ring amino protecting groups include t-butoxycarbonyl group, which can be made with BOC-ON, exist as appreciated by those skilled in the art and further described herein.

The Specific Methods and Examples described in detail below further exemplify the synthesis of compounds of Formulas I, II and III, generally described in Schemes 1-3 above.

Analytical methods:

Unless otherwise indicated all LC-MS sample analysis and/or HPLC analysis of exemplary compounds, intermediates and starting materials described here were conducted using one of the following methods:

Run on an HP-1000 or HP-1050 system with an HP Zorbax™ SB-C₁₈ (5μ) reverse phase column (4.6 x 150mm) run at 30 °C with a flow rate of 1.00 mL/min. The mobile phase used solvent A (H₂O/0.1% TFA) and solvent B (CH₃CN/0.1% TFA) with

- 77 -

a 20 min gradient from 10% to 90% CH₃CN. The gradient was followed by a 2 min return to 10% CH₃CN and a 3 min flush.
Method A (LC-MS):

Samples were run on an HP-1100 system with an HP
5 Zorbax™ SB-C₈ (5 μ) reverse phase column (4.6 x 50mm) run at
30°C with a flow rate of 0.75 mL/min. The mobile phase used
solvent A (H₂O/0.1% AcOH) and solvent B (CH₃CN/0.1% AcOH)
with a 10 min gradient from 10% to 90% CH₃CN. The gradient
was followed by a 1 min return to 10% CH₃CN and a 2 min
10 flush.

Method B (LC-MS):

Samples were run on an HP-1100 system with an HP
Zorbax™ SB-C₈ (5 μ) reverse phase column (4.6 x 50mm) run at
30°C with a flow rate of 1.5 mL/min. The mobile phase used
15 solvent A (H₂O/0.1% AcOH) and solvent B (CH₃CN/0.1% AcOH)
with a 5 min gradient from 10% to 90% CH₃CN. The gradient
was followed by a 0.5 min return to 10% CH₃CN and a 1.5 min
flush.

Method C:

20 Samples were run on an Agilent™-1100 system with a
Phenomenex Luna C₈ (5 μ) reverse phase column (4.6 x 100mm)
run at 40 °C with a flow rate of 1.0 mL/min. The mobile
phase used solvent A (H₂O/0.1% TFA) and solvent B
(CH₃CN/0.1% TFA) with a 7 min gradient from 10% to 100%
25 CH₃CN, and a 2.5 min hold at 100% CH₃CN. The gradient was
followed by a 1 min return to 10% CH₃CN and a 2 min flush.

Method D:

Samples were run on an Agilent™-1100 system with a
Phenomenex-Synergy MAX (4 μ) reverse phase column (2.0 x
30 50mm) run at 40 °C with a flow rate of 0.8 mL/min. The
mobile phase used solvent A (H₂O/0.1% TFA) and solvent B
(CH₃CN/0.1% TFA) with a 3 min gradient from 10% to 100%
CH₃CN. The gradient was followed by a 0.5 min return to 10%
CH₃CN and a 1.5 min flush.


- 78 -

Proton NMR Spectra:

Unless otherwise indicated all ^1H NMR spectra were run on an Varian series Mercury™ 300 or 400 MHz instrument, or Bruker 400 MHz instrument. All observed protons, where reported, are as parts per million (ppm) downfield from tetramethylsilane (TMS) or other internal reference in the appropriate solvent indicated.

Example 1 (Method A)

10



Synthesis of N-(2-amino-5-pyrimidinyl)-2-methyl-5-((3-(trifluoromethyl)phenyl)carbonyl)benzamide

15

Step 1. Pyrimidine-2,5-diamine

A round bottom flask equipped with a stir bar was charged with 5-nitropyrimidin-2-amine 6 (3.0 g, 21.4 mmol), wet Raney™ Ni (~ 8 g) and EtOH (30 mL). The mixture was purged with H_2 (3 vacuum and back-fill cycles) then allowed to stir under an H_2 balloon. The reaction was monitored by TLC and LCMS for the complete consumption of starting

20

- 79 -

material, which occurred after about 20 h. The mixture was filtered through a pad of CeliteTM with EtOH and CH₂Cl₂. The crude material was purified on a short plug using automated medium pressure chromatography (Isco - 40 g column; eluting with a linear gradient from 100% CH₂Cl₂ (A line) to 100% 90/10/1 CH₂Cl₂/MeOH/NH₃ (B line) on silica gel) to afford pyrimidine-2,5-diamine **7** as an orange solid.

Step 2. N-(2-Aminopyrimidin-5-yl)-2-methyl-5-nitrobenzamide

2-methyl-5-nitrobenzoic acid (659 mg, 3.64 mmol) was heated to reflux in SOCl₂ (6 mL) for 1 h. After cooling to room temperature and concentrating to dryness, the crude acid chloride was taken up in CH₂Cl₂ (25 mL). Pyrimidine-2,5-diamine **7** (400 mg, 3.64 mmol) was added to the solution and the mixture was allowed to stir at rt over night. The mixture became a thick white suspension. NEt₃ (700 μ L, 4.73 mmol) was added. After 2 h, a thick white suspension remained. The mixture was filtered through a Buchner funnel and washed with copious amounts of CH₂Cl₂ to remove NEt₃HCl salt, affording N-(2-aminopyrimidin-5-yl)-2-methyl-5-nitrobenzamide **8** as an off-white solid.

Step 3. 5-Amino-N-(2-aminopyrimidin-5-yl)-2-methylbenzamide

A round bottom flask equipped with a stir bar was charged with N-(2-aminopyrimidin-5-yl)-2-methyl-5-nitrobenzamide **8** (300 mg, 1.1 mmol), 10% Pd/C (~ 150 mg), EtOAc (24 mL) and MeOH (6 mL). The mixture was purged with H₂ (3x evacuation and back-fill cycles) then allowed to stir under an H₂ balloon. After 24 h, TLC and LCMS indicated that the starting material was completely consumed. The mixture was filtered through a pad of CeliteTM, washing with MeOH and CH₂Cl₂. Recrystallization from MeOH/CH₂Cl₂ afforded 5-amino-N-(2-aminopyrimidin-5-yl)-2-methylbenzamide **9** as a pale yellow crystalline solid.

- 80 -

Step 4. N-(2-amino-5-pyrimidinyl)-2-methyl-5-(((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide

5-Amino-N-(2-aminopyrimidin-5-yl)-2-methylbenzamide **9**
5 (86 mg, 0.353 mmol) was taken up in CH₂Cl₂ (3 mL) and 3-(trifluoromethyl)benzoyl chloride (0.052 mL, 0.353 mmol) was added. The mixture was allowed to stir at rt for 2 h, becoming a thick yellow suspension. NEt₃ (0.064 mL, 0.459 mmol) was added. After 0.5 h, a thick yellow suspension
10 remained. Complete consumption of the amine starting material was indicated by LCMS. The crude reaction mixture was concentrated and the title compound was purified using automated medium pressure chromatography (Isco - 40 g column; eluting with a linear gradient from 100% CH₂Cl₂ (A
15 line) to 100% 90/10/1 CH₂Cl₂/MeOH/NH₃ (B line) on silica gel) to afford N-(2-amino-5-pyrimidinyl)-2-methyl-5-(((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide **10** as an off-white solid. MS: m/z found 416 [MH⁺] (by ESI, positive ion); MS calculated for C₂₀H₁₆F₃N₅O₂ = 415.13.


20

Alternatively, compound **10** may be made using the following conditions: Step 1. H₂, PtO₂; Step 2. acid chloride, NEt₃, THF; Step 3. H₂, 10%-Pd/C, 2-methoxyethanol; and Step 4: same as above.

25

Example 2 (Method Q)

- 81 -



Synthesis of 2-methyl-N-(2-((2-(4-morpholino)ethyl)amino)-5-pyrimidinyl)-5-((3-trifluoromethyl)phenyl)carbamoyl)benzamide

5

Step 1. N-(2-iodopyrimidin-5-yl)-2-methyl-5-nitrobenzamide

N-(2-Aminopyrimidin-5-yl)-2-methyl-5-nitrobenzamide

[prepared according to Specific Method 1] (200 mg, 0.732 mmol), CuI (140 mg, 0.732 mmol) and CH₂I₂ (0.30 mL, 3.73 mmol) were taken up in THF (3.7 mL) in a 16 x 100 mm resealable pyrex tube. The tube was sealed and the mixture was heated at 70 °C for 2 h. After cooling to rt, the crude reaction mixture was taken up in 1:1 EtOAc:1N HCl and the layers were separated. The organics were washed with saturated NH₄Cl then dried over Na₂SO₄. Purification by MPLC (Isco - 100% EtOAc eluent) afforded N-(2-iodopyrimidin-5-yl)-2-methyl-5-nitrobenzamide as a pale yellow solid.

20

Step 2. 2-Methyl-N-(2-(2-morpholinoethylamino)pyrimidin-5-yl)-5-nitrobenzamide

N-(2-iodopyrimidin-5-yl)-2-methyl-5-nitrobenzamide (60 mg, 0.156 mmol), 2-morpholinoethanamine (~200 mg, 1.5 mmol), and DIEA (0.041 mL, 0.234 mmol) were taken up in IPA (2.5 mL) in a 16 x 100 mm resealable pyrex tube and heated at 70

- 82 -

°C for 4 h. The mixture was concentrated and purified by preparative TLC (2.5% MeOH/CH₂Cl₂) to afford 2-methyl-N-(2-(2-morpholinoethylamino)pyrimidin-5-yl)-5-nitrobenzamide.

5 Step 3. 5-Amino-2-methyl-N-(2-(2-morpholinoethylamino)pyrimidin-5-yl)benzamide

The title intermediate was prepared in a manner analogous to the method described in Step 3 of Example 1.


10 Step 4. 2-methyl-N-(2-((2-(4-morpholino)ethyl)amino)-5-pyrimidinyl)-5-((3-trifluoromethyl)phenyl)carbonyl)amino)benzamide

The title compound was prepared in a manner analogous to the method described in Step 4 of Example 1. MS: m/z found 529.0 [MH⁺] (by ESI, positive ion); MS calculated for C₂₆H₂₇F₃N₆O₃ = 528.

2-NR⁸R⁹ substituted diamino-pyrimidine R¹ groups may be made utilizing the methods described in Examples 3-8

20

Example 3



Synthesis of N2-(3-morpholinopropyl)pyrimidine-2,5-diamine

25 16

Step 1.

2-Chloro-5-nitropyrimidine 15 (500 mg, 3.13 mmol), 3-morpholinopropan-1-amine (1.35 g, 9.39 mmol) and DIEA (3.4 mL, 4.7 mmol) were taken up in IPA (20 mL) in a resealable


- 83 -

pyrex tube and heated at 70 °C for 20 h. After cooling to
rt, N-(3-morpholinopropyl)-5-nitropyrimidin-2-amine
precipitated out of solution and was collected by filtration
through a Buchner micro membrane, and washing with MeOH,
5 then drying to afford the 5-nitro intermediate as a pale
yellow solid.

Step 2.


The crude N-(3-morpholinopropyl)-5-nitropyrimidin-2-
10 amine was combined with 10% Pd/C (500 mg) in EtOAc (20 mL)
and MeOH (10 mL) was added. The mixture was purged with H₂
and allowed to stir under 1 atm H₂ overnight. Filtration
through a pad of celite and concentration afforded N2-(1-
methyloperidin-4-yl)pyrimidine-2,5-diamine **16** as a thick
15 rust colored oil, which may be used without further
purification. MS: m/z found 270 [MH⁺].

Example 4



Synthesis of N2-cyclopropylpyrimidine-2,5-diamine

The title compound was prepared by a method similar to
that described in Example 3, starting with 2-chloro-5-
25 nitropyrimidine **15**. MS: m/z found 151 [MH⁺].

Example 5

5 Synthesis of N2-(1-methylpiperidin-4-yl)pyrimidine-2,5-
diamine 17

Step 1.


1-Methylpiperidin-4-amine (358 mg, 3.13 mmol) and NaH (60% dispersion in mineral oil) (126 mg, 3.13 mmol) were taken up in THF (16 mL) under an atmosphere of dry N₂. After stirring at rt for 10 min, 2-chloro-5-nitropyrimidine **15** (500 mg, 3.13 mmol) was added. The mixture was allowed to stir at rt for 1 h then quenched with 1 N HCl and concentrated to dryness.

15 Step 2.

The crude N-(1-methylpiperidin-4-yl)-5-nitropyrimidin-2-amine was combined with 10% Pd/C (500 mg) in EtOAc (8 mL) and MeOH (20 mL) was added. The mixture was purged with H₂ and allowed to stir under 1 atm H₂ overnight. Filtration through a pad of celite and concentration afforded N2-(1-methylpiperidin-4-yl)pyrimidine-2,5-diamine **17** as a tan solid, which may be used without further purification. MS: m/z found 285 [MH⁺].

25 2-Chloro-pyrimidin-5-yl compounds may be synthesized from the 2-amino pyrimidine intermediate directly in a single step utilizing the method described in Example 6 below.

- 85 -

Example 6


Synthesis of 2-methyl-N-(((2-chloro)-5-pyrimidinyl)-5-(((2-methyl)-3-trifluoromethyl)phenyl)carbonyl)aminobenzamide

- 5 In a 16 x120 mm resealable pyrex tube, 2-methyl-N-
 ((2-amino)-5-pyrimidinyl)-5-(((2-methyl)-3-
 trifluoromethyl)phenyl)carbonyl)aminobenzamide **18** (0.100 g,
 0.23 mmol) was taken up in DCE (2.0 mL) and DMF (0.2 mL).
 The solution was treated in one portion with
 10 tetrabutylammonium chloride (0.065 g, 0.23 mmol). After 5
 min, trimethylsilyl chloride (0.030 mL, 0.23 mmol) was added
 slowly. After 15 min, tert-butyl nitrite (0.028 mL, 0.23
 mmol) was added dropwise and the mixture was purged with N₂
 then the tube was sealed and the mixture was heated at 50 °
 15 C for 7 h. After cooling, the crude reaction mixture was
 taken up in minimal CH₂Cl₂ and purified by MPLC (Isco -
 Redi-Sep® pre-packed silica gel column (40 g); eluent
 gradient: 5-80% EtOAc in hexanes over 20 min) to afford the
 title compound **19** as a white solid. MS: m/z found 449 [MH⁺].

20

25

- 86 -

Example 7 (Method I)

5 Synthesis of 2-methyl-N-(4-methyl-3-(((2-(3-pyridinylamino))-
5-pyrimidinyl)amino)carbonyl)phenyl)-3-
(trifluoromethyl)benzamide


A small microwave reaction vessel was charged with N-
 (3-(((2-chloro-5-pyrimidinyl)amino)carbonyl)-4-
 10 methylphenyl)-2-methyl-3-(trifluoromethyl)benzamide **19**
 (0.100 g, 0.22 mmol), and pyridin-3-amine (0.10 g, 1.1 mmol)
 in IPA (1.0 mL). Trifluoroacetic acid (0.034 mL, 0.45 mmol)
 was added and the vessel was sealed. The reaction mixture
 was stirred and heated in a Smith Synthesizer® microwave
 15 reactor (Personal Chemistry, Inc., Upssala, Sweden) at 140
 °C for 10 min. Monitored the reaction by LCMS and found 50%
 conversion. Added another 105 mg aniline and 0.05 mL TFA
 and resumed microwave heating the reaction at 140 °C for 15
 min. After about >90% conversion was found by LCMS, the
 20 crude reaction mixture was filtered through a Buchner
 apparatus with micromembrane filter, and the filtrate was
 washed with copious amounts of MeOH to afford 2-methyl-N-(4-
 methyl-3-(((2-(3-pyridinylamino))-5-
 pyrimidinyl)amino)carbonyl)phenyl)-3-
 25 (trifluoromethyl)benzamide **20** as an off-white solid after

- 87 -

drying. MS m/z found 507.1 [MH⁺], calc. for C₂₆H₂₁F₃N₆O₂ = 506.17.

Example 8 (Method J)

5






Synthesis of 2-methyl-N-(4-methyl-3-(((2-((2-pyridinylmethyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide





A small microwave reaction vessel was charged with N-(3-(((2-chloro-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-2-methyl-3-(trifluoromethyl)benzamide **19** (0.100 g, 0.22 mmol), pyridin-3-ylmethanamine (0.091 ml, 0.89 mmol) and IPA (1 mL). DIEA (0.058 ml, 0.33 mmol) was added and the vessel was sealed. The reaction mixture was stirred and heated in a Smith Synthesizer® microwave reactor (Personal Chemistry, Inc., Upssala, Sweden) at 140 °C for 30 min. After monitoring the reaction by LCMS and finding >95% conversion, the reaction was concentrated to dryness, and taken up in minimal CH₂Cl₂/MeOH. The crude reaction solution was injected onto the Isco {Redi-Sep® pre-packed silica gel column (40 g); eluent gradient: 3-80% 90/10/1 CH₂Cl₂/MeOH/NH₃ in CH₂Cl₂ over 20 min} to afford pure 2-methyl-N-(4-methyl-3-(((2-((2-pyridinylmethyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-





- 88 -

(trifluoromethyl)benzamide **21** as a white solid. MS m/z found 521.1 [MH⁺]; calc. for C₂₇H₂₃F₃N₆O₂ = 520.18.





The following compounds, Examples 9-86 were made using
5 a procedure similar to that described in Examples 1-8.




Ex. No.	Structure	Name	MS	Method
9		N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-2-(thiophen-2-yl)thiazole-4-carboxamide	611.1	A
10		N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-5-phenyloxazole-4-carboxamide	589.2	A
11		2-methyl-N-(2-((3-(4-morpholinyl)propyl)amino)-5-pyrimidinyl)-5-((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide	543	A





Ex. No.	Structure	Name	MS	Method
12		2-fluoro-N-(4-methyl-3-(((2-((3-(4-morpholinyl)propyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	561	A
13		5-(((3-fluoro-5-(trifluoromethyl)phenyl)carbonyl)amino)-2-methyl-N-(2-((3-(4-morpholinyl)propyl)amino)-5-pyrimidinyl)benzamide	561.2	A
14		2-methyl-N-(2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)-5-(((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide	590.2	A
15		2-methyl-N-(4-methyl-3-(((2-((3-(4-morpholinyl)propyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	557.1	A




Ex. No.	Structure	Name	MS	Method
16		2-methyl-N-(2-((1-methyl-4-piperidinyl)amino)-5-pyrimidinyl)-5-(((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide	513.2	A
17		N-(2-amino-5-pyrimidinyl)-2-methyl-5-((phenylcarbonyl)amino)benzamide	348	A
18		N-(2-amino-5-pyrimidinyl)-2-methyl-5-((phenylacetyl)amino)benzamide	362.0	A
19		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-3-(1,1-dimethylethyl)-1-methyl-1H-pyrazole-5-carboxamide	407.8	A





- 91 -





Ex. No.	Structure	Name	MS	Method
20		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-3-chloro-2,6-difluorobenzamide	417.8	A
21		N-(2-aminopyrimidin-5-yl)-5-(cyclohexanecarboxamido)-2-methylbenzamide	353.9	A
22		N-(2-aminopyrimidin-5-yl)-2-methyl-5-(3-phenylpropanamido)benzamide	375.9	A
23		N-(2-aminopyrimidin-5-yl)-5-(3-cyclopentylpropanamido)-2-methylbenzamide	367.9	A

Ex. No.	Structure	Name	MS	Method
24		N-(2-Amino-pyrimidin-5-yl)-5-(3-iodo-benzoylamino)-2-methyl-benzamide	473.7	A
25		N-(2-Amino-pyrimidin-5-yl)-5-(3-bromo-benzoylamino)-2-methyl-benzamide	425.8	A
26		N-(2-Amino-pyrimidin-5-yl)-5-(3-chloro-benzoylamino)-2-methyl-benzamide	381.8	A





Ex. No.	Structure	Name	MS	Method
27		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-2-fluoro-5-(trifluoromethyl)benzamide	433.8	A
28		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-2-chloro-5-(trifluoromethyl)benzamide	449.8	A
29		N-(2-amino-5-pyrimidinyl)-5-(((3-fluoro-5-(trifluoromethyl)phenyl)carbonyl)amino)-2-methylbenzamide	433.8	A
30		N-(2-amino-5-pyrimidinyl)-5-(((3,5-bis(methoxy)phenyl)carbonyl)amino)-2-methylbenzamide	407.9	A

Ex. No.	Structure	Name	MS	Method
31		N-(2-amino-5-pyrimidinyl)-5-(((3,5-difluorophenyl) carbonyl) amino)-2-methylbenzamide	383.8	A
32		N-(2-amino-5-pyrimidinyl)-2-methyl-5-(((4-(methyloxy)-3-(trifluoromethyl)phenyl) carbonyl) amino) benzamide	445.8	A
33		N-(2-amino-5-pyrimidinyl)-5-(((4-fluoro-3-(trifluoromethyl)phenyl) carbonyl) amino)-2-methylbenzamide	433.8	A




Ex. No.	Structure	Name	MS	Method
34		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-2-fluoro-3-(trifluoromethyl)benzamide	433.8	A
35		2-methyl-N-(4-methyl-3-(((2-((4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	604.3	A
36		5-(((3,5-bis(methoxy)phenyl)carbonyl)amino)-2-methyl-N-(2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)benzamide	582.3	A
37		5-(((3-fluoro-5-(trifluoromethyl)phenyl)carbonyl)amino)-2-methyl-N-(2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)benzamide	608.1	A

Ex. No.	Structure	Name	MS	Method
38		2-fluoro-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	608.2	A
39		5-(((4-(1,1-dimethylethyl)phenyl)carbonyl)amino)-2-methyl-N-(2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)benzamide	578.2	A
40		2,2-difluoro-N-(4-methyl-3-(((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbonyl)phenyl)benzo[d][1,3]dioxole-5-carboxamide	602.2	A
41		N-(2-amino-5-pyrimidinyl)-5-(((4-chloro-3-(trifluoromethyl)phenyl)carbonyl)amino)-2-methylbenzamide	449.8	A

- 97 -

Ex. No.	Structure	Name	MS	Method
42		N-(2-aminopyrimidin-5-yl)-5-(cyclopentanecarboxamido)-2-methylbenzamide	340.2	A
43		N-(2-Amino-pyrimidin-5-yl)-5-(3-fluorobenzoylamino)-2-methyl-benzamide	366.2	A
44		N-(3-(((2-amino-5-pyrimidinyl) amino) carbonyl)-4-methylphenyl)-2-methyl-3-(trifluoromethyl)benzamide	429.8	A
45		N-(3-(((2-amino-5-pyrimidinyl) amino) carbonyl)-4-methylphenyl)-2,3-dichlorobenzamide	415.7	A




- 98 -

Ex. No.	Structure	Name	MS	Method
46		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-3-chloro-2-fluorobenzamide	399.8	A
47		N-(3-((2-aminopyrimidin-5-yl)carbonyl)-4-methylphenyl)-2,2-difluorobenzo[d][1,3]dioxole-4-carboxamide	428.1	A
48		N-(3-((2-aminopyrimidin-5-yl)carbonyl)-4-methylphenyl)-1-naphthamide	398.2	A




- 99 -

Ex. No.	Structure	Name	MS	Method
49		N-(2-Amino-pyrimidin-5-yl)-2-methyl-5-(4-trifluoromethyl-benzoylamino)-benzamide	416.1	A
50		N-(2-Amino-pyrimidin-5-yl)-2-methyl-5-(4-trifluoromethoxy-benzoylamino)-benzamide	432.1	A
51		N-(2-Amino-pyrimidin-5-yl)-5-(4-tert-butyl-benzoylamino)-2-methyl-benzamide	404.3	A




- 100 -

Ex. No.	Structure	Name	MS	Method
52		N-(2-Amino-pyrimidin-5-yl)-5-(4-ethyl-benzoylamino)-2-methyl-benzamide	376.2	A
53		N-(2-Amino-pyrimidin-5-yl)-5-(4-cyano-benzoylamino)-2-methyl-benzamide	373.2	A
54		Biphenyl-4-carboxylic acid [3-(2-amino-pyrimidin-5-ylcarbonyl)-4-methyl-phenyl]-amide	424.2	A

- 101 -






Ex. No.	Structure	Name	MS	Method
55		N-[3-(2-Aminopyrimidin-5-ylcarbamoyl)-4-methyl-phenyl]-2,3-difluoro-4-trifluoromethyl-benzamide	452.2	A
56		N-[3-(2-Aminopyrimidin-5-ylcarbamoyl)-4-methyl-phenyl]-3-chloro-2,4-difluorobenzamide	418.1	A
57		N-(3-((2-aminopyrimidin-5-yl)carbamoyl)-4-methylphenyl)-2-naphthamide	398.2	A

- 102 -






Ex. No.	Structure	Name	MS	Method
58		N-[3-(2-Amino-pyrimidin-5-ylcarbamoyl)-4-methyl-phenyl]-3,4,5-trifluoro-benzamide	402.2	A
59		N-[3-(2-Amino-pyrimidin-5-ylcarbamoyl)-4-methyl-phenyl]-2,4-dichloro-5-fluoro-benzamide	434.2	A
60		N-[3-(2-Amino-pyrimidin-5-ylcarbamoyl)-4-methyl-phenyl]-4-chloro-2,5-difluoro-benzamide	417.4	A

Ex. No.	Structure	Name	MS	Method
61		N-[3-(2-Amino-4-methyl-phenyl)-2-chloro-6-fluoro-3-methyl-benzamido]pyrimidin-5-ylcarbamoyl-4-methyl-phenyl	414.2	A
62		N-[3-(2-Amino-4-methyl-phenyl)-6-chloro-2-fluoro-3-methyl-benzamido]pyrimidin-5-ylcarbamoyl-4-methyl-phenyl	414.2	A
63		N-(2-aminopyrimidin-5-yl)-2-methyl-5-((1S,2S)-2-phenylcyclopropanecarboxamido)benzamide	387.5	A
64		N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-1-naphthamide	572.3	A

- 104 -

Ex. No.	Structure	Name	MS	Method
65		5-Benzoylamino-2-methyl-N-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl}-benzamide	522.2	A
66		5-acetamido-2-methyl-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)benzamide	460.2	A
67		5-methyl-N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)isoxazole-4-carboxamide	527.2	A
68		2-fluoro-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-5-(trifluoromethyl)benzamide	608.1	A
69		2-Methyl-N-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl}-5-(4-trifluoromethoxy-benzoylamino)-benzamide	606.2	A

- 105 -

Ex. No.	Structure	Name	MS	Method
70		Biphenyl-4-carboxylic acid (4-methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-ylcarbamoyl}-phenyl)-amide	598.2	A
71		N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-2-naphthamide	572.3	A
72		3,4,5-Trifluoro-N-(4-methyl-3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-ylcarbamoyl}-phenyl)-benzamide	576.2	A
73		2,6-Dimethyl-N-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-5-yl}-3-(3-trifluoromethyl-benzoylamino)-benzamide	604.2	A
74		2,2-difluoro-N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)benzo[d][1,3]dioxole-4-carboxamide	602.2	A



- 106 -

Ex. No.	Structure	Name	MS	Method
75		4-fluoro-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	608.2	A
76		2-chloro-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	624.1	A
77		2-methoxy-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)benzamide	552	A
78		3-cyano-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)benzamide	547	A
79		N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-nitro-5-(trifluoromethyl)benzamide	635	A

- 107 -

Ex. No.	Structure	Name	MS	Method
80		mesityl 4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl) carbamoyl)phenyl carbamate	580	A
81		3-iodo-N-(4-methyl-3-((2-(4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino) carbonyl)phenyl) benzamide	648	A
82		3-bromo-N-(4-methyl-3-((2-(4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino) carbonyl)phenyl) benzamide	601	A
83		3-chloro-N-(4-methyl-3-((2-(4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino) carbonyl)phenyl) benzamide	557	A
84		N-(3-((2-(cyclopropylamino)-5-pyrimidinyl)amino) carbonyl)-4-methylphenyl)-2-methyl-3-(trifluoromethyl)benzamide	470	A


- 108 -

Ex. No.	Structure	Name	MS	Method
85		2-methyl-N-(4-methyl-3-(((2-(3-phenylamino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	505.1	I
86		2-methyl-N-(4-methyl-3-(((2-((2-pyridinyl)methyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	521.1	J

Urea linkers "L" between the B rings and R³ groups may be synthesized from N-R¹R²-5-amino-2-methylbenzamide intermediates directly in a single step utilizing desired isocyanates, as described in Example 87 below.

Example 87 illustrates how desired -NR⁸R⁹ groups can be made on a pyrimidyl R¹ ring. The methodology described in Example 87 is also applicable to amino substitutions of other heterocyclic R¹ rings as well, including those defined for R¹ herein.

- 109 -

Example 87

5 Synthesis of 5-amino-2-methyl-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)benzamide

Step 1. Preparation of 5-nitro-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidine

10 To a mixture of 4-(4-Methylpiperazino)aniline (57.7g, 302 mmol), 2-chloro-5-nitropyrimidine (48.1 g, 302 mmol) in IPA (500 mL) was added trifluoroacetic acid (46 mL, 603 mmol). The mixture was heated to 80 °C for 4 h then allowed to cool to room temperature. The solid was collected by
 15 suction filtration, washed twice with IPA (80 mL), methanol (100 mL) then dried under vacuum. Obtained the title compound 22 as a yellowish solid. MS *m/z* found 315 [MH⁺]; Calc'd for C₁₅H₁₈N₆O₂: 314.35.

- 110 -

Step 2. Preparation of N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,5-diamine

A mixture of the salt 22 of Step 1 (96 g, 224 mmol,) was suspended in water (400 mL) and 2 N NaOH was added until the aqueous layer was pH=14. The brick red solid was collected by suction filtration and dried under vacuum overnight. The compound was taken up in EtOH (500 mL) and Palladium on Carbon added (10 g, 10% by weight wet). The mixture was placed in a stirred pressure vessel under 50 psi Hydrogen atmosphere for 48 hrs. The catalyst was removed by suction filtration and washed with EtOH. The organics were concentrated under reduced pressure and dried under vacuum. The crude N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,5-diamine 23 was used without any additional purification.

Step 3. Preparation of 5-nitro-2-methyl-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)benzamide

To a mixture of 2-Methyl-5-nitrobenzoic acid (46.0 g, 181 mmol) in methylene chloride (2 L) was added EDC (61.0 g, 318 mmol). The mixture was allowed to stir for 30 min at rt. N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,5-diamine 23 (60 g, 211 mmol) was added and the mixture allowed to stir 70 hrs. Water (2 L) was added and 2N NaOH added until pH= 14. The organics were extracted into EtOAc (4 L). The aqueous layer was extracted with additional EtOAc (2 L). The combined organics were dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was taken up in 1 L methylene chloride. The solid formed was collected by suction filtration and washed twice with methylene chloride (250 mL). The solid was dried under vacuum to obtain the title compound 24. MS m/z found 448 [MH+]; Calc'd for C₂₃H₂₅N₇O₃: 447.5.


- 111 -

Step 4. 5-amino-2-methyl-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)benzamide

In a 2 L stainless steel pressure vessel with overhead stirring was charged a mixture of the product **24** of Step C (25 g, 55.9 mmol), Absolute ethanol (300 mL), EtOAc (200 mL) and Palladium on Carbon (15 g, 10% by weight wet). The reactor was charged with 65 psi Hydrogen atmosphere for 72 hrs. The catalyst was removed by suction filtration and washed with EtOH. The organics were concentrated under reduced pressure and dried under vacuum. The solid was dried under vacuum to obtain 5-amino-2-methyl-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)benzamide **25**. MS m/z found 418[MH⁺]; Calc'd for C₂₃H₂₇N₇O₁: 417.5.

15

Example 88 (Method B)






1-(4-methyl-3-(pyrimidin-5-ylcarbamoyl)phenyl)-3-(3-(trifluoromethyl)phenyl)urea

To a suspension of 5-amino-2-methyl-N-(pyrimidin-5-yl)benzamide **26** (0.068 g, 0.30 mmol) in benzene (5 mL) was added 1-isocyanato-3-(trifluoromethyl)benzene (0.046 mL, 0.33 mmol). The reaction was heated at 75°C for 2 hours, producing a solid precipitate. The mixture was concentrated and chromatographed on silica gel with 94/6 CH₂Cl₂/MeOH to afford 1-(4-methyl-3-(pyrimidin-5-ylcarbamoyl)phenyl)-3-(3-


- 112 -

(trifluoromethyl)phenyl)urea **27** as a white solid. MS m/z: found 416 [MH⁺], calc. for C₂₀H₁₆F₃N₅O₂ = 415.13.

The following compounds, **Examples 89-91** were made using a procedure similar to that described in Examples 87 and 88.

Ex. No.	Structure	Name	MS	Method
89		1-ethyl-3-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)urea	489.1	B
90		N-(2-amino-5-pyrimidinyl)-2-methyl-5-(((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)benzamide	431	B
91		2-methyl-N-(2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)-5-(((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)benzamide	605.1	B

- 113 -




Example 92 (Method C)


Synthesis of N-(2-aminopyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)phenylsulfonylamino)benzamide.

To a solution of 5-amino-N-(2-aminopyrimidin-5-yl)-2-methylbenzamide **28** (85 mg, 0.349 mmol) in CHCl₃ (2 mL) was added triethylamine (0.453 mmol) and 3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.064 mL, 0.401 mmol). The reaction mixture was heated to reflux for 12 h, cooled to rt and concentrated *in vacuo*. The crude residue was adsorbed on SiO₂ and purified by flash chromatography (CH₂Cl₂/MeOH 99:1) on SiO₂ to afford N-(2-aminopyrimidin-5-yl)-2-methyl-5-(3-(trifluoromethyl)phenylsulfonylamino)benzamide **29**. MS m/z found 452 [MH⁺]; calc. for C₁₉H₁₆F₃N₅O₃S = 451.09.

The following compounds, Examples 93-95 were made using a procedure similar to that described in Example 92.

- 114 -

Ex. No.	Structure	Name	MS	Method
93		N-(2-amino-5-pyrimidinyl)-2-methyl-5-((phenylsulfonyl)amino)benzamide	384.0	C
94		N-(2-aminopyrimidin-5-yl)-5-(3-cyanophenylsulfonylamido)-2-methylbenzamide	408.8	C
95		N-(2-aminopyrimidin-5-yl)-5-(cyclopropanesulfonylamido)-2-methylbenzamide	347.5	C

Example 96 (Method D)

- 115 -

Synthesis of 1-methyl-N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-1H-indole-2-carboxamide.

In a 16 x120 mm resealable pyrex tube, 1-methyl-1H-indole-2-carboxylic acid (0.11 g, 0.62 mmol), HATU (0.24 g, 0.62 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.17 ml, 0.96 mmol) were taken up in DMF (5 mL) and allowed to stir at rt for 30 min. 5-amino-2-methyl-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)benzamide **30** (0.200 g, 0.48 mmol) was added and the mixture was stirred at rt overnight. The crude reaction mixture was taken up in minimal MeOH/DMSO and purified by preparative HPLC (acidic Shimadzu: 15-85% (0.1% TFA in CH₃CN) in H₂O over 20 min). Clean fractions were combined and neutralized with saturated NaHCO₃ then extracted with CH₂Cl₂, dried over Na₂SO₄, filtered and concentrated to afford 1-methyl-N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-1H-indole-2-carboxamide **31** as a tan solid. MS m/z found 575.2 [MH⁺]; calc. for C₃₃H₃₄N₈O₂ = 574.28.




Alternatively, compound **31** may be made using the following various conditions:




- a) desired A-ring acid (RCO₂H), EDC.HCl, HOBT.H₂O, DIEA, DMF ;
- 25 b) desired A-ring acid (RCO₂H), HATU, HOAt, DIEA, DMF;
- or

c) desired A-ring acid (RCO₂H), EDC, HOAt, DIEA, DMF




The following compounds, Examples 97-113 were made using a procedure similar to that described in Examples 96.




- 116 -

Ex. No.	Structure	Name	MS	Method
97		N-(2-amino-5-pyrimidinyl)-2-methyl-5-((3-(methyloxy)propanoyl)amino)benzamide	329.9	D
98		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-4-chloro-2-pyridinecarboxamide	383.0	D
99		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-1-benzofuran-2-carboxamide	387.8	D




Ex. No.	Structure	Name	MS	Method
100		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide	402	D
101		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-3,5-dimethyl-4-(methyloxy)benzamide	406	D
102		N-(2-amino-5-pyrimidinyl)-5-((cyclopropylcarbonyl)amino)-2-methylbenzamide	311.9	D

- 118 -



Ex. No.	Structure	Name	MS	Method
103		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-1,2,3,4-tetrahydro-1-naphthalenecarboxamide	401.9	D
104		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-5-chloro-3-pyridinecarboxamide	382.8	D
105		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-1-methyl-1H-indole-2-carboxamide	400.8	D


Ex. No.	Structure	Name	MS	Method
106		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-1-methyl-3-(trifluoromethyl)-1H-thieno[2,3-c]pyrazole-5-carboxamide	476	D
107		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazole-5-carboxamide	469.9	D
108		N-(3-(((2-amino-5-pyrimidinyl)amino)carbonyl)-4-methylphenyl)-4-bromo-3,5-bis(methoxy)benzamide	487.7	D

- 120 -

Ex. No.	Structure	Name	MS	Method
109		N-(3-((2-aminopyrimidin-5-yl)carbamoyl)-4-methylphenyl)benzo[d]thiazole-6-carboxamide	404.8	D
110		N-(3-((2-aminopyrimidin-5-yl)carbamoyl)-4-methylphenyl)-1H-indole-5-carboxamide	387.2	D
111		N-(4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)quinoline-4-carboxamide	573	D

- 121 -

Ex. No.	Structure	Name	MS	Method
112		2-hydroxy-5-iodo-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)benzamide	664	D
113		4-chloro-N-(4-methyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	625	D

Example 114 (Method E)

- 122 -

Synthesis of 2-fluoro-N-(4-methyl-3-(((2-(phenylamino)-5-pyrimidinyl)amino)carbonyl)phenyl)-5-(trifluoromethyl)benzamide 33

Step 1. Preparation of 5-(2-fluoro-5-

5 (trifluoromethyl)benzamido)-2-methylbenzoic acid

To a 250 mL round-bottomed flask was added 2-methyl-5-nitrobenzoic acid (5.0 g, 28 mmol) and palladium 10% on carbon (1.5 g, 14 mmol). The mixture was taken up in EtOAc (30 mL) then EtOH (70 mL) was added. The mixture was purged with H₂ then allowed to stir at 1 atm. H₂ for 24 h. LCMS indicated about 10 % conversion to product. About 0.5 g 10% Pd/C and ~30 mL MeOH was added to the reaction. The reaction was purged with H₂ and let to stir at 1 atm H₂ for 20 h. The reaction was monitored for complete conversion by LCMS. The mixture was passed through a pad of celite, washing with MeOH and concentrated to afford 5-amino-2-methylbenzoic acid as an off-white solid MS m/z found 152.1 (ESI, neg. ion).

Step 2.

20 To a 100 mL round-bottomed flask containing 2-fluoro-5-(trifluoromethyl)benzoyl chloride (0.44 mL, 2.9 mmol) in CH₂Cl₂ (30 mL) was added triethylamine (0.48 mL, 3.4 mmol). After 10 min, 5-amino-2-methylbenzoic acid (0.400 g, 2.6 mmol) was added. The solution was stirred at rt overnight. 25 After cooling, the crude reaction mixture was concentrated to remove excess NEt₃ then diluted with CH₂Cl₂ and washed with 1 N HCl once, and brine & salt once then dried over Na₂SO₄ to afford 5-(2-fluoro-5-(trifluoromethyl)benzamido)-2-methylbenzoic acid 32 as an off-white solid. MS m/z found: 30 342.1 (ESI, pos. ion).


Step 3:

5-(2-fluoro-5-(trifluoromethyl)benzamido)-2-methylbenzoic acid 32 (0.25 g, 0.73 mmol), HATU (0.28 g,

- 123 -





0.73 mmol), and N-ethyl-N-isopropylpropan-2-amine (0.20 mL, 1.1 mmol) were taken up in DMF (6 mL). The solution was stirred at rt for 30 min then N2-phenylpyrimidine-2,5-diamine (0.105 g, 0.56 mmol) was added and the mixture was
 5 allowed to stir at rt overnight. The crude reaction mixture was taken up in minimal MeOH/DMSO and purified by preparative HPLC (acidic Gilson: 10-90% (0.1% TFA in CH₃CN) in H₂O over 15 min). Clean fractions were combined and allowed to stand for 2 h. Some product.TFA salt crashed out
 10 and was collected and neutralized with saturated NaHCO₃ then extracted with CH₂Cl₂, dried over Na₂SO₄, filtered and concentrated to afford 2-fluoro-N-(4-methyl-3-((2-(phenylamino)-5-pyrimidinyl) amino) carbonyl)phenyl)-5-(trifluoromethyl)benzamide **33** as a white solid. MS m/z
 15 found 510.1 [MH⁺]; calc. for C₂₆H₁₉F₄N₅O₂ = 509.15.

The following compounds, Examples 115-126 were made using a procedure similar to that described in Examples 114.




Ex. No.	Structure	Name	MS	Method
115		N-(4-chloro-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl) carbamoyl)phenyl)-2,2-difluorobenzo[d][1,3]dioxole-5-carboxamide	622	E

Ex. No.	Structure	Name	MS	Method
116		2-chloro-N-(2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)-5-((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide	610.2	E
117		2-methyl-N-(4-chloro-3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-3-(trifluoromethyl)benzamide	624.1	E
118		2-chloro-5-((4-(1,1-dimethylethyl)phenyl)carbonyl)amino)-N-(2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)benzamide	598.3	E
119		2-fluoro-N-(4-chloro-3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl)amino)carbonyl)phenyl)-5-(trifluoromethyl)benzamide	628.2	E


- 125 -

Ex. No.	Structure	Name	MS	Method
120		N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2-methyl-3-(trifluoromethyl)benzamide	524	E
121		N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2,2-difluorobenzo[d][1,3]dioxole-4-carboxamide	522.1	E
122		N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2,2-difluorobenzo[d][1,3]dioxole-5-carboxamide	522.1	E
123		2-chloro-N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide	544	E

- 126 -

Ex. No.	Structure	Name	MS	Method
124		N-(3-((6,7-dimethoxyquinolin-3-yl) carbamoyl)-4-ethylphenyl)-2-methyl-3-(trifluoromethyl)benzamide	538.2	E
125		2-methyl-N-(4-ethyl-3-(((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)-5-pyrimidinyl) carbonyl)phenyl)-3-(trifluoromethyl)benzamide	618.2	E
126		4-methyl-N3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)-N1-(naphthalen-1-yl)isophthalamide	572	E

- 127 -

Example 127 (Method F)

5 Synthesis of N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-N3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)isophthalamide

10 Step 1. N-(2-Fluoro-5-(trifluoromethyl)phenyl)-3-iodo-4-methylbenzamide

10 A solution of 3-iodo-4-methylbenzoic acid (10.0 g, 38.2 mmol) in thionyl chloride (30.0 mL) was heated at reflux for 3 hours. The resulting yellow solution was cooled to room temperature and concentrated under reduced pressure to afford 3-iodo-4-methylbenzoyl chloride. A

15 solution of 3-iodo-4-methylbenzoyl chloride (1 g, 4 mmol) in dichloromethane (10 mL) was added slowly to a 0 °C solution of 3-amino-4-fluorobenzotrifluoride (0.7 mL, 4 mmol) and diisopropylethylamine (0.9 mL, 5 mmol) in dichloromethane (10 mL). The reaction stirred at 0 °C and warmed to room

20 temperature over 20 hours. The reaction mixture was purified via column chromatography on silica gel (gradient elution with 0 to 100% ethyl acetate-hexane) to afford N-(2-

- 128 -

fluoro-5-(trifluoromethyl)phenyl)-3-iodo-4-methylbenzamide
34 MS m/z found 423.9 [MH⁺]; calc. for C₁₅H₁₀F₄INO = 423.14.

Step 2. Methyl 5-((2-fluoro-5-
5 (trifluoromethyl)phenyl)carbamoyl)-2-methylbenzoate

A stainless steel cylinder equipped with a glass liner
was charged with N-(2-fluoro-5-(trifluoromethyl)phenyl)-3-
iodo-4-methylbenzamide 34 (1.089 g, 2.57 mmol), methanol (20
mL), and a magnetic stir bar. Argon gas was bubbled through
10 this solution for one minute, and then triethylamine (0.358
ml, 2.57 mmol), 1,3-bis(diphenylphosphino)propane (0.0584 g,
0.142 mmol), and palladium(II) acetate (0.0289 g, 0.129
mmol) were added. The cylinder was sealed, charged to 200
psi of CO gas, placed into an oil bath at 75 °C and stirred
15 for 2 hours. The reaction was cooled to room temperature,
and palladium(II) acetate (0.0289 g, 0.129 mmol), DMF (2
mL), 1,3-bis(diphenylphosphino)propane (0.0584 g, 0.142
mmol), and triethylamine (0.358 ml, 2.57 mmol) were added.
The cylinder was sealed, charged to 200 psi of CO gas,
20 placed into an oil bath at 75 °C and stirred 48 hours. The
reaction mixture was cooled to room temperature and
concentrated. The residue was purified via column
chromatography on silica gel (gradient elution 0 to 100%
ethylacetate in hexane) to afford methyl 5-((2-fluoro-5-
25 (trifluoromethyl)phenyl)carbamoyl)-2-methylbenzoate 35 as
pale yellow solid. MS m/z found 356 [MH⁺]; calc. for
C₁₇H₁₃F₄NO₃ = 355.28.

Step 3. 5-((2-fluoro-5-(trifluoromethyl)phenyl)carbamoyl)-
30 2-methylbenzoic acid

A solution of methyl 5-((2-fluoro-5-
(trifluoromethyl)phenyl)carbamoyl)-2-methylbenzoate 35
(0.904 g, 2.5 mmol), THF (20 mL), lithium hydroxide (0.18 g,
7.6 mmol), and water (5 mL) was heated at 55 °C for 24 hours

- 129 -





and then cooled to room temperature. The aqueous layer was separated, cooled in an ice-water bath, and acidified with 6 M HCl (aq) to pH 1. This solution was extracted with ethyl acetate (3 x 10 mL), and the combined organic phases were
 5 dried over anhydrous sodium sulfate, filtered, and concentrated to afford 5-((2-fluoro-5-(trifluoromethyl)phenyl)carbamoyl)-2-methylbenzoic acid **36**. MS m/z found 342 [MH⁺]; calc. for C₁₆H₁₁F₄NO₃ = 341.26.

10 Step 4. N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-N3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)isophthalamide




A 16x100 mm vial was charged with 5-((2-fluoro-5-(trifluoromethyl)phenyl)carbamoyl)-2-methylbenzoic acid **36**
 15 (0.100 g, 0.293 mmol), dichloromethane (3 mL), diisopropylethylamine (0.200 mL, 1.15 mmol), 1-hydroxybenzotriazole (0.0396 g, 0.293 mmol), EDC·HCl (0.0562 g, 0.293 mmol), and N2-(4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,5-diamine (0.0875 g, 0.308 mmol), and
 20 the mixture stirred at room temperature for 24 hours. The reaction mixture was purified via column chromatography on silica gel (gradient elution with 0 to 20% methanol in dichloromethane) to afford N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-N3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)isophthalamide **37** as a light yellow solid. MS m/z found
 25 608 [MH⁺]; calc. for C₃₁H₂₉F₄N₇O₂ = 607.60.


The following compounds, Examples 128-134 were made
 30 using a procedure similar to that described in Examples 127.

- 130 -

Ex. No.	Structure	Name	MS	Method
128		N3-(6,7-dimethoxyquinolin-3-yl)-4-methyl-N1-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)isophthalamide	622.2	F
129		N3-(6,7-dimethoxyquinolin-3-yl)-N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methylisophthalamide	528.1	F
130		4-methyl-N3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)-N1-(3-(trifluoromethyl)phenyl)isophthalamide	590.2	F
131		4-methyl-N1-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-N3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)isophthalamide	351.7	F

- 131 -


Ex. No.	Structure	Name	MS	Method
132		4-methyl-N3-(quinolin-3-yl)-N1-(3-(trifluoromethyl)phenyl)isophthalamide	450.1	F
133		4-methyl-N1-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-N3-(quinolin-3-yl)isophthalamide	562	F
134		N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-N3-(quinolin-3-yl)isophthalamide	468	F

Example 135 (Method G)

5 Synthesis of N-(4-ethyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-2,2-
difluorobenzo[d][1,3]dioxole-5-carboxamide

A resealable tube was charged with N-(4-chloro-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-2,2-difluorobenzo[d][1,3]dioxole-5-carboxamide **38** (0.050 g, 0.080 mmol), palladium(II) acetate (0.0018 g, 0.0080 mmol), 2-(dicyclohexylphosphino)-2',6'-dimethoxy-1,1'-biphenyl (0.0066 g, 0.016 mmol), potassium phosphate (0.068 g, 0.32 mmol), and DMF (2.0 mL). A solution of triethylborane (0.12 mL, 0.12 mmol) (1M in THF) was added. The reaction tube was evacuated and purged with argon, and then sealed. The mixture stirred at 100° C for 6 h. The reaction mixture was filtered through a pad of Celite and concentrated to afford a yellow green solid. This material was purified via preparative thin layer chromatography (eluting three times with 95:5:0.5, dichloromethane/methanol/ammonium hydroxide) to afford N-(4-ethyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenyl)-2,2-difluorobenzo[d][1,3]dioxole-5-carboxamide **39** as an off-white solid. MS m/z found 616.2 [MH⁺]; calc. for C₃₂H₃₁F₂N₇O₄ = 615.63.

- 133 -

Example 136 (Method H)


Synthesis of 2-methyl-5-(((2-((1-methyl-4-piperidinyl)oxy)-5-(trifluoromethyl)phenyl)carbonyl)amino)-N-(2-(phenylamino)-5-pyrimidinyl)benzamide

To a suspension of potassium t-butoxide (17 mg, 0.151 mmol) in THF (2mL) was added 1-methylpiperidin-4-ol (15 mg, 0.130 mmol). The mixture was allowed to stir at rt for 15 min, at which time 2-fluoro-N-(4-methyl-3-((2-(phenylamino)-5-pyrimidinyl)amino)carbonyl)phenyl)-5-(trifluoromethyl)benzamide **40** (55mg, 0.108 mmol) was added. The reaction mixture was stirred at room temperature for 24 h, at which time the LCMS showed complete conversion. The reaction mixture was diluted with CH₂Cl₂, washed with water (3 x 20 mL), dried over Na₂SO₄ and concentrated. The crude residue was taken up in MeOH/DMSO and purified on the Shimadzu reversed phase HPLC with a 15-85% gradient. Pure fractions were combined, basified with saturated sodium bicarbonate and extracted with CH₂Cl₂ (4 x 20mL). Combined organic extracts were dried over sodium sulfate and concentrated to afford 2-methyl-5-(((2-((1-methyl-4-piperidinyl)oxy)-5-(trifluoromethyl)phenyl)carbonyl)amino)-N-(2-(phenylamino)-5-pyrimidinyl)benzamide **41**. MS m/z found 605.3 [MH⁺]; calc. for C₃₂H₃₁F₃N₆O₃ = 604.24.

5

3-amino-N-(2-aminopyrimidin-5-yl)-2-methylbenzamide **42**
(113 mg, 0.464 mmol) [prepared according to the procedure
described for methylbenzamide-5-amino-N-(2-aminopyrimidin-5-
yl)-2-methylbenzamide in Example 1] was taken up in CH₂Cl₂
(4 mL) and pyridine (3 mL) and 3-(trifluoromethyl)benzoyl
chloride (0.31 mL, 2.09 mmol) was added followed by NEt₃
(0.13 mL, 0.928 mmol). Complete consumption of the amine
starting material was indicated by LCMS. The crude
reaction mixture was concentrated and the product purified
using automated medium pressure chromatography (Isco - 40 g
column; eluting with a linear gradient from 97% CH₂Cl₂ (A
line) to 100% 90/10/1 CH₂Cl₂/MeOH/NH₃ (B line) on silica gel)
to afford N-(2-amino-5-pyrimidinyl)-2-methyl-3-(((3-
(trifluoromethyl)phenyl)carbonyl)amino)benzamide **43** as an
off-white solid. MS m/z found 416 [MH⁺]; calc. for
C₂₀H₁₆F₃N₅O₂ = 415.13; and 2-methyl-3-(((3-
(trifluoromethyl)phenyl)carbonyl)amino)-N-(2-(((3-
(trifluoromethyl)phenyl)carbonyl)amino)-5-
pyrimidinyl)benzamide **44** as an off-white solid. MS m/z
found 588 [MH⁺]; calc. for C₂₈H₁₉F₆N₅O₃ = 587.14.

- 135 -

Example 138 (Method L)

5 Synthesis of 2-methyl-N-(5-pyrimidinyl)-5-((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide

Step 1.

The method followed in step 1 was analogous to that described in Can. J. Chem. vol.77, 216-222 (1999). A high-pressure 1L reaction vessel was charged with ether (300mL) and a catalyst, palladium 10% on carbon wet (50% water) (1.68g) was added, followed by 4,6-dichloropyrimidin-5-amine (21g). A sodium hydroxide solution 50% (168mL) was diluted with water (150mL) and added to the previous mixture. The biphasic mixture was pressurized at 35psi of H₂ and mechanically stirred for 24h. More catalyst was added at this point (1.5g) and the reaction was resubmitted to H₂ for 24h. The reaction was complete as monitored by LCMS and was filtered through celite and rinsed with water. The biphasic mixture was separated and the aqueous phase was extracted 3 times with ether. The organics were combined, dried over MgSO₄, filtered and concentrated down to afford the crude 5-amino-pyrimidine product as a yellow solid. It was

- 136 -

recrystallized from toluene/MeOH. The aqueous phase was re-extracted twice using EtOAc, the organics were dried over MgSO₄, filtered and concentrated down to afford more desired product. The solids were all combined to yield product
5 pyrimidin-5-amine.

Step 2.

In a 2L round bottom flask with mechanical stirring was charged with 2-methyl-5-nitrobenzoic acid (20g), HATU
10 (38g) and diisopropylamine (32mL) in DMF (90mL). This mixture was stirred for 30 min then pyrimidin-5-amine was added and the reaction was stirred for 18hr. The LCMS showed complete conversion. DMF was removed under vacuum as much as possible then water was added and a solid
15 precipitated out (use mechanical stirring). The tan solid was filtered and rinsed with water, then taken up in EtOAc, washed with brine, dried over MgSO₄, filtered and concentrated down. The crude was taken up in EtOAc and the product **45** precipitated out. This was filtered and the
20 filtrate was concentrated down and taken up in EtOAc/Hex. After standing overnight, more solids were filtered and were combined with the first crop. 2-methyl-5-nitro-N-(pyrimidin-5-yl)benzamide **45** was obtained as a light yellow solid.

25

Step 3. 5-amino-2-methyl-N-(pyrimidin-5-yl)benzamide

A 2L high-pressure vessel was charged with Palladium 10% on carbon wet (50% water) and EtOAc (50mL). 2-methyl-5-nitro-N-(pyrimidin-5-yl)benzamide **45** (18.79g) was dissolved
30 in methanol (400mL) and added to the previous mixture. The reaction vessel was pressurized to 30 psi of H₂ and mechanically stirred until the hydrogen intake stopped. The reduction of the nitro group was complete by LCMS and the mixture was filtered off through paper and glass paper. The
35 crude 5-amino-2-methyl-N-(pyrimidin-5-yl)benzamide **46** was

- 137 -


obtained as a yellow solid and used without further purification.

Step 4.

- 5 The title compound, 2-methyl-N-(5-pyrimidinyl)-5-((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide, was prepared from compound 46 obtained in Step 3 according to the procedure described in the Step 4 of Example 1. MS m/z found 400.7 [MH⁺]; calc. for C₂₀H₁₅F₃N₄O₂ = 400.11.


10

Example 139 (Method N)



15 Synthesis of mesityl 4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenylcarbamate

- A 16x100 mm vial was charged with 5-amino-2-methyl-N-(2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)benzamide **30** (0.100 g, 0.24 mmol), 4-(dimethylamino)pyridine (0.0059 g, 0.048 mmol),
 20 dichloromethane (2 mL), and diisopropylethylamine (0.050 mL, 0.29 mmol). A solution of mesityl carbonochloridate (0.048 g, 0.24 mmol) in dichloromethane (1 mL) was added dropwise and the reaction mixture stirred at room temperature for 20 hours. The reaction mixture was purified via column
 25 chromatography on silica gel (gradient elution with 0 to 20% methanol in dichloromethane) to afford mesityl 4-methyl-3-((2-(4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-5-yl)carbamoyl)phenylcarbamate **47** as a bright yellow solid. MS m/z found 580 [MH⁺]; calc. for C₃₃H₃₇N₇O₃ = 579.69.

Example 140 (Method O)

5

Synthesis of N3-(4-amino-2-(methylamino)pyrimidin-5-yl)-4-methyl-N1-(2-methyl-3-(trifluoromethyl)phenyl)isophthalamide

Step 1. 2-chloro-5-nitropyrimidin-4-amine

10 To a rapidly stirred solution of saturated aqueous ammonium hydroxide (50 mL) and ice in a 0 deg. C bath was added 2,4-dichloro-5-nitropyrimidine (6.0 g, 31 mmol) in portions. The resulting yellow foamy mixture was allowed to stir for 30 min, at which point the precipitate was isolated
15 by filtration. The solid was rinsed several times with ice-cold water and once with ice cold ethanol to give a peach-colored solid. The crude solid was purified by adsorption onto 18 g silica gel, followed by silica gel chromatography, eluting with 0-20% MeOH/dichloromethane to give 2-chloro-5-nitropyrimidin-4-amine as an off-white solid. MS (ES⁺): 175
20 (M+H)⁺; Calc. for C₄H₃ClN₄O₂ = 174.55.

Step 2. N2-methyl-5-nitropyrimidine-2,4-diamine

25 A mixture of 2-chloro-5-nitropyrimidin-4-amine (1.0 g, 5.8 mmol) and methylamine (2.0 M solution in THF, 14 mL, 28 mmol) was allowed to stir in a sealed vessel for 1 h. The

- 139 -

mixture was then heated to 60 deg. C for 30 min. The reaction was cooled to ambient temperature, and an additional amount of methylamine (2.0 M solution in THF, 8 mL, 16 mmol) was added and the reaction was sealed and
5 heated to 60 deg. C for 30 min. The reaction was cooled, diluted with water, and the precipitate was collected by filtration. The solid was rinsed with small portions of water followed by diethyl ether. The material was dried in under reduced pressure to give N2-methyl-5-nitropyrimidine-
10 2,4-diamine **48** as a light yellow solid. MS (ES⁺): 170 (M+H)⁺; Calc. for C₅H₇N₅O₂=169.14.

Step 3. N2-methylpyrimidine-2,4,5-triamine

N2-methyl-5-nitropyrimidine-2,4-diamine **48** (0.83 g, 4.9 mmol) and 10% palladium on carbon (0.52 g, .49 mmol)
15 were combined under nitrogen. Methanol (16 mL) was added, and the atmosphere replaced with hydrogen from a balloon. The reaction was stirred rapidly for 6 h, at which point the atmosphere was replaced with nitrogen and the reaction
20 mixture was filtered through celite, rinsing with methanol. The filtrate was concentrated in vacuo to give N2-methylpyrimidine-2,4,5-triamine **49** as a light pink solid. MS (ES⁺): 140 (M+H)⁺; Calc. for C₅H₉N₅= 139.16.

25 Step 4. N3-(4-amino-2-(methylamino)pyrimidin-5-yl)-4-methyl-N1-(2-methyl-3-(trifluoromethyl)phenyl)isophthalamide


To a small glass vessel was added N2-methylpyrimidine-2,4,5-triamine **49** (0.050 g, 0.36 mmol), 3-iodo-4-methyl-N-(2-methyl-3-(trifluoromethyl)phenyl)benzamide (0.15 g, 0.36
30 mmol) [prepared from 3-iodo-4-methylbenzoic acid and 2-methyl-3-(trifluoromethyl)benzenamine as shown in the first step of Example 127], and Bis(triphenylphosphine)palladium(II) dichloride (0.013 g, 0.018 mmol). A septum was attached and the mixture was

- 140 -


purged with N₂. 2,6-Lutidine (0.054 ml, 0.47 mmol) was added via syringe and the mixture was flushed with CO(g) in a pressure reaction vessel and placed under 95 psi then heated at 120 C for 24 h. The reaction was allowed to cool to rt then the pressure was released and the sticky red residue was analyzed by LCMS. MS for the title compound was found to be (ESI, pos. ion) m/z: 459.1 [M+1]. The crude residue was triturated with MeOH and allowed to stir at rt overnight. The crude reaction mixture was filtered through a Buchner apparatus with micromembrane filter, and the filtrate was washed with copious amounts of MeOH. The mother liquors were concentrated to a sticky deep red solid after drying. This material was taken up in minimal amount of CH₂Cl₂ and the solution was injected onto the Isco {Redi-Sep® pre-packed silica gel column (40 g); eluent gradient: 3-80% 90/10/1 CH₂Cl₂/MeOH/NH₃ in CH₂Cl₂ over 20 min} to afford N3-(4-amino-2-(methylamino)pyrimidin-5-yl)-4-methyl-N1-(2-methyl-3-(trifluoromethyl)phenyl)isophthalamide **50** as off-white solid. MS m/z found 459.1 [M+]; calc. for C₂₂H₂₁F₃N₆O₂ = 459.17.

Additional examples 141-143 were prepared by methods described above.


Example 141




- 141 -

Example 142

5

Example 143

10

Example 144

51

Synthesis of N3-(6-aminopyridin-3-yl)-N1-(2-cyclopentylethyl)-4-methylisophthalamide (51)

15 Step 1:

In a round-bottomed flask was charged 3-iodo-4-methylbenzoic acid (1.4 g, 5.4 mmol), dichloromethane (4 ml), and DMF (2

- 142 -

ml). This mixture was cooled to 0 °C and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.2 g, 6.3 mmol) was added. The reaction mixture was stirred for 10 min before 2-cyclopentylethanamine (0.47 g, 4.2 mmol) was introduced. The reaction mixture was stirred at 0 °C for 1 h, then at RT under N₂ for 16 h. The reaction was partitioned between DCM (60 ml) and brine (50 mL). The aqueous layer was back extracted with DCM (4 × 20 mL) and the combined DCM layer was dried (Na₂SO₄) and concentrated. The crude product was dissolved in DCM and purified by chromatography through a Redi-sep pre-packed silica gel column (330 g), eluting with a gradient of 5% to 15% EtOAc in hexane, to provide N-(2-cyclopentylethyl)-3-iodo-4-methylbenzamide as a white solid. MS (ESI, pos. ion) m/z: 358.1 (M+1).

Step 2:

Into a 120mL pressure cylinder with glass liner was placed N-(2-cyclopentylethyl)-3-iodo-4-methylbenzamide (1.7 g, 4.9 mmol) and methanol (25 mL). Nitrogen was bubbled through this mixture, then palladium acetate (55 mg, 0.24 mmol), 1,3-bis(diphenylphosphino)propane (0.11 g, 0.27 mmol), and triethylamine (1.6 ml, 11.6 mmol) were added. The cylinder was capped with a pressure gauge and charged to 40 psi of CO gas. The reaction was heated in a 75 °C oil bath for 20 h. The orange precipitate was filtered off and the filtrate was concentrated under vacuum. The red residue was dissolved in DCM and purified by chromatography through a Redi-Sep® pre-packed silica gel column (120 g), eluting with a gradient of 10% to 25% of EtOAc in hexane, to provide methyl 5-((2-cyclopentylethyl)carbamoyl)-2-methylbenzoate as a white solid. MS (ESI, pos. ion) m/z: 290.2 (M+1).

- 143 -

Step 3:

To methyl 5-((2-cyclopentylethyl) carbamoyl)-2-methylbenzoate (1.2 g, 4.3 mmol) dissolved in THF (15 mL) was added a solution of LiOH, monohydrate (0.27 g, 6.4 mmol) in water (15 mL). The reaction mixture was stirred at RT for 18 h. THF was removed, the residue was extracted with ether (5 mL) and the layers were separated. To the aqueous layer was added 2N HCl until pH 4-5 (a lot of precipitate formed). The solid was collected by filtration, washed with water, dried to give 5-((2-cyclopentylethyl) carbamoyl)-2-methylbenzoic acid as a white solid. MS (ESI, pos. ion) m/z : 276.2 (M+1).


Step 4:

In a RBF was charged 5-((2-cyclopentylethyl) carbamoyl)-2-methylbenzoic acid (0.25 g, 0.91 mmol), DCM (3 ml), *n,n*-diisopropylethylamine (0.6 ml, 3.5 mmol), HOBt (0.14 g, 1.0 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.21 g, 1.1 mmol), and 2,5-diaminopyridine (0.1 g, 0.91 mmol) in that order. This mixture was stirred at RT under N₂ for 18 h. The reaction was partitioned between DCM (30 ml) and brine (20 mL). The precipitate formed was collected, washed with water, dried in a vacuum oven overnight to give N3-(6-aminopyridin-3-yl)-N1-(2-cyclopentylethyl)-4-methylisophthalamide as a purple solid. MS (ESI, pos. ion) m/z : 367.2 (M+1).

Example 145


Synthesis of N1-(2-cyclopentylethyl)-4-methyl-N3-(6-(3-methylbutanamido)pyridin-3-yl)isophthalamide (52)

- 144 -



To a 25 mL round-bottomed flask was added N3-(6-aminopyridin-3-yl)-N1-(2-cyclopentylethyl)-4-methylisophthalamide (0.19 g, 0.52 mmol) and Triethylamine (0.18 mL, 1.3 mmol) to stir at 0 °C. Isovaleryl chloride (0.14 mL, 1.0 mmol) was added to the solution dropwise. The reaction was allowed to stir for one hour. At which time was shown to be at completion by LC/MS. DI water was added to the reaction. The reaction was transferred to a separatory funnel, where the aqueous layer was extracted 3 times with DCM. The combined organic layers were washed with brine, saturated NaHCO₃, dried with MgSO₄, filtered, and concentrated. The crude product was adsorbed onto a plug of silica gel and chromatographed through a Biotage pre-packed silica gel column (25M), eluting with a gradient of 1% to 10% MeOH in CH₂Cl₂, to provide N1-(2-cyclopentylethyl)-4-methyl-N3-(6-(3-methylbutanamido)pyridin-3-yl)isophthalamide as a white solid. MS (ESI, pos. ion) *m/z*: 451.3 (M+1).

20

Example 146

- 145 -

Synthesis of N3-(6-aminopyridin-3-yl)-N1-
(cyclopropylmethyl)-4-methylisophthalamide (53)

Step 1:

5 A pressure vessel was charged with methyl 3-bromo-4-methylbenzoate (5.0 g, 22 mmol), DMF (20 ml), water (1.25 ml) and tributylamine (8 ml, 34 mmol). Cesium acetate (2.1 g, 11 mmol) was then added and the flask was purged with N₂. Palladium acetate (0.25 g, 1.0 mmol) and triphenylphosphine
10 (2.9 g, 11 mmol) were added and the flask was purged with CO gas. The reaction mixture was then heated at 90 °C under 20 psi of CO gas with vigorous stirring overnight. The reaction mixture was diluted with 50 mL of toluene and extracted with saturated NaHCO₃ (3 × 50 mL). The combined aqueous layer was
15 washed with EtOAc (10 mL), then acidified using 2 N HCl to pH 5. The volume was reduced to about 50 mL and the resulting precipitate was collected by filtration, washed with water and dried to give 5-(methoxycarbonyl)-2-methylbenzoic acid as a white solid. MS (ESI, pos. ion) m/z:
20 193.1 (M-1).

Step 2:

In a round-bottomed flask was charged 5-(methoxycarbonyl)-2-methylbenzoic acid (0.2 g, 1.0 mmol), dichloromethane (3 ml),
25 n,n-diisopropylethylamine (0.7 ml, 4.0 mmol), HOBt (0.16 g, 1.2 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.24 g, 1.2 mmol), and 2,5-diaminopyridine (0.11 g, 1.0 mmol) in that order. The reaction mixture was stirred at RT under N₂ for 18 h. The reaction was
30 partitioned between DCM (30 ml) and brine (20 mL). The aqueous layer was back extracted with DCM (3 × 15 mL) and the combined DCM layer was dried (Na₂SO₄) and concentrated. The crude product was dissolved in MeOH and absorbed on silica gel, purified by chromatography through a Redi-Sep 40

- 146 -

g column, eluting with a gradient of 0% to 10% MeOH in CH₂Cl₂, to provide methyl 3-((6-aminopyridin-3-yl)carbamoyl)-4-methylbenzoate as a tan solid. MS (ESI, pos. ion) *m/z*: 286.2 (M+1).

5 Step 3:

To methyl 3-((6-aminopyridin-3-yl)carbamoyl)-4-methylbenzoate (0.11 g, 0.39 mmol) dissolved in tetrahydrofuran (1.5 mL) was added a solution of lithium hydroxide, monohydrate (24 mg, 0.58 mmol) in water (1.5 mL).

10 The reaction mixture was stirred at RT for 4 h. THF was removed in vacuo and to the aqueous layer was added 2N HCl until pH 4-5. The precipitate formed was collected by filtration, washed with water, dried to give 3-((6-aminopyridin-3-yl)carbamoyl)-4-methylbenzoic acid as a tan
15 solid. MS (ESI, pos. ion) *m/z*: 272.1 (M+1).

Step 4:


In a round-bottomed flask was charged 3-((6-aminopyridin-3-yl)carbamoyl)-4-methylbenzoic acid (70 mg, 0.26 mmol), DCM
20 (1 mL), and DMF (1 mL). 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (74 mg, 0.39 mmol) was then added. The reaction mixture was stirred for 10 min before (aminomethyl)cyclopropane (27 μ L, 0.31 mmol) was introduced. The reaction mixture was stirred at RT under N₂ for 16 h.

25 The reaction was partitioned between DCM (15 mL) and brine (10 mL). The aqueous layer was back extracted with DCM (3 $\times$ 10 mL) and the combined DCM layer was dried (Na₂SO₄) and concentrated. The crude product was dissolved in DCM and purified by chromatography through a Redi-Sep® pre-packed
30 silica gel column (40 g), eluting with a gradient of 0% to 10% MeOH in CH₂Cl₂, to provide N³-(6-aminopyridin-3-yl)-N¹-(cyclopropylmethyl)-4-methylisophthalamide as an off-white solid. *m/z*: 325.2 (M+1).

- 147 -


Examples 147 and 148, building block materials for compounds of Formulas I-III, were prepared according to the literature references provided below.

5

Example 147

U.S. Pat. Appl. Publ. (2005), 43 pp. CODEN: USXXCO US
2005256125 A1 20051117 CAN 143:460185 AN 2005:1224270

10

Example 148

Synthesis 2005, 15, 2503-2506.

Each of the following examples 149-221 of Formulas I-III were made using a procedure analogous to that described in examples 1, 2, 88, 96, 114, 127, 136-140 or 144-146.

Ex. No.	M+H	Compound Name
149	421.1	2-chloro-N-5-pyrimidinyl-5-((3-(trifluoromethyl)phenyl)carbonyl)amino)benzamide
150	452.2	2-chloro-5-(((4-(4-morpholinylmethyl)phenyl)carbonyl)amino)-N-5-pyrimidinylbenzamide
151	381.1	2-chloro-5-(((4-ethylphenyl)carbonyl)amino)-N-5-pyrimidinylbenzamide
152		2-chloro-5-((3-cyclopentylpropanoyl)amino)-N-5-pyrimidinylbenzamide
153		5-(acetylamino)-2-chloro-N-5-pyrimidinylbenzamide
154		2-chloro-N-5-pyrimidinyl-5-((3-(1-pyrrolidinyl)propanoyl)amino)benzamide

155	400.1	4-methyl-N~3~-3-pyridinyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
156	434	N~3~- (6-chloro-3-pyridinyl)-4-methyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
157	418	N~1~- (2-fluoro-5- (trifluoromethyl)phenyl)-4-methyl-N~3~-3-pyridinyl-1,3-benzenedicarboxamide
158	433	N~3~- (6-amino-3-pyridinyl)-N~1~- (2-fluoro-5- (trifluoromethyl)phenyl)-4-methyl-1,3-benzenedicarboxamide
159	401.1	4-methyl-N~3~-5-pyrimidinyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
160	401.1	4-methyl-N~3~-2-pyrimidinyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
161	401.1	4-methyl-N~3~-2-pyrazinyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
162	415.1	N~3~- (6-amino-3-pyridinyl)-4-methyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
163	416.1	N~3~- (2-amino-5-pyrimidinyl)-4-methyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
164	401.1	4-methyl-N~3~-4-pyridazinyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
165	418.1	N~3~- (3,5-dimethyl-4-isoxazolyl)-4-methyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
166	457.1	N~3~- (6- (acetylamino)-3-pyridinyl)-4-methyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
167	458.2	N~3~- (2- (acetylamino)-5-pyrimidinyl)-4-methyl-N~1~- (3- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
168	353.2	N~1~- (2-cyclopentylethyl)-4-methyl-N~3~-5-pyrimidinyl-1,3-benzenedicarboxamide
169	367.2	N~3~- (6-amino-3-pyridinyl)-N~1~- (2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
170	415.1	N~3~- (6-amino-3-pyridinyl)-4-methyl-N~1~- (4- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
171	401.1	4-methyl-N~3~-5-pyrimidinyl-N~1~- (4- (trifluoromethyl)phenyl)-1,3-benzenedicarboxamide

- 149 -

172	445.1	N~3~~(6-amino-3-pyridinyl)-4-methyl-N~1~~(4-(methyloxy)-3-(trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
173	409.2	N~3~~(6-(acetylamino)-3-pyridinyl)-N~1~~(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
174	431.1	4-methyl-N~1~~(4-(methyloxy)-3-(trifluoromethyl)phenyl)-N~3~~5-pyrimidinyl-1,3-benzenedicarboxamide
175	395.2	N~1~~(2-cyclopentylethyl)-N~3~~(6-(ethylamino)-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
176	368.2	N~3~~(2-amino-5-pyrimidinyl)-N~1~~(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
177	410.2	N~3~~(2-(acetylamino)-5-pyrimidinyl)-N~1~~(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
178	381.2	N~3~~(6-amino-5-methyl-3-pyridinyl)-N~1~~(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
179	382.2	N~1~~(2-cyclopentylethyl)-4-methyl-N~3~~(6-(methyloxy)-3-pyridinyl)-1,3-benzenedicarboxamide
180	391.3	N~1~~(2-cyclopentylethyl)-4-methyl-N~3~~1H-pyrrolo[2,3-b]pyridin-5-yl-1,3-benzenedicarboxamide
181	420.2	N~1~~(2-cyclopentylethyl)-4-methyl-N~3~~(6-(trifluoromethyl)-3-pyridinyl)-1,3-benzenedicarboxamide
182	381.3	N~3~~(6-amino-3-pyridinyl)-N~1~~(2-cyclohexylethyl)-4-methyl-1,3-benzenedicarboxamide
183	451.3	N~1~~(2-cyclopentylethyl)-N~3~~(6-((2,2-dimethylpropanoyl)amino)-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
184	435.2	N~1~~(2-cyclopentylethyl)-N~3~~(6-((cyclopropylcarbonyl)amino)-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
185	449.2	N~1~~(2-cyclopentylethyl)-4-methyl-N~3~~(6-((3-methyl-2-butenoyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
186	393.3	N~1~~(2-cyclopentylethyl)-N~3~~(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-methyl-1,3-benzenedicarboxamide
187	424.2	N~1~~(2-cyclopentylethyl)-4-methyl-N~3~~(6-((methylamino)carbonyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
188	368.3	N~3~~(6-amino-3-pyridinyl)-4-methyl-N~1~~(2-(1-pyrrolidinyl)ethyl)-1,3-benzenedicarboxamide

- 150 -

189	449.3	N~3~-(6-(cyclohexylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
190	402.2	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(3-quinolinyl)-1,3-benzenedicarboxamide
191	395.2	N~1~-(2-cyclopentylethyl)-N~3~-(6-(dimethylamino)-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
192	381.2	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(6-(methylamino)-3-pyridinyl)-1,3-benzenedicarboxamide
193	463.2	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(6-((trifluoroacetyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
194	451.3	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(6-((3-methylbutanoyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
195	461.2	N~1~-(2-cyclopentylethyl)-N~3~-(6-((2-furanylcarbonyl)amino)-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
196	407.3	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(2-oxo-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-1,3-benzenedicarboxamide
197	421.3	N~1~-(2-cyclopentylethyl)-N~3~-(6-((cyclopropylmethyl)amino)-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
198	370.2	N~1~-(2-cyclopentylethyl)-N~3~-(6-fluoro-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
199	452.3	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(6-(((1-methylethyl)amino)carbonyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
200	471.2	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(6-((phenylcarbonyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
201	477.2	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(6-((2-thienylcarbonyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
202	449.2	N~3~-(6-((cyclobutylcarbonyl)amino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
203	501.2	N~1~-(2-cyclopentylethyl)-4-methyl-N~3~-(6-(((3-methyloxy)phenyl)carbonyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide

- 151 -


204	366.3	N~1--(2-cyclopentylethyl)-4-methyl-N~3--(6-methyl-3-pyridinyl)-1,3-benzenedicarboxamide
205	463.3	N~3--(6-((cyclopentylcarbonyl)amino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide
206	461.2	N~1--(2-cyclopentylethyl)-N~3--(6-((1H-imidazol-4-ylcarbonyl)amino)-3-pyridinyl)-4-methyl-1,3-benzenedicarboxamide
207	464.2	N~1--(2-cyclopentylethyl)-4-methyl-N~3--(6-(D-prolylamino)-3-pyridinyl)-1,3-benzenedicarboxamide
208	355.2	N~3--(6-amino-3-pyridinyl)-4-methyl-N~1--(tetrahydro-2-furanylmethyl)-1,3-benzenedicarboxamide
209	396.2	N~3--(6-amino-3-pyridinyl)-4-methyl-N~1--(3-(2-oxo-1-pyrrolidinyl)propyl)-1,3-benzenedicarboxamide
210	325.2	N~3--(6-amino-3-pyridinyl)-N~1--(cyclopropylmethyl)-4-methyl-1,3-benzenedicarboxamide
211	371.3	N~3--(6-amino-3-pyridinyl)-4-methyl-N~1--(3-(1-methylethyl)oxy)propyl)-1,3-benzenedicarboxamide
212		N~1--(2-cyclopentylethyl)-4-methyl-N~3--(6-(((1R,2R)-2-phenylcyclopropyl)carbonyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
213	379.3	N~3--(6-amino-3-pyridinyl)-N~1--(2-(1-cyclohexen-1-yl)ethyl)-4-methyl-1,3-benzenedicarboxamide
214	381.2	N~3--(6-amino-3-pyridinyl)-4-methyl-N~1--(2-(2-thienyl)ethyl)-1,3-benzenedicarboxamide
215	355.2	N~3--(6-amino-3-pyridinyl)-N~1--(3,3-dimethylbutyl)-4-methyl-1,3-benzenedicarboxamide
216	401.2	N~3--(6-amino-3-pyridinyl)-N~1--(2,3-dihydro-1H-inden-2-ylmethyl)-4-methyl-1,3-benzenedicarboxamide
217	421	4-chloro-N~3--5-pyrimidinyl-N~1--(3-(trifluoromethyl)phenyl)-1,3-benzenedicarboxamide
218	387.2	N~3--(6-amino-3-pyridinyl)-4-chloro-N~1--(2-cyclopentylethyl)-1,3-benzenedicarboxamide

219	469.2	4-chloro-N~1~-(2-cyclopentylethyl)-N~3~-(6-((3-methyl-2-butenoyl)amino)-3-pyridinyl)-1,3-benzenedicarboxamide
-----	-------	---

The following compounds in Tables 1 and 2 are additional representative examples of compounds of Formula I, II and III, as provided by the present invention.

5

Table 1



Ex. No.	R ¹	L	R ⁴	R ³
220	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	-NHCO-	Methyl	acetyllindoline
221	piperidine-(CH ₂) ₂ -pyrimidinyl-	-NHCO-	chloro	dimethylindoline
222	NH ₂ -pyridin-3-yl-	-CONH-	Methyl	pyrimidine
223	Pyrimidin-5-yl	-CONH-	Methyl or chloro	2-CH ₃ -phenyl
224	NH ₂ -pyrimidin-5-yl-	-CONH-	Methyl or chloro	4-CF ₃ -phenyl
225	1-piperidinyl-N-pyridin-3-yl-	-CONH-	Methyl or chloro	3-CF ₃ -phenyl
226	cyclohexyl-N-pyridin-3-yl-	-NHCO-	Methyl or chloro	6-CH ₃ -phenyl
227	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	-NHCONH-	Methyl or chloro	2-OCH ₃ -phenyl
228	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	-NHCONH-	Methyl or chloro	4-OCH ₃ -phenyl
229	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	-NHCO-	Methyl or chloro	pyridine

Ex. No.	R ¹	L	R ⁴	R ³
230	3-OH-pyrimidin-5-yl	-NHCO-	Methyl or chloro	indole
231	3-amido-pyridinyl	-CONH-	Methyl or chloro	indoline
232	4-amido-2-pyridinyl	-CONH-	Methyl or chloro	benzofuran
233	3-amido-5-pyrimidinyl	-CONH-	Methyl or chloro	2-F-phenyl
234	4-CH ₃ -pyridazinyl	-CONH-	Methyl or chloro	4-F-phenyl
235	NH ₂ -pyrazinyl	-NHCO-	Methyl or chloro	Dihydrobenzofuran
236	NH ₂ -quinazolinyl	-NHCONH-	Methyl or chloro	cyclohexyl-(CH ₂) ₂ -
237	CH ₃ -isoquinazolinyl	-NHCONH-	Methyl or chloro	cyclopropyl-(CH ₂) ₂ -
238	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	-NHCO-	Methyl or chloro	2-CH ₃ -phenyl
239	piperidine-(CH ₂) ₂ -pyrimidinyl-	-NHCO-	Methyl or chloro	4-CF ₃ -phenyl
240	NH ₂ -pyridin-3-yl-	-CONH-	Methyl or chloro	3-CF ₃ -phenyl
241	Pyrimidin-5-yl	-CONH-	Methyl or chloro	6-CH ₃ -phenyl
242	NH ₂ -pyrimidin-5-yl-	-CONH-	Methyl or chloro	2-OCH ₃ -phenyl
243	1-piperidinyl-N-pyridin-3-yl-	-CONH-	Methyl or chloro	4-OCH ₃ -phenyl
244	cyclohexyl-N-pyridin-3-yl-	-NHCO-	Methyl or chloro	pyridine
245	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	-NHCONH-	Methyl or chloro	indole
246	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	-NHCO-	Methyl or chloro	indoline


Ex. No.	R ¹	L	R ⁴	R ³
247	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	-NHCO-	Methyl or chloro	benzofuran
248	3-OH-pyrimidin-5-yl	-CONH-	Methyl or chloro	2-F-phenyl
249	3-amido-pyridinyl	-CONH-	Methyl or chloro	4-F-phenyl
250	4-amido-2-pyridinyl	-CONH-	Methyl or chloro	dihydrobenzofuran
251	3-amido-5-pyrimidinyl	-CONH-	Methyl or chloro	2-CH ₃ -phenyl
252	4-CH ₃ -pyridazinyl	-NHCO-	Methyl or chloro	4-CF ₃ -phenyl
253	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	-NHCONH-	Methyl or chloro	3-CF ₃ -phenyl
254	piperidine-(CH ₂) ₂ -pyrimidinyl-	-NHCONH-	Methyl or chloro	6-CH ₃ -phenyl
255	NH ₂ -pyridin-3-yl-	-NHCO-	Methyl or chloro	2-OCH ₃ -phenyl
256	Pyrimidin-5-yl	-NHCO-	Methyl or chloro	4-OCH ₃ -phenyl
257	NH ₂ -pyrimidin-5-yl-	-CONH-	Methyl or chloro	pyridine
258	1-piperidinyl-N-pyridin-3-yl-	-CONH-	Methyl or chloro	indole
259	cyclohexyl-N-pyridin-3-yl-	-CONH-	Methyl or chloro	indoline
260	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	-CONH-	Methyl or chloro	benzofuran
261	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	-NHCO-	Methyl or chloro	2-F-phenyl
262	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	-NHCONH-	Methyl or chloro	4-F-phenyl
263	3-OH-pyrimidin-5-yl	-NHCONH-	Methyl or chloro	dihydrobenzofuran
264	3-amido-pyridinyl	-NHCO-	Methyl or chloro	cyclohexyl-(CH ₂) ₂ -

Ex. No.	R ¹	L	R ⁴	R ³
265	4-amido-2-pyridinyl	-NHCO-	Methyl or chloro	cyclopropyl-(CH ₂) ₂ -
266	3-amido-5-pyrimidinyl	-CONH-	Methyl or chloro	2-CH ₃ -phenyl
267	4-CH ₃ -pyridazinyl	-CONH-	Methyl or chloro	4-CF ₃ -phenyl
268	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	-CONH-	Methyl or chloro	3-CF ₃ -phenyl
269	piperidine-(CH ₂) ₂ -pyrimidinyl-	-CONH-	Methyl or chloro	6-CH ₃ -phenyl
270	NH ₂ -pyridin-3-yl-	-NHCO-	Methyl or chloro	2-OCH ₃ -phenyl
271	Pyrimidin-5-yl	-NHCONH-	Methyl or chloro	4-OCH ₃ -phenyl
272	NH ₂ -pyrimidin-5-yl-	-NHCONH-	Methyl or chloro	pyridine
273	1-piperidinyl-N-pyridin-3-yl-	-NHCO-	Methyl or chloro	indole
274	cyclohexyl-N-pyridin-3-yl-	-NHCO-	Methyl or chloro	indoline
275	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	-CONH-	Methyl or chloro	benzofuran
276	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	-CONH-	Methyl or chloro	2-F-phenyl
277	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	-CONH-	Methyl or chloro	4-F-phenyl
278	3-OH-pyrimidin-5-yl	-CONH-	Methyl or chloro	dihydrobenzofuran
279	3-pyridinyl-amido-pyridin-3-yl	-NHCO-	Methyl or chloro	cyclohexyl-(CH ₂) ₂ -
280	N-phenyl-amido-3-pyridinyl	-NHCONH-	Methyl or chloro	cyclopropyl-(CH ₂) ₂ -
281	3-amido-5-pyrimidinyl	-NHCONH-	Methyl or chloro	2-thiophene
282	4-CH ₃ -pyridazinyl	-NHCO-	Methyl or chloro	3-thiophene

- 156 -

Ex. No.	R ¹	L	R ⁴	R ³
283	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	-NHCO-	Methyl or chloro	2-pyridine
284	piperidine-(CH ₂) ₂ -pyrimidinyl-	-CONH-	Methyl or chloro	1-morpholinyl
285	NH ₂ -pyridin-3-yl-	-CONH-	Methyl or chloro	1-piperazinyl
286	Pyrimidin-5-yl	-CONH-	Methyl or chloro	1-piperidinyl

Table 2



Ex. No.	R ^{1a}	A ⁵	L	R ³
287	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	N	-NHCO-	2-CH ₃ -phenyl
288	piperidine-(CH ₂) ₂ -pyrimidinyl-	N	-NHCO-	4-CF ₃ -phenyl
289	NH ₂ -pyridin-3-yl-	N	-CONH-	3-CF ₃ -phenyl
290	Pyrimidin-5-yl	N	-CONH-	6-CH ₃ -phenyl
291	NH ₂ -pyrimidin-5-yl-	CH	-CONH-	2-OCH ₃ -phenyl
292	1-piperidinyl-N-pyridin-3-yl-	CH	-CONH-	4-OCH ₃ -phenyl
293	cyclohexyl-N-pyridin-3-yl-	CH	-NHCO-	pyridine
294	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	CH	-NHCONH-	indole
295	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	CH	-NHCONH-	indoline

Ex. No.	R ^{1a}	A ⁵	L	R ³
296	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	CH	-NHCO-	benzofuran
297	3-OH-pyrimidin-5-yl	CH	-NHCO-	2-F-phenyl
298	3-amido-pyridinyl	CH	-CONH-	4-F-phenyl
299	4-amido-2-pyridinyl	N	-CONH-	Dihydrobenzofuran
300	3-amido-5-pyrimidinyl	N	-CONH-	cyclohexyl-(CH ₂) ₂ -
301	4-CH ₃ -pyridazinyl	N	-CONH-	cyclopropyl-(CH ₂) ₂ -
302	NH ₂ -pyrazinyl	N	-NHCO-	2-CH ₃ -phenyl
303	NH ₂ -quinazolinyl	N	-NHCONH-	4-CF ₃ -phenyl
304	CH ₃ -isoquinazolinyl	CH	-NHCONH-	3-CF ₃ -phenyl
305	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	CH	-NHCO-	6-CH ₃ -phenyl
306	piperidine-(CH ₂) ₂ -pyrimidinyl-	CH	-NHCO-	2-OCH ₃ -phenyl
307	NH ₂ -pyridin-3-yl-	CH	-CONH-	4-OCH ₃ -phenyl
308	Pyrimidin-5-yl	CH	-CONH-	pyridine
309	NH ₂ -pyrimidin-5-yl-	CH	-CONH-	indole
310	1-piperidinyl-N-pyridin-3-yl-	CH	-CONH-	indoline
311	cyclohexyl-N-pyridin-3-yl-	CH	-NHCO-	benzofuran
312	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	N	-NHCONH-	2-F-phenyl
313	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	N	-NHCO-	4-F-phenyl
314	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	N	-NHCO-	dihydrobenzofuran
315	3-OH-pyrimidin-5-yl	N	-CONH-	2-CH ₃ -phenyl
316	3-amido-pyridinyl	N	-CONH-	4-CF ₃ -phenyl
317	4-amido-2-pyridinyl	N	-CONH-	3-CF ₃ -phenyl
318	3-amido-5-pyrimidinyl	N	-CONH-	6-CH ₃ -phenyl

Ex. No.	R ^{1a}	A ⁵	L	R ³
319	4-CH ₃ -pyridazinyl	N	-NHCO-	2-OCH ₃ -phenyl
320	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	N	-NHCONH-	4-OCH ₃ -phenyl
321	piperidine-(CH ₂) ₂ -pyrimidinyl-	N	-NHCONH-	pyridine
322	NH ₂ -pyridin-3-yl-	N	-NHCO-	indole
323	Pyrimidin-5-yl	N	-NHCO-	indoline
324	NH ₂ -pyrimidin-5-yl-	CH	-CONH-	benzofuran
325	1-piperidinyl-N-pyridin-3-yl-	CH	-CONH-	2-F-phenyl
326	cyclohexyl-N-pyridin-3-yl-	CH	-CONH-	4-F-phenyl
327	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	CH	-CONH-	dihydrobenzofuran
328	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	CH	-NHCO-	cyclohexyl-(CH ₂) ₂ -
329	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	CH	-NHCONH-	cyclopropyl-(CH ₂) ₂ -
330	3-OH-pyrimidin-5-yl	CH	-NHCONH-	2-CH ₃ -phenyl
331	3-amido-pyridinyl	CH	-NHCO-	4-CF ₃ -phenyl
332	4-amido-2-pyridinyl	CH	-NHCO-	3-CF ₃ -phenyl
333	3-amido-5-pyrimidinyl	CH	-CONH-	6-CH ₃ -phenyl
334	4-CH ₃ -pyridazinyl	CH	-CONH-	2-OCH ₃ -phenyl
335	cyclohexyl-HN-(CH ₂) ₂ -pyridin-2-yl-	CH	-CONH-	4-OCH ₃ -phenyl
336	piperidine-(CH ₂) ₂ -pyrimidinyl-	CH	-CONH-	pyridine
337	NH ₂ -pyridin-3-yl-	N	-NHCO-	indole
338	Pyrimidin-5-yl	N	-NHCONH-	indoline
339	NH ₂ -pyrimidin-5-yl-	N	-NHSO ₂ NH-	benzofuran
340	1-piperidinyl-N-pyridin-3-yl-	N	-NHCO-	2-F-phenyl
341	cyclohexyl-N-pyridin-3-yl-	N	-NHCO-	4-F-phenyl

Ex. No.	R ^{1a}	A ⁵	L	R ³
342	morpholine-(CH ₂) ₂ -N-pyridin-3-yl-	N	-CONH-	dihydrobenzofuran
343	(CH ₃) ₂ N-(CH ₂) ₂ -N-pyridin-3-yl--	N	-CONH-	cyclohexyl-(CH ₂) ₂ -
344	(C ₂ H ₅) ₂ N-(CH ₂) ₂ -pyrimidin-5-yl-	N	-CONH-	cyclopropyl-(CH ₂) ₂ -
345	3-OH-pyrimidin-5-yl	N	-SO ₂ NH-	2-thiophene
346	3-pyridinyl-amido-pyridin-3-yl	N	-NHSO ₂ -	3-thiophene
347	N-phenyl-amido-3-pyridinyl	N	-NHCONH-	2-pyridine
348	3-amido-5-pyrimidinyl	N	-NHCONH-	1-morpholinyl
349	4-CH ₃ -pyridazinyl	CH	-NHCO-	1-piperazinyl
350	cyclohexyl-HN-(CH ₂) ₂ -pyridin-3-yl-	N	-NHSO ₂ -	1-piperidinyl

The following compounds are additional representative examples of compounds of the present invention:

- 5 N~3--(6-isopropoylamino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-(3,3,3-trifluoroethanoylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 10 N~3--(6-methoxyacetylamino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-(phenoxyacetylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-(trans-2-phenyl-1-cyclopropanoylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 15 N~3--(6-(1s-trans-2-fluorocyclopropanoylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-®(-)-2-phenylglycinecarbonylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-phenacylamino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 20 N~3--(6-(2-chlorobenzoylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;

- 160 -

- N~3~-(6-(2-methoxybenzoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(2-trifluoromethylbenzoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 5 N~3~-(6-(o-toluoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(2-trifluoromethoxybenzoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 10 N~3~-(6-(2-fluorobenzoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(3-fluorobenzoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(4-fluorobenzoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 15 N~3~-(6-(6-chloronicotinoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(thiophene-2-carbonylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(4-methyloxazole-5-carbonylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 20 N~3~-(6-(4-methyl-1,2,3-thiadiazole-5-carbonylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(N,N-dimethylcarbamoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 25 N~3~-(6-(N-methyl-N-phenylcarbamoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(phenylcarbamoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 30 N~3~-(6-(isopropylcarbamoylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(4-methyl-1-piperazinecarbonylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3~-(6-(1-piperidinecarbonylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 35 N~3~-(6-(4-morpholinecarbonylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;

- 161 -

- N~3--(6-(1-pyrrolidinecarbonylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-amino-4-methyl-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 5 N~3--(6-amino-2-methyl-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-cyclopropylamino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 10 N~3--(6-phenylamino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-quinolinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-methoxy-3-quinolinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 15 N~3--(6-quinoxaliny1)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(1,3,4-thiadiazol-2-yl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(5-methyl-pyrazol-3-yl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 20 N~3--(5-methyl-isoxazol-3-yl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(imidazol-4-yl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 25 N~3--(6-chloro-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-pyridin-2-ylamino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-pyrimidylamino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 30 N~3--(6-benzimidazolylmino-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-(5-methyl-1,3,4-thiadiazol-2-yl-amino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- 35 N~3--(6-cyano-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;
- N~3--(6-(5-methylimidazolylamino)-3-pyridinyl)-N~1--(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;

- 162 -

N~3~-(6-(1,2,4-triazolylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;

N~3~-(6-(5-methylisoxazolylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide;

5 N~3~-(6-(pyrimidinemethylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide; and

N~3~-(6-(3-methylpyridinemethylamino)-3-pyridinyl)-N~1~-(2-cyclopentylethyl)-4-methyl-1,3-benzenedicarboxamide.

10 All process steps described herein can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or
15 neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the H⁺ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about -100 °C to about 190 °C, preferably from about -80 °C to
20 about 150 °C, for example at about -80 to about 60 °C, at RT, at about -20 to about 40 °C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example, under argon or nitrogen.

25 Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed.

In certain cases, typically in hydrogenation
30 processes, it is possible to achieve stereoselective reactions, allowing for example easier recovery of individual isomers.

The solvents from which those can be selected which are suitable for the reaction in question include, for
35 example, water, esters, typically lower alkyl-lower

- 163 -

alkanoates, e.g EtOAc, ethers, typically aliphatic ethers, e.g. Et₂O, or cyclic ethers, e.g. THF, liquid aromatic hydrocarbons, typically benzene or toluene, alcohols, typically MeOH, EtOH, IPA or 1-propanol, nitriles, typically
5 AcCN, halogenated hydrocarbons, typically CH₂Cl₂, acid amides, typically DMF, bases, typically heterocyclic nitrogen bases, e.g. pyridine, carboxylic acids, typically lower alkanecarboxylic acids, e.g. HOAc, carboxylic acid anhydrides, typically lower alkane acid anhydrides, e.g.
10 acetic anhydride, cyclic, linear, or branched hydrocarbons, typically cyclohexane, hexane, or isopentane, or mixtures of these solvents, e.g. aqueous solutions, unless otherwise stated in the description of the process.

The invention relates also to those forms of the
15 process in which one starts from a compound obtainable at any stage as a transient species and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative
20 or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ. In the preferred embodiment, one starts from those starting materials which lead to the compounds described above as preferred.

25 The compounds of formula I, II or III, including their salts, are also obtainable in the form of hydrates, or their crystals can include for example the solvent used for crystallization (present as solvates).

New starting materials and/or intermediates, as well
30 as processes for the preparation thereof, are likewise the subject of this invention. In one embodiment, such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.

- 164 -

Starting materials of the invention, are known, are commercially available, or can be synthesized in analogy to or according to methods that are known in the art.

5 In the preparation of starting materials, existing functional groups which do not participate in the reaction should, if necessary, be protected. Preferred protecting groups, their introduction and their removal are described above or in the examples.

10 All remaining starting materials are known, capable of being prepared according to known processes, or commercially obtainable; in particular, they can be prepared using processes as described in the examples.

15 The examples above serve to illustrate various embodiments of the invention. The tables also contain the method by which these examples were prepared, with respect to the various schemes and examples presented above. The schematic illustrations, detailed description of the methods and preparation of compounds of Formulas I, II or III, and compounds described above fall within the scope, and serve
20 to exemplify the scope of compounds contemplated in the invention. These detailed method descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the present invention.

BIOLOGICAL ASSAYS

25 The following assays can be employed to determine the degree of activity of a compound as a protein kinase inhibitor. Compounds described herein have been tested in one or more of these assays, and have shown activity. Representative compounds of the invention were tested and
30 found to exhibit IC₅₀ values of at least < 10 μ M in any one of the described assays, thereby demonstrating and confirming the utility of the compounds of the invention as

- 165 -

protein kinase inhibitors and in the prophylaxis and treatment of autoimmune diseases, hyperproliferative disorders, etc.

5 **LCK-Homogeneous Time Resolved Fluorescent (HTRF) Kinase Assay:**

The LCK HTRF assay begins with LCK in the presence of ATP phosphorylating the biotinylated peptide Gastrin. The reaction incubates for 90 min. To quench the assay
10 detection reagents are added which both stop the reaction by diluting out the enzyme and chelating the metals due to the presence of EDTA. Once the detection reagents are added the assay incubates for 30 min to allow for equilibration of the detection reagents.

15 The LCK HTRF assay is comprised of 10 μ L of compound in 100% DMSO, 15 μ L of ATP and biotinylated Gastrin, and 15 μ L of LCK KD GST (225-509) for a final volume of 40 μ L. The final concentration of gastrin is 1.2 μ M. The final concentration of ATP is 0.5 μ M (K_m app= 0.6 μ M $\pm$ 0.1) and the
20 final concentration of LCK is 250pM. Buffer conditions are as follows: 50mM HEPES pH 7.5, 50mM NaCl, 20mM MgCl, 5mM MnCl, 2mM DTT, 0.05% BSA.

The assay is quenched and stopped with 160 μ L of detection reagent. Detection reagents are as follows:
25 Buffer made of 50mM Tris, pH 7.5, 100mM NaCl, 3mM EDTA, 0.05% BSA, 0.1% Tween20. Added to this buffer prior to reading is Steptavidin allophycocyanin (SA-APC) at a final conc in the assay of 0.0004 mg/mL, and europilated anti-phosphotyrosine Ab (Eu-anti-PY) at a final conc of 0.025nM.

30 The assay plate is read in either a Discovery or a RubyStar. The eu-anti-PY is excited at 320 nm and emits at 615 nm to excite the SA-APC which in turn emits at 655 nm. The ratio of SA-APC at 655 nm (excited due to close proximity to the Eu-anti-PY because of phosphorylation of

- 166 -

the peptide) to free Eu-anti-PY at 615 nm will give substrate phosphorylation.

Assays for other kinases are done in a similar way as described above, varying the concentrations of enzyme, peptide substrate, and ATP added to the reaction, depending on the specific activity of the kinase and measured K_m 's for the substrates.

Of the compounds which were tested, exemplary compounds 1, 2, 11-20, 22-72, 74-86, 88, 90-94, 96, 98-101, 103-136 and 140-143 exhibited an average IC_{50} value of 10uM or less in a human HTRF assay, for the inhibition of the Lck kinase enzyme. The majority of the exemplary compounds tested above exhibited an average IC_{50} value of 1uM or less in the human Lck kinase HTRF assay.

15

Human mixed lymphocyte reaction (huMLR):

The purpose of this assay is to test the potency of T cell activation inhibitors in an in vitro model of allogeneic T cell stimulation. Human peripheral blood lymphocytes (hPBL; 2×10^5 /well) are incubated with mitomycin C-treated B lymphoblastoid cells (JY cell line; 1×10^5 /well) as allogeneic stimulators in the presence or absence of dilutions of potential inhibitor compound in 96-well round-bottom tissue culture plates. These cultures are incubated at 37 °C in 5% CO_2 for 6 days total. The proliferative response of the hPBL is measured by ^3H -thymidine incorporation overnight between days 5 and 6 after initiation of culture. Cells are harvested onto glass fiber filters and ^3H -thymidine incorporation into DNA is analyzed by liquid scintillation counter.

30

Jurkat proliferation/survival assay:

The purpose of this assay is to test the general anti-proliferative/cytotoxic effect of compounds on the Jurkat

- 167 -

human T cell line. Jurkat cells (1×10^5 /well) are plated in 96-well flat-bottom tissue culture plates with or without compound dilutions and cultured for 72 h at 37 °C in 5% CO₂. Viable cell number is determined during the last 4 h of culture by adding 10 µL/well WST-1 dye. WST-1 dye conversion relies on active mitochondrial electron transport for reduction of the tetrazolium dye. The dye conversion is read by OD at 450-600 nm.

10 **Anti-CD3/CD28-induced T cell IL-2 secretion and proliferation assay:**

The purpose of this assay is to test the potency of T cell receptor (TCR; CD3) and CD28 signaling pathway inhibitors in human T cells. T cells are purified from human peripheral blood lymphocytes (hPBL) and pre-incubated with or without compound prior to stimulation with a combination of an anti-CD3 and an anti-CD28 antibody in 96-well tissue culture plates (1×10^5 T cells/well). Cells are cultured for ~20 h at 37 °C in 5% CO₂, then secreted IL-2 in the supernatants is quantified by cytokine ELISA (Pierce/Endogen). The cells remaining in the wells are then pulsed with ³H-thymidine overnight to assess the T cell proliferative response. Cells are harvested onto glass fiber filters and ³H-thymidine incorporation into DNA is analyzed by liquid scintillation counter. For comparison purposes, phorbol myristic acid (PMA) and calcium ionophore can be used in combination to induce IL-2 secretion from purified T cells. Potential inhibitor compounds can be tested for inhibition of this response as described above for anti-CD3 and -CD28 antibodies.

cKIT-Homogeneous Time Resolved Fluorescent (HTRF) Kinase Assay:

- 168 -

The purpose of this assay is to measure the inhibition of cKIT enzyme activity (autophosphorylation and phosphorylation of substrate) by small molecule test compounds. The cKIT HTRF assay begins with cKIT-catalyzed phosphorylation of biotinylated peptide Her-2 (N-GGMEDIYFEFMGGKKK-C) in the presence of ATP. The cKIT enzyme reaction is comprised of 1 μ L of compound in 100% DMSO, 15 μ L of 2X substrate mix (50 μ M ATP and 2 μ M biotinylated Her-2) and 15 μ L of 2X cKIT (6.25 μ M) (catalytic domain, N-terminal GST tagged, unphosphorylated) in 4mM DTT all diluted in enzyme buffer (25mM HEPES pH 7.5, 12.5mM NaCl, 50mM MgCl, 0.05% BSA). The reaction incubates for 90 min at room temperature. One-hundred and sixty microliters of detection mixture containing 0.47 μ g/mL streptavidin allophycocyanin and 29.7pM europylated anti-phosphotyrosine Ab (PT66, Perkin Elmer) in HTRF buffer (100 mM Hepes pH 7.5, 100 mM NaCl, 0.1% BSA, 0.05% TweenTM 20) is then added to stop the reaction by diluting out the enzyme as well as to enable quantitation of phosphorylated Her-2. After 3 h at room temperature, the detection reaction is read in a Packard DiscoveryTM (model BD1000) plate reader. The wells are excited with coherent 320nm light and the ratio of delayed (50ms post excitation) emissions at 620nm (native europium fluorescence) and 665nm (europium fluorescence transferred to allophycocyanin - an index of substrate phosphorylation) is determined. The proportion of substrate phosphorylated in the kinase reaction in the presence of compound compared with that phosphorylated in the presence of DMSO vehicle alone (HI control) is calculated using the formula:

% control (POC) = (cpd - average LO) / (average HI - average LO) * 100. Data (consisting of POC and inhibitor concentration in μ M) is fitted to a 4-parameter equation ($y = A + ((B - A) / (1 + ((x/C)^D)))$), where A is the minimum y (POC) value, B is the maximum y (POC), C is the x (cpd concentration) at

- 169 -

the point of inflection and D is the slope factor) using a Levenburg-Marquardt non-linear regression algorithm.

Of the compounds tested, exemplary compounds 1, 2, 11-40, 22-40, 42-46, 48-63, 69-72, 74-76, 81-86, 88, 90, 96, 5 98-100, 102-105, 109, 110, 112, 113, 120-130, 134-138, 141, 144-146, 149-152, 154-159, 161-164, 166-174, 176-180, 182, 184-190, 192-204, 206 and 217-219 exhibited an average IC₅₀ value of 10uM or less in a human HTRF assay, for the inhibition of the c-kit kinase enzyme. The majority of the 10 exemplary compounds tested above exhibited an average IC₅₀ value of 1uM or less in the human c-kit kinase HTRF assay.

MO7e phosphorylated-c-kit (Tyr721) Electrochemiluminescent Immunoassay:

15 The purpose of this assay is to test the potency of small molecule and biologic compounds on SCF-stimulated c-kit receptor phosphorylation of tyrosine 721 (Tyr721) in MO7e cells. Activation of c-kit upon binding with it's ligand, stem cell factor (SCF), leads to 20 dimerization/oligomerization and autophosphorylation. Activation of c-kit results in the recruitment and tyrosine phosphorylation of downstream SH2-containing signaling components - such as the p85 subunit of PI3 kinase (Sattler, M. et al. (1997) *J. Biol. Chem.* 272, 10248-10253). C-kit 25 phosphorylated at Tyr721 binds to the p85 subunit of PI3 kinase (Blume-Jensen, P et al. (2000) *Nature Genet.* 24, 157-162). MO7e cells are a human megakaryoblastic factor dependent leukemia cell line (these cells have been confirmed to carry wild type c-kit receptor). Cells are 30 maintained in growth media (IMDM, 10% HI-FBS, 1XPGS, 5ng/mL GM-CSF). To measure SCF-induced c-kit phosphorylation, cells are washed and re-suspended to 3.3E5c/mL in assay media (RPMI 1640/4% HI-FBS, 1XPGS) and plated at 30uL/well for 10000c/well. Small molecule compounds are diluted in

- 170 -

100% DMSO, antibodies and other biologics are diluted in assay media only. Cells are pre-incubated with 0.5 - 2 μ L compound for 1h at room temperature. Ten microliters of 4XSCF (100ng/mL) in room temperature assay media is then
5 added. After 30min incubation at room temperature, the cells are lysed with the addition of 20 μ L of ice cold 3X lysis buffer (20mM Tris[™]-Cl, 1mM EDTA, 150mM NaCl, 1% NP-40, 2mM NaF, 20mM β -glycerophosphate, 1mM Na₃VO₄ and 1 Complete Proteinase inhibitor tablet/50mL 1X lysis buffer (Roche Cat
10 # 1697498, in stock room)). Twenty-five microliters of lysate is transferred to blocked MSD plates (blocked with 5% BSA in Tris[™]-buffered saline, 0.01% Tween[™] (TBS-T) for 1h with shaking, then washed 3X with TBS-T) coated with anti-c-kit antibody (Labvision MS-289). After the plates are incubated
15 with shaking for 1h at room temperature, 25 μ L of 10nM ruthenylated detection antibody (Zymed 34-9400) is added and the plate is incubated again with shaking for 1h at room temperature. The plates are then washed 3X with TBS-T, 150 μ L of MSD Read Buffer T is added, and the
20 electrochemiluminescence (ECL) reaction is read on the Sector Imager[™] 6000. A low voltage is applied to the ruthenylated phos-c-kit(Tyr721) immune complexes, which in the presence of TPA (the active component in the ECL reaction buffer, Read Buffer T), results in a cyclical redox
25 reaction generating light at 620nm. The amount of phosphorylated c-kit (Tyr721) in the presence of compounds compared with that in the presence of vehicle alone (HI control) is calculated using the formula: % control (POC) = (cpd - average LO)/(average HI - averageLO)*100. Data
30 (consisting of POC and inhibitor concentration in μ M) is fitted to a 4-parameter equation ($y = A + ((B-A)/(1 + ((x/C)^D)))$), where A is the minimum y (POC) value, B is the maximum y (POC), C is the x (cpd concentration) at the point

- 171 -

of inflection and D is the slope factor) using a Levenburg-Marquardt non-linear regression algorithm.

SCF and GM-CSF stimulated UT7 proliferation/survival assay:

5 The purpose of this assay is to test the general anti-proliferative/cytotoxic effect of small molecule and biologic compounds on SCF or GM-CSF-stimulated UT-7 cells. Preventing SCF stimulated proliferation/survival is consistent with an on-mechanism effect whereas inhibition of
10 GM-CSF driven proliferation/survival is indicative of off-target effects. UT-7 is a factor dependent human megakaryoblastic leukemia cell line that can be grown in either IL-3, GM-CSF, EPO or SCF (these cells have been confirmed to carry wild type c-kit receptor). Cells are
15 maintained in growth media (IMDM, 10% HI-FBS, 1XPGS, 1ng/mL GM-CSF). To measure SCF or GM-CSF-induced proliferation, cells are washed and re-suspended to 5e4c/mL in assay media (RPMI 1640/4% HI-FBS, 1XPGS) and plated at 50uL/well for 2500c/well. Small molecule compounds are first diluted in
20 100% DMSO, then diluted 1:4 in room temperature assay media. Antibodies and other biologics are diluted in assay media only. Five microliters of 11X SCF (55ng/mL) or 11X GM-CSF (11ng/mL) in assay media plus 1uL of diluted drug are added to the cell plates. The treated cells are incubated in a
25 37 °C humidified incubator with 5% CO₂ for 3 days. The amount of ATP is then measured as a surrogate marker for cell viability. This is accomplished by adding 50uL of Perkin Elmer ATP 1step reagent (as per instructed in the reagent manual, Cat. No. 6016739), incubating at room
30 temperature for 15min and reading the luminescence with a Perkin Elmer Topcount NXTTMHTS (model c384) plate reader. The amount of SCF or GM-CSF stimulated viable cells in the presence of compound compared with in the presence of vehicle alone (HI control) is calculated using the formula:

- 172 -

% control (POC) = (cpd - average LO)/(average HI - average LO)*100. Data (consisting of POC and inhibitor concentration in μM) is fitted to a 4-parameter equation ($y = A + ((B - A)/(1 + ((x/C)^D)))$), where A is the minimum y (POC) value, B is the maximum y (POC), C is the x (cpd concentration) at the point of inflection and D is the slope factor) using a Levenburg-Marquardt non-linear regression algorithm.

Methods of Use

10 For the treatment of Lck-mediated diseases, c-kit mediated diseases and/or other diseases listed above, the compounds of the present invention may be administered by several different modes, including without limitation, oral, parental, by spray inhalation, rectal, or topical, as
15 discussed herein. The term parenteral as used herein, includes subcutaneous, intravenous, intramuscular, intrasternal, infusion techniques or intraperitoneal administration.

Treatment of diseases and disorders herein is intended
20 to also include therapeutic administration of a compound of the invention (or a pharmaceutical salt, derivative or prodrug thereof) or a pharmaceutical composition containing said compound to a subject (i.e., an animal, preferably a mammal, most preferably a human) believed to be in need of
25 preventative treatment, such as, for example, pain, inflammation and the like. Treatment also encompasses administration of the compound or pharmaceutical composition to subjects not having been diagnosed as having a need thereof, i.e., prophylactic administration to the
30 subject. Generally, the subject is initially diagnosed by a licensed physician and/or authorized medical practitioner, and a regimen for prophylactic and/or therapeutic treatment via administration of the compound(s) or compositions of the invention is suggested, recommended or prescribed.

- 173 -

"Treating" or "treatment of" within the context of the instant invention, means an alleviation, in whole or in part, of symptoms associated with a disorder or disease, or halt of further progression or worsening of those symptoms, or prevention or prophylaxis of the disease or disorder. Similarly, as used herein, an "effective amount" or "therapeutically effective amount" of a compound of the invention refers to an amount of the compound that alleviates, in whole or in part, symptoms associated with a disorder or disease, or halts of further progression or worsening of those symptoms, or prevents or provides prophylaxis for the disease or disorder. For example, within the context of treating patients in need of an inhibitor of c-kit, successful treatment may include a reduction in tumor adhesion and anchorage; an alleviation of symptoms related to a cancerous growth or tumor, or proliferation of diseased tissue; a halting in the progression of a disease such as cancer or in the growth of cancerous cells.

While it may be possible to administer a compound of the invention alone, in the methods described, the compound administered is generally present as an active ingredient in a desired dosage unit formulation, such as pharmaceutically acceptable composition containing conventional pharmaceutically acceptable carriers. Thus, in another embodiment of the invention, there is provided a pharmaceutical composition comprising a compound of this invention in combination with a pharmaceutically acceptable carrier. Acceptable pharmaceutical carriers generally include diluents, excipients, adjuvants and the like as described herein.

A pharmaceutical composition of the invention may comprise an effective amount of a compound of the invention or an effective dosage amount of a compound of the

- 174 -

invention. An effective dosage amount of a compound of the invention includes an amount less than, equal to, or greater than an effective amount of the compound. For example, a pharmaceutical composition in which two or more
5 unit dosages, such as in tablets, capsules and the like, are required to administer an effective amount of the compound, or alternatively, a multi-dose pharmaceutical composition, such as powders, liquids and the like, in which an effective amount of the compound may be
10 administered by administering a portion of the composition.

The pharmaceutical compositions may generally be prepared by mixing one or more compounds of Formula I, II or III including stereoisomers or tautomers, solvates, pharmaceutically acceptable salts, derivatives or prodrugs
15 thereof, with pharmaceutically acceptable carriers, excipients, binders, adjuvants, diluents and the like, to form a desired administrable formulation to treat or ameliorate a variety of disorders related to the activity of Lck, particularly inflammation, or related to the activity
20 c-kit, particularly autoimmune disease.

Pharmaceutical compositions can be manufactured by methods well known in the art such as conventional granulating, mixing, dissolving, encapsulating, lyophilizing, emulsifying or levigating processes, among
25 others. The compositions can be in the form of, for example, granules, powders, tablets, capsules, syrup, suppositories, injections, emulsions, elixirs, suspensions or solutions. The instant compositions can be formulated for various routes of administration, for example, by oral
30 administration, by transmucosal administration, by rectal administration, or subcutaneous administration as well as intrathecal, intravenous, intramuscular, intraperitoneal, intranasal, intraocular or intraventricular injection. The compound or compounds of the instant invention can also be

- 175 -

administered in a local rather than a systemic fashion, such as injection as a sustained release formulation.

Besides those representative dosage forms described herein, pharmaceutically acceptable excipients and carriers
5 are generally known to those skilled in the art and are thus included in the instant invention. Such excipients and carriers are described, for example, in "Remingtons Pharmaceutical Sciences" Mack Pub. Co., New Jersey (2000); and "Pharmaceutics The Science of Dosage Form Design, 2nd
10 Ed. (Aulton, ed.) Churchill Livingstone (2002). The following dosage forms are given by way of example and should not be construed as limiting the invention.

For oral, buccal, and sublingual administration, powders, suspensions, granules, tablets, pills, capsules,
15 gelcaps, and caplets are acceptable as solid dosage forms. These can be prepared, for example, by mixing one or more compounds of the instant invention, or stereoisomers, solvates, prodrugs, pharmaceutically acceptable salts or tautomers thereof, with at least one additive or excipient
20 such as a starch or other additive and tableted, encapsulated or made into other desirable forms for conventional administration. Suitable additives or excipients are sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, sorbitol, starch, agar, alginates,
25 chitins, chitosans, pectins, tragacanth gum, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers or glycerides, methyl cellulose, hydroxypropylmethyl-cellulose, and/or polyvinylpyrrolidone. Optionally, oral dosage forms can contain other ingredients
30 to aid in administration, such as an inactive diluent, or lubricants such as magnesium stearate, or preservatives such as paraben or sorbic acid, or anti-oxidants such as ascorbic acid, tocopherol or cysteine, a disintegrating agent, binders, thickeners, buffers, sweeteners, flavoring agents

- 176 -

or perfuming agents. Additionally, dyestuffs or pigments may be added for identification. Tablets and pills may be further treated with suitable coating materials known in the art.

5 Liquid dosage forms for oral administration may be in the form of pharmaceutically acceptable emulsions, syrups, elixirs, suspensions, slurries and solutions, which may contain an inactive diluent, such as water. Pharmaceutical formulations may be prepared as liquid suspensions or
10 solutions using a sterile liquid, such as, but not limited to, an oil, water, an alcohol, and combinations of these. Pharmaceutically suitable surfactants, suspending agents, emulsifying agents, and the like may be added for oral or parenteral administration.

15 For nasal administration, the pharmaceutical formulations may be a spray or aerosol containing an appropriate solvent and optionally other compounds such as, but not limited to, stabilizers, antimicrobial agents, antioxidants, pH modifiers, surfactants, bioavailability
20 modifiers and combinations of these. A propellant for an aerosol formulation may include compressed air, nitrogen, carbon dioxide, or a hydrocarbon based low boiling solvent. The compound or compounds of the instant invention are conveniently delivered in the form of an aerosol spray
25 presentation from a nebulizer or the like.

 Injectable dosage forms for parenteral administration generally include aqueous suspensions or oil suspensions, which may be prepared using a suitable dispersant or wetting agent and a suspending agent. Injectable forms may be in
30 solution phase or a powder suitable for reconstitution as a solution. Both are prepared with a solvent or diluent. Acceptable solvents or vehicles include sterilized water, Ringer's solution, or an isotonic aqueous saline solution. Alternatively, sterile oils may be employed as solvents or

- 177 -

suspending agents. Typically, the oil or fatty acid is non-volatile, including natural or synthetic oils, fatty acids, mono-, di- or tri-glycerides. For injection, the formulations may optionally contain stabilizers, pH
5 modifiers, surfactants, bioavailability modifiers and combinations of these. The compounds may be formulated for parenteral administration by injection such as by bolus injection or continuous infusion. A unit dosage form for injection may be in ampoules or in multi-dose containers.

10 For rectal administration, the pharmaceutical formulations may be in the form of a suppository, an ointment, an enema, a tablet or a cream for release of compound in the intestines, sigmoid flexure and/or rectum. Rectal suppositories are prepared by mixing one or more
15 compounds of the instant invention, or pharmaceutically acceptable salts or tautomers of the compound, with acceptable vehicles, for example, cocoa butter or polyethylene glycol, which is solid phase at room temperature but liquid phase at those temperatures suitable
20 to release a drug inside the body, such as in the rectum. Various other agents and additives may be used in the preparation of suppositories as is well known to those of skill in the art.

The formulations of the invention may be designed to
25 be short-acting, fast-releasing, long-acting, and sustained-releasing as described below. Thus, the pharmaceutical formulations may also be formulated for controlled release or for slow release. The instant compositions may also comprise, for example, micelles or liposomes, or some other
30 encapsulated form, or may be administered in an extended release form to provide a prolonged storage and/or delivery effect. Therefore, the pharmaceutical formulations may be compressed into pellets or cylinders and implanted intramuscularly or subcutaneously as depot injections or as

- 178 -

implants such as stents. Such implants may employ known inert materials such as silicones and biodegradable polymers.

Specific dosages may be adjusted depending on
5 conditions of disease, the age, body weight, general health conditions, sex, and diet of the subject, dose intervals, administration routes, excretion rate, and combinations of drugs. Any of the above dosage forms containing effective amounts are well within the bounds of routine
10 experimentation and therefore, well within the scope of the instant invention.

A therapeutically effective dosage amount or dose may vary depending upon the route of administration and dosage form. Typically, the compound or compounds of the instant
15 invention are selected to provide a formulation that exhibits a high therapeutic index. The therapeutic index is the dose ratio between toxic and therapeutic effects which can be expressed as the ratio between LD₅₀ and ED₅₀. The LD₅₀ is the dose lethal to 50% of the population and the
20 ED₅₀ is the dose therapeutically effective in 50% of the population. The LD₅₀ and ED₅₀ are determined by standard pharmaceutical procedures in animal cell cultures or experimental animals.

The dosage regimen for treating Lck-mediated diseases,
25 C-kit mediated diseases, and other diseases listed above with the compounds of this invention and/or compositions of this invention is based on a variety of factors, including the type of disease, the age, weight, sex, medical condition of the patient, the severity of the condition,
30 the route of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. Dosage levels of the order from about 0.01 mg to 30 mg per kilogram of body weight per day, preferably from about 0.1

- 179 -

mg to 10 mg/kg, more preferably from about 0.25 mg to 1 mg/kg are useful for all methods of use disclosed herein.

For oral administration, the pharmaceutical composition may be in the form of, for example, a capsule, a tablet, a suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a given amount of the active ingredient. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg, more preferably from about 5 to 150 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.

The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water. The daily parenteral dosage regimen will be from about 0.1 to about 30 mg/kg of total body weight, preferably from about 0.1 to about 10 mg/kg, and more preferably from about 0.25 mg to 1 mg/kg.

Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose. A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.

The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as

- 180 -

sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. The pharmaceutically active compounds of this invention can be processed in accordance
5 with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals.

While the compounds of the present invention can be administered as the sole active pharmaceutical agent, they
10 can also be used in combination with one or more compounds of the invention or with one or more other agents. When administered as a combination, the therapeutic agents can be formulated and given to the subject as a single composition or the combination of therapeutic agents can be
15 formulated and given to the subject as separate compositions that are given at the same time or different times.

For example, the compounds of the invention may be used in combination with a second therapeutic agent such as
20 those described herein. Thus, in some embodiments, therapeutic compositions are provided that include a compound of the invention and a second therapeutic agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a subject with a disease
25 or condition modulated by Lck kinase or c-kit kinase. In some embodiments, therapeutic compositions are provided that include a compound of the invention and a second therapeutic agent as a combined preparation for simultaneous, separate or sequential use in the prophylactic treatment of a subject
30 at risk for a disease or condition modulated by Lck kinase or c-kit kinase. In some such embodiments, the components are provided as a single composition. In other embodiments, the compound and the second therapeutic agent are provided separately as parts of a kit.

- 181 -

Treatment may also include administering the pharmaceutical formulations of the present invention in combination with other therapies. For example, the compounds and pharmaceutical formulations of the present invention may be administered before, during, or after surgical procedure and/or radiation therapy. Alternatively, the compounds of the invention can also be administered in conjunction with other anti-proliferative agents including those used in antisense and gene therapy.

One category of suitable antiproliferative agents useful in the present invention is the alkylating agents, a group of highly reactive chemotherapeutics that form covalent linkages with nucleophilic centers (e.g., hydroxyl and carboxyl). Chemically, the alkylating agents can be divided into five groups: nitrogen mustards, ethylenimines, alkylsulfonates, triazenes, and nitrosureas. The nitrogen mustards are frequently useful in, for example, the treatment of chronic lymphocytic leukemia, Hodgkin's disease, malignant lymphoma, small cell lung cancer and breast and testicular cancer. Exemplary nitrogen mustards include chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan and uracil mustard. The ethylenimines, the most common of which is thiotepa, may be useful in bladder tumors and in breast and ovarian adenocarcinomas. The alkyl sulfonates are useful in the treatment of chronic myelogenous leukemia and other myeloproliferative disorders. Exemplary alkyl sulfonates include busulfan and piposulfan. The triazines, which include, e.g., dacarbazine, are useful in the treatment of malignant melanomas and sarcomas. Temozolomide, an analog of dacarbazine, may also be used in the methods and compositions of the present invention. Finally, the nitrosureas are especially useful against brain tumors, but also are effective for, e.g., multiple myeloma, malignant

- 182 -

melanoma, and lymphoma. Exemplary nitrosureas include carmustine and lomustine.

Another category of antiproliferative agents suitable for use in the present invention is the antimetabolites, structural analogs of normally occurring metabolites that interfere with normal nucleic acid biosynthesis. This category of agents may be subdivided into the folic acid analogs, purine analogs and pyrimidine analogs based on the function of the metabolite with which the agent interferes. The most common folic acid analog is methotrexate, useful in the treatment of choriocarcinoma, leukemias, neoplasms and psoriasis. The purine analogs, such as mercaptopurine, thioguanine and azathioprine, may be useful in leukemias. The pyrimidine analogs are useful in the treatment of, for example, leukemia and carcinomas of the gastrointestinal tract, mammary gland, and bladder. Exemplary pyrimidine analogs include fluorouracil (5-FU), UFT (uracil and ftorafur), capecitabine, gemcitabine and cytarabine.

The vinca alkaloids, natural product-based agents that exert their cytotoxicity by binding to tubulin, represent another category of antiproliferative agents suitable for use in the present invention. The vinca alkaloids are useful in, for example, the treatment of lymphomas, leukemias, and lung, breast, testicular, bladder and head and neck cancers. Exemplary agents include vinblastine, vincristine, vinorelbine and vindesine. The taxanes, agents which promote microtubule assembly, and the podophyllotoxins, agents which inhibit topoisomerases, represent related categories of antiproliferative agents that may be useful in the methods and compositions of the present invention. Exemplary taxanes include paclitaxol and docetaxol, which are useful in breast and lung cancers, among others. Exemplary podophyllotoxins include etoposide (useful in, for example, lymphoma and Hodgkin's disease),

- 183 -

teniposide, irinotecan (useful in, for example, colon, rectal and lung cancer) and topotecan, the latter two of which act via inhibition of topoisomerase I.

Antineoplastic antibiotics represent another category
5 of antiproliferative agents useful in the methods and compositions of the present invention. These agents exert their effects by binding to or complexing with DNA. Exemplary agents include daunorubicin, doxorubicin, epirubicin, mitoxantrone, mitomycin, dactinomycin,
10 plicamycin, and bleomycin. The antibiotics are useful in a diverse range of disorders, including Hodgkin's disease, leukemia, lymphoma, and lung cancer.

The methods and compositions of the present invention may comprise other antiproliferative agents, including the
15 platinum complexes (e.g., cisplatin and carboplatin, which are especially useful in the treatment of lung, head and neck, ovarian and breast cancer); enzymes (e.g., L-asparaginase); hormone-related therapy hormone (e.g., tamoxifen, leuprolide, flutamide, megestrol acetate,
20 diethylstilbestrol, prednisone and estradiol cypionate); hydroxyurea; methylhydrazine derivatives such as procarbazine; adrenocortical suppressants, e.g., mitotane, aminoglutethimide; aromatase inhibitors (e.g., anastrozole); and biologic response modifiers (e.g., interferon-A).

25 Furthermore, the methods and compositions of the present invention may comprise antiproliferative agents that result from the combination of two or more agents including, for example, prednimustine (a conjugate of prednisone and chlorambucil) and estramustine (a conjugate of nornitrogen
30 mustard and estradiol).

The methods and compositions of the present invention may comprise a combination with another kinase inhibitor. Although the present invention is not limited to any particular kinase, kinase inhibitors contemplated for use

- 184 -

include, without limitation, tyrphostin AG490 (2-cyano-3-(3,4-dihydroxyphenyl)-N-(benzyl)-2-propenamide), IressaTM (ZD1839; Astra Zeneca); GleevecTM (STI-571 or imatinib mesylate; Novartis); SU5416 (Pharmacia Corp./Sugen); and
5 TarcevaTM (OSI-774; Roche/Genentech/OSI Pharmaceuticals).


The foregoing description is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds, compositions and methods.

The scope of the claims should not be limited by
10 the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole.

15

What is claimed is:

1. A compound of Formula I:



I

or a tautomer or pharmaceutically acceptable salt thereof, wherein

A^1 is CR^4 ;

A^2 is CR^5 ;

A^3 is CR^6 ;

A^4 is CR^7 ; provided that when L is $-NHC(O)-$, A^1 is CR^4 , A^2 is CR^5 , A^3 is CR^6 and A^4 is CR^7 , then R^6 is H;

L is $-C(O)NR^7-$ or $-NR^7C(O)-$;

R^1 is 3-quinolinyl, said ring optionally substituted independently with 1-3 substituents of R^8 , R^9 , NR^8R^8 , NR^8R^9 , OR^8 , OR^9 , SR^8 , SR^9 , $C(O)R^8$, $C(O)R^9$, $OC(O)R^8$, $C(O)OR^8$, $C(O)NR^8R^8$, $C(O)NR^8R^9$, $NR^8C(O)R^8$, $NR^8C(O)R^9$, $NR^8C(O)NR^8R^8$, $NR^8C(O)NR^8R^9$, $NR^8C(O)OR^8$, $NR^8C(O)OR^9$, $S(O)_2R^8$, $S(O)_2R^9$, $S(O)_2NR^8R^8$, $S(O)_2NR^8R^9$, $NR^8S(O)_2NR^8R^8$, $NR^8S(O)_2NR^8R^9$, $NR^8S(O)_2R^8$ or $NR^8S(O)_2R^9$;

R^2 is H, C_{1-10} -alkyl, C_{2-10} -alkenyl or C_{2-10} -alkynyl, each of the C_{1-10} -alkyl, C_{2-10} -alkenyl and C_{2-10} -alkynyl optionally comprising 1-3 heteroatoms selected from N, O and S and optionally substituted with 1-3 substituents of R^9 or R^{10} ;

R^3 is a ring selected from phenyl and benzo[1.3]dioxolyl wherein said ring is optionally substituted independently with 1-5 substituents of R^{11} , R^{12} , R^{13} , $NR^{11}R^{11}$, $NR^{11}R^{12}$, OR^{11} , SR^{11} , OR^{12} , SR^{12} , $C(O)R^{11}$, $C(S)R^{11}$, $CN(CN)R^{11}$, $C(O)R^{12}$, $C(S)R^{12}$, $CN(CN)R^{12}$, $C(O)C(O)R^{11}$,

OC(O)R¹¹, COOR¹¹, C(O)SR¹¹, C(O)C(O)R¹², OC(O)R¹², COOR¹², C(O)SR¹², C(O)NR¹¹R¹¹, C(S)NR¹¹R¹¹, C(O)NR¹¹R¹², C(S)NR¹¹R¹², OC(O)NR¹¹R¹², NR¹¹C(O)R¹¹, NR¹¹C(O)R¹², NR¹¹C(S)R¹¹, NR¹¹C(S)R¹², NR¹¹C(O)NR¹¹R¹¹, NR¹¹C(O)NR¹¹R¹², NR¹¹C(S)NR¹¹R¹¹, NR¹¹C(S)NR¹¹R¹², NR¹¹C(O)OR¹¹, NR¹¹C(O)OR¹², NR¹¹C(O)C(O)R¹¹, NR¹¹C(O)C(O)R¹², NR¹¹C(O)C(O)NR¹¹R¹², S(O)₂R¹¹, S(O)₂R¹², S(O)₂NR¹¹R¹¹, S(O)₂NR¹¹R¹², NR¹¹S(O)₂NR¹¹R¹², NR¹¹S(O)₂R¹¹ or NR¹¹S(O)₂R¹²;

R⁴ is H or C₁₋₁₀-alkyl;

R⁵ is H;

R⁶ is H;

R⁷ is H;

R⁸ is H, halo, haloalkyl, CN, NO₂, acetyl, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl or C₃₋₁₀-cycloalkyl, each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl and C₃₋₁₀-cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with 1-3 substituents of NR⁸R⁹, NR⁹R⁹, OR⁸, SR⁸, OR⁹, SR⁹, C(O)R⁸, OC(O)R⁸, COOR⁸, C(O)R⁹, OC(O)R⁹, COOR⁹, C(O)NR⁸R⁹, C(O)NR⁹R⁹, NR⁹C(O)R⁸, NR⁹C(O)R⁹, NR⁹C(O)NR⁸R⁹, NR⁹C(O)NR⁹R⁹, NR⁹(COOR⁸), NR⁹(COOR⁹), OC(O)NR⁸R⁹, OC(O)NR⁹R⁹, S(O)₂R⁸, S(O)₂NR⁸R⁹, S(O)₂R⁹, S(O)₂NR⁹R⁹, NR⁹S(O)₂NR⁸R⁹, NR⁹S(O)₂NR⁹R⁹, NR⁹S(O)₂R⁸, NR⁹S(O)₂R⁹ or R⁹;

R⁹ is a partially or fully saturated or unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R¹⁰, oxo, NR¹⁰R¹⁰, OR¹⁰, SR¹⁰, C(O)R¹⁰, COOR¹⁰, C(O)NR¹⁰R¹⁰, NR¹⁰C(O)R¹⁰, NR¹⁰C(O)NR¹⁰R¹⁰, OC(O)NR¹⁰R¹⁰, S(O)₂R¹⁰, S(O)₂NR¹⁰R¹⁰ or NR¹⁰S(O)₂R¹⁰;

R¹⁰ is H, halo, haloalkyl, CN, OH, NO₂, NH₂, acetyl, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, C₄₋₁₀-cycloalkenyl, C₁₋₁₀-alkylamino-, C₁₋₁₀-dialkylamino-, C₁₋₁₀-alkoxyl, C₁₋₁₀-thioalkoxyl or a saturated or partially or fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system

formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl, C₃₋₁₀-cycloalkyl, C₄₋₁₀-cycloalkenyl, C₁₋₁₀-alkylamino-, C₁₋₁₀-dialkylamino-, C₁₋₁₀-alkoxyl, C₁₋₁₀-thioalkoxyl and ring of said ring system is optionally substituted independently with 1-3 substituents of halo, haloalkyl, CN, NO₂, NH₂, OH, oxo, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine, diisopropylamine, benzyl or phenyl;

R¹¹ is H, halo, haloalkyl, CN, NO₂, acetyl, C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl or C₃₋₁₀-cycloalkyl, each of the C₁₋₁₀-alkyl, C₂₋₁₀-alkenyl, C₂₋₁₀-alkynyl and C₃₋₁₀-cycloalkyl optionally comprising 1-4 heteroatoms selected from N, O and S and optionally substituted with one or more substituents of NR¹²R¹³, NR¹³R¹³, OR¹², SR¹², OR¹³, SR¹³, C(O)R¹², OC(O)R¹², COOR¹², C(O)R¹³, OC(O)R¹³, COOR¹³, C(O)NR¹²R¹³, C(O)NR¹³R¹³, NR¹³C(O)R¹², NR¹³C(O)R¹³, NR¹³C(O)NR¹²R¹³, NR¹³C(O)NR¹³R¹³, NR¹³C(O)OR¹², NR¹³C(O)OR¹³, OC(O)NR¹²R¹³, OC(O)NR¹³R¹³, S(O)₂R¹², S(O)₂NR¹²R¹³, S(O)₂R¹³, S(O)₂NR¹³R¹³, NR¹³S(O)₂NR¹²R¹³, NR¹³S(O)₂NR¹³R¹³, NR¹³S(O)₂R¹², NR¹³S(O)₂R¹³ or R¹³;

R¹² is a partially or fully saturated or unsaturated 3-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and wherein each ring of said ring system is optionally substituted independently with 1-3 substituents of R¹³, oxo, NR¹³R¹³, OR¹³, SR¹³, C(O)R¹³, COOR¹³, C(O)NR¹³R¹³, NR¹³C(O)R¹³, NR¹³C(O)NR¹³R¹³, OC(O)NR¹³R¹³, S(O)₂R¹³, S(O)₂NR¹³R¹³ or NR¹³S(O)₂R¹³;

alternatively, R¹¹ and R¹² taken together form a partially or fully saturated or unsaturated 5-6 membered ring of carbon atoms optionally including 1-3 heteroatoms selected from O, N, or S, and the ring optionally substituted independently with 1-5 substituents of R¹³; and

R¹³ is H, halo, haloalkyl, CN, OH, NO₂, NH₂, OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, oxo, acetyl, benzyl, cyclopropyl, cyclobutyl or a partially or fully saturated or unsaturated 3-8 membered monocyclic or 6-12 membered bicyclic

ring system, said ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic or 1-6 heteroatoms if bicyclic, said heteroatoms selected from O, N, or S, and optionally substituted independently with 1-5 substituents of halo, haloalkyl, CN, NO₂, NH₂, OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamino, dimethylamino, ethylamino, diethylamino, isopropylamino, benzyl or phenyl.

2. The compound of claim 1 wherein

A¹ is CR⁴, wherein R⁴ is C₁₋₁₀-alkyl;

A² is CH;

A³ is CH; and

A⁴ is CH.

3. The compound of Claim 1 wherein

R² is H or C₁₋₁₀-alkyl.

4. The compound of Claim 1 wherein R³ is phenyl optionally substituted as defined in claim 1.

5. The compound of Claim 1, wherein the compound is N3-(6,7-dimethoxyquinolin-3-yl)-4-methyl-N1-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)isophthalamide, or a pharmaceutically acceptable salt thereof.

6. The compound of Claim 1, wherein the compound is N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2-methyl-3-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.

7. The compound of Claim 1, wherein the compound is N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2,2-difluorobenzo[d][1,3]dioxole-4-carboxamide, or a pharmaceutically acceptable salt thereof.

8. The compound of Claim 1, wherein the compound is N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-2,2-difluorobenzo[d][1,3]dioxole-5-carboxamide, or a pharmaceutically acceptable salt thereof.

9. The compound of Claim 1, wherein the compound is N3-(6,7-dimethoxyquinolin-3-yl)-N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methylisophthalamide, or a pharmaceutically acceptable salt thereof.

10. The compound of Claim 1, wherein the compound is 2-chloro-N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-methylphenyl)-3-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.

11. The compound of Claim 1, wherein the compound is N-(3-((6,7-dimethoxyquinolin-3-yl)carbamoyl)-4-ethylphenyl)-2-methyl-3-(trifluoromethyl)benzamide, or a pharmaceutically acceptable salt thereof.

12. The compound of Claim 1, wherein the compound is 4-methyl-N3-(quinolin-3-yl)-N1-(3-(trifluoromethyl)phenyl)isophthalamide, or a pharmaceutically acceptable salt thereof.

13. The compound of Claim 1, wherein the compound is 4-methyl-N1-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)-N3-(quinolin-3-yl)isophthalamide, or a pharmaceutically acceptable salt thereof.

14. The compound of Claim 1, wherein the compound is N1-(2-fluoro-5-(trifluoromethyl)phenyl)-4-methyl-N3-(quinolin-3-yl)isophthalamide, or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound defined in any one of Claims 1 to 14, or a pharmaceutically acceptable salt thereof.

16. A use of the compound defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for the lowering of plasma concentrations of any one or combination of TNF-a, IL-1, IL-6 and IL-8 in a subject.

17. A use of the compound defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the lowering of plasma concentrations of any one or combination of TNF-a, IL-1, IL-6 and IL-8 in a subject.

18. A use of the compound defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for the treatment of rheumatoid arthritis, Pagets disease,

osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses, herpes zoster infection or a combination thereof in a subject.

19. A use of the compound defined in any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of rheumatoid arthritis, Paget's disease, osteoporosis, multiple myeloma, uveitis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses, herpes zoster infection or a combination thereof in a subject.

20. A use of the compound defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for the treatment of an abnormal condition associated with inappropriate c-kit kinase mediated signal transduction in a subject.

21. A use of the compound defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of an abnormal condition associated with inappropriate c-kit kinase mediated signal transduction in a subject.


22. A use of the compound defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for the treatment of a fibrotic disease, mastocytosis, mast cell tumors,

asthma, rheumatoid arthritis, scleroderma, multiple sclerosis idiopathic pulmonary fibrosis or allergy associated chronic rhinitis.


23. A use of the compound defined in any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a fibrotic disease, mastocytosis, mast cell tumors, asthma, rheumatoid arthritis, scleroderma, multiple sclerosis idiopathic pulmonary fibrosis or allergy associated chronic rhinitis.

24. The composition of claim 15, for use in combination with one or more compounds selected from tyrphostin AG490, Iressa™, STI-571, SU5416 and Tarceva™.

25. A method of making the compound defined in Claim 1, the method comprising the step of reacting a compound 51



wherein A^1 , A^2 , A^3 , A^4 , R^1 and R^2 are as defined in Claim 1 and L^1 is NH_2 , $COOH$ or $C(O)Cl$, with a compound having a general formula L^2-R^3 , wherein L^2 is NH_2 , $COOH$, $C(O)Cl$, and R^3 is as defined in claim 1, wherein one of L^1 and L^2 is NH_2 , and the other of L^1 and L^2 is $COOH$ or $C(O)Cl$, and wherein where L^1 or L^2 is $COOH$, the $COOH$ group is activated with an activating reagent, to make the compound defined in claim 1.



I